The Pathology of Adrenocortical Hyperfunction and the In Vitro Biosynthesis of Adrenal Androgens by Neville, Alexander Munro
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
THE PATHOLOGY OF ADRENOCORTICAL HYPERFUNCTION 
AND THE IN VITRO BIOSYNTHESIS OF ADRENAL ANDROGENS
THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
OF THE UNIVERSITY OF GLASGOW 
BY
ALEXANDER MUNRO NEVILLE, M.B. Ch.B. (COMMENDATION)
JUNE 1965
ProQuest Number: 10984225
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10984225
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
PAGE
ASSAY OF THE A -3P-HYDROXYSTEROID DEHYDROGENASE 
SYSTEM UTILIZING DHA 128
ASSAY OF THE A -3p-HYDROXYSTEROID DEHYDROGENASE 
SYSTEM UTILIZING DHA-4- C 1^5
IDENTIFICATION OF UNKNOWN STEROIDS 160
RE-I INTERPRETATION OF THE RESULTS OF THE ASSAY OF,. THE
Ac-3P-HYDROXYSTEROID DEHYDROGENASE USING DHA-4- C 167
5
MECHANISM OF 7-KETO-DHA FORMATION 172
1 4
UTILIZATION OF DHA-4- C BY HUMAN ADRENAL GLANDS 176
THE FORMATION OF lip-HYDROXYANDROSTENEDIONE AND 
TESTOSTERONE BY HUMAN ADRENAL GLANDS 184
THE ROUTES OF FORMATION OF 7-KETO-DHA 189
THE ROUTES OF FORMATION OF lip-HYDROXYANDROSTENEDIONE, 
TESTOSTERONE AND ADRENOSTERONE 200
THE FORMATION OF DHA-4-1^C FROM ANDR0STENEDI0NE-4-^C 207
IN VITRO STUDY OF A BENIGN VIRILISING ADRENAL TUMOUR 211
14
UTILIZATION OF DHA-4- C BY HUMAN AND BOVINE ADRENAL 
GLANDS IN THE PRESENCE OF PREGNENOLONE AND 17a- 
HYDROXYPREGNENOLONE 221
14-
UTILIZATION OF DHA-4-'^c BY A BENIGN VIRILISING 
ADRENAL TUMOUR 232
A STUDY OF THE A -30-HYDROXYSTEROID DEHYDROGENASE 
SYSTEMS IN AN ADRENOCORTICAL TUMOUR OF THE MOUSE 244
DISCUSSION 236
SUMMARY 274
ACKNOWLEDGEMENTS 277
REFERENCES 279
P A R T  I
THE PATHOLOGY OF HYPERCORTICALISM
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INTRODUCTION
THE STRUCTURE OF THE ADRENAL GLAND
The human adrenal glands are two small flattened structures 
situated retroperitoneally in the posterior part of the abdomen 
immediately above and to a lesser extent, in front of the upper 
poles of both kidneys. Each normal gland, removed surgically, 
weighs *f.O g., while the weight of a normal gland at autopsy is 
6.0 g. (Studzinski et al., 1963)* The adrenal gland is divisible 
into two distinct structures, an outer cortex and an inner medulla, 
which are different not only embryologically but also functionally. 
Whereas the medulla is neuroectodermal in origin, both the foetal 
and adult cortex arise from the coelomic mesothelium. The 
catecholamines, noradrenaline and adrenaline are elaborated, stored 
and secreted by the medulla, while the cortex forms and secretes 
steroid hormones, of which the most important are cortisol, 
corticosterone, aldosterone and dehydroepiandrosterone. No 
significant store of preformed steroid exists in the normal human 
cortex, only 20 yg. of cortisol being found per gram of adrenal 
tissue (O'Donnell & McCaig, 1962).
The existence of the adrenal glands was known in the 
sixteenth century, but it was not until the middle of the nineteenth 
century that significant advances occurred toward understanding 
its structure and possible function. In 18^9* Thomas Addison
read a paper to the South London Medical Society describing HThe 
Constitutional and Local Effects of Disease of the Suprarenal 
Capsules1’ • A treatise on ’’Disease of the Suprarenal Capsules” 
followed in 1835* in which the adrenal disorder which bears his 
name is discussed together with his classical description of 
pernicious anaemia (Major, 1955)* In the same year, March 
(quoted by Major, 1955) noted the occurrence of metastatic deposits 
of tumour in the suprarenal glands but that these subjects lacked 
evidence of Addison’s disease. The first experimental 
demonstration of the importance of these glands was made by 
Brown-Sequard (1858) who noted that their removal from animals 
always resulted in death. It was not until 1927 that survival of 
bilaterally adrenalectomised animals was achieved by the adminis­
tration of extracts of the adrenal cortex (Rogoff & Stewart, 1927)*
In 1866, Arnold studied the reticular framework of macerated 
and teased sections of the human adrenal gland and described the 
three zones, namely the outer zona glomerulosa, the inner zona 
reticularis and between them, the zona fasciculata. Using 
histological techniques, the same zones were also described on the 
basis of their cellular arrangements and patterns (Gottschau, 1883)• 
The same terminology is still in use at the present time.
Structural differences exist between the adrenal cortex of 
man and animals. While the rat gland possesses the three
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classical zones, it contains a further lipid-free zone, the
sudanophobe zone, placed below the prominent zona glomerulosa.
In ruminants, by contrast, the zona fasciculata and zona
reticularis form a unified lipid-sparse zone occupying the majority
of the width of the cortex and lying beneath a broad zona
glomerulosa. While all three zones are present in the human
adrenal cortex, the zona glomerulosa is never prominent and is
in fact, focal in its distribution around the periphery of the
gland, being present in some areas and absent in others
(Symington, I960) (Fig. 1). Its component cells are small and
are arranged in alveoli lying parallel to the surface. Some
lipid is present in their cytoplasm and by histochemical techniques
the DPN and TPN diaphorase systems (Dawson et al., 196l) and the
Ac-JP-hydroxysteroid dehydrogenase systems (Wattenberg, 1958) are 
5
demonstrable. Ribonucleoprotein (RNA) and abundant mitochondria are 
also present (Symington, I960).
No sharp division exists between the zona glomerulosa and 
the zona fasciculata and in the areas where the former is absent, 
the cells of the zona fasciculata extend to the capsule.
This zone occupies between one half and two-thirds of the total 
width of the cortex and is composed of cells filled with large 
lipid globules, so that they appear to contain empty spaces 
in paraffin sections (Fig. 1). They are
Fig. 1»- Normal human adult adrenal gland. A narrow compact
cell zona reticularis occupies the inner aspect and is sharply 
divided from the outer clear cell zona fasciculata. The zona 
glomerulosa forms a patchy zone under the capsule. H & E x90.
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called the ’'clear” cells (Symington et al., 1955)* They form 
long cords lying in close apposition and they contain few 
mitochondria, little stainable RNA and are poor in the dehydro­
genase enzymes of the citric acid cycle and acid and alkaline 
phosphatase (Symington et al., 1955)* The a ^-3p-hydroxysteroid 
dehydrogenase is demonstrable in these cells, especially in the 
outer part of the zone (Wattenberg, 1958; Dawson et al», 1961).
The change from the zona fasciculata to the zona reticularis is 
abrupt (Fig. 1). This latter area of the cortex is composed of 
small cells with an eosinophilic slightly granular cytoplasm which 
is poor in stainable lipid. They are referred to as the "compact” 
cells (Symington et al., 1955), and can be seen to contain 
abundant mitochondria,stainable RNA and to be rich in acid and 
alkaline phosphatase, and the DPN and TPN diaphorase systems.
The A -3|3-hydroxysteroid dehydrogenase system, by contrast,
5
cannot be demonstrated histochemically in this zone (Wattenberg, 
1958; Dawson et al., 1961) although it can be shown to be present 
using biochemical techniques (Grant, 1962).
THE FUNCTIONAL ZONATION OF THE ADRENAL CORTEX
The functional significance of the three separate zones has 
attracted much attention. Gottschau (1883) proposed the "cell 
migration” theory in which it was postulated that the adrenocortical
- 6 -
cells were formed below the capsule, migrated to the zona 
fasciculata where they produced their secretions and then died in 
the zona reticularis. Working with the cat adrenal cortex,
Bennett (19^0) treated sections of the gland with phenylhydrazine 
and noted a yellow deposit especially in the outer part of the 
zona fasciculata which was thought to be due to the presence of the 
carbonyl groups of the stored steroids. He modified Gottschau’s 
theory and proposed that the outer zona fasciculata was the site 
of formation of the hormones, while the inner zona fasciculata 
was the site of their secretion, the zona reticularis representing 
the post-secretory area. This theory has become untenable due to 
the inability to demonstrate centripetal movement of the cortical 
cells (Calma & Foster, 19^3) and due to the finding of a high 
acid and alkaline phosphatase activity in the zona reticularis of 
the rat gland (Yoffey, 1953; 1955)•
Based upon observations in mice and rat adrenal glands and 
the human adrenal cortex in the adrenogenital syndrome, a "zonal11 
theory has been proposed by Chester Jones (1957)* The zona 
fasciculata is thought to be the site of formation of the 
corticosteroids and the zona reticularis that of the formation 
of adrenal androgens and oestrogens. This is founded upon a 
positive Vine’s fuchsinophil reaction noted in the zona reticularis 
and thought to represent the presence of sex hormones. However,
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due to the trace amounts of steroids present in the glands of 
both normal and virilised patients (Rogers & Williams, 19^7; 
Bongiovanni, 1958; Neher, 1958; O’Donnell & McCaig, 1962), it is 
extremely unlikely that any histochemical procedure will 
demonstrate their presence (Symington, 1962)* Similar objections 
can be raised to negate the histochemical staining of "ketosteroids” 
in the adrenal cortex (Ashbel & Seligman, 19^9; Camber, 19^9)•
The morphological appearance of the human adrenal cortex 
at autopsy presented many problems in interpretation of its 
function. Sudden death was found to be associated with an adrenal 
gland which was well stocked with lipid, while in persons dying 
of infections, varying degrees of loss of lipid were observed 
(Sarason, 19^3; Rogers & Williams, 19^ +7; Ayres et al., 1951*
Zambeck, 1951; Stoner et al., 1953)* When all the lipid had been 
lost from the cortex, the term ’’exhausted” adrenal was applied to 
its appearance, implying loss of function (Stoner et al., 1953)*
ACTH was also known to lead to cortical lipid depletion (O’Donnell 
et al., 1951; Sokoloff et al., 1951; Lanman, 1953)* The 
correlation of these observations and their interpretation in 
terms of functional zonation of the adrenal cortex is due to the 
work of Symington and his colleagues (1955; 1956). Stress, 
such as is caused by severe burning, infections, or myocardial 
infarction produces a marked change in the morphology of the gland.
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Lipid was lost from the cells of the zona fasciculata in a focal 
manner while other adjacent areas retained their lipid content.
The lipid-laden cells which were converted to lipid-poor cells 
now resembled the cells of the zona reticularis not only 
morphologically but also in their enzymic, RNA and mitochondrial 
content* This appearance of alternating zones of clear and 
compact cells shown diagrammatically in Figure 2, is referred to 
as "focal lipid depletion" (Symington et al*, 1955)• If the 
stress is severe and long continued such as results from severe 
acute infections, the entire cortex loses its lipid content 
and the zona fasciculata and zona reticularis form a unified zone 
of compact cells referred to as "complete lipid depletion"
(Symington et al*, 1955) (Fig, 3)* Children respond to stress 
by showing "complete lipid depletion" only (Fig. 2) and this 
difference may be related to the peculiar arrangement of the central 
adrenal venous musculature, the longitudinal muscle bundles of 
which may control blood flow from the cortex. They only become 
well developed during adult life (Dobbie & Symington, 1965)*
During the process of recovery from stress, lipid is initially 
redeposited in the zona fasciculata from within outwards so that 
the cells in the outer part of the zona fasciculata are the last 
to be restocked with lipid* This appearance is referred to as 
the "reversion pattern" (Sarason, 19^5) (Fig. 3)*
REACTION of HUMAN ADRENAL 
CORTEX to TRAUMA
ADULT CHILD
CapsuleCapsule 
ZG-------
Capsule 
ZG-------
Clear
Compact Compact
Clear
Medulla
Fig. 2.- Diagramatic representation of the reaction of the human 
adrenal cortex to stress, with the development of focal lipid 
depletion in the adult and a uniform pattern of lipid depletion in 
the child.
REACTION 
of HUMAN ADRENAL CORTEX to TRAUMA
COMPLETE LIPID DEPLETION REVERSION
CapsuleCapsule
Compact
Compact
MedullaMedulla
Fig. 3.- Diagramatic representation of complete lipid depletion 
developing in response to severe stress in the adult adrenal cortex 
and the reversion pattern found during recovery from stress.
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These results led to the hypothesis of a unified concept 
of function for the zona reticularis and zona fasciculata in which 
the latter zone represented the site of storage of steroid hormone 
precursor which could be made available in times of stress 
through the agency of ACTH (Symington, I960), Confirmation of 
this hypothesis was observed when ACTH was administered to 
patients undergoing therapeutic bilateral adrenalectomy for 
metastatic mammary carcinoma (Symington et al., 1956),
The intravenous administration of a crude preparation of 
ACTH led to an increase in the output of adrenal corticosteroids 
in the adrenal venous effluent within four minutes, yet no 
histological changes could be demonstrated (Grant et al., 1957).
By performing the adrenalectomy in two stages, the first gland to 
be removed served as a control for the morphological and weight 
changes which occurred in the second gland following the 
administration of ACTH. A 110% increment in adrenal weight 
together with morphological and histochemical changes was observed 
when the crude type of ACTH was administered for four days prior 
to the second stage of the bilateral adrenalectomy (Studzinski 
et al., 1963). An alteration in the cell type, from clear to 
compact, occurred in the zona fasciculata from within out and in 
some cases, the entire cortex was changed into compact cells 
(Fig. 1+). By using a more purified type of ACTH, the
Fig. Adult human adrenal. Response to crude ACTH. There
is broadening of the zona reticularis with the conversion of clear 
cells to compact cells, leaving only a narrow rim of clear cells 
in the outer aspect of the gland. H & E x95*
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steroidogenic effect was found to be similar but only a slight
widening of the compact cell zone occurred (Studzinski et al.,
1963) (Fig. 5)• Consequently the changes due to stress and ACTH
are similar in form although different in degree depending upon
the type and dose of ACTH. The change from clear to compact
cells occurs initially in the cells of the zona fasciculata
nearest to the zona reticularis with subsequent outward
131progression. It was in this zone that I-labelled ACTH was
localised in the rat by autoradiography (Sonenberg et al., 1951) 
and the highest concentrations of glucose-6-phosphate dehydrogenase 
and 6-phosphogluconic acid dehydrogenase were detected in the 
human and rat cortices respectively (Greenberg, 1962; Studzinski 
et al», 1962). In vitro incubation of slices of the human adrenal 
gland obtained from the zona fasciculata and zona reticularis 
showed that corticosteroids were formed by both zones, but that 
the subsequent addition of ACTH to the medium led to an increase 
in steroid production principally by the cells of the zona 
fasciculata (Grant & Griffiths, 1962; Griffiths et al., 1963).
From these studies, it is evident that the zona fasciculata 
and zona reticularis of the human gland represent different 
morphological aspects of one functional zone. Both zones may 
contribute to the daily secretion of adrenal steroids (Griffiths 
etal., 1963) but the proportion of this secretion contributed
Fig. 5." Adult human adrenal. Response to a
purified form of ACTH. Slight broadening of the
zona reticularis is present. The outer half of the
cortex is occupied by the clear cells of the zona 
fasciculata. H & E x!50.
IX
by each zone remains to be elucidated* The zona glomerulosa 
of both animals and man is primarily concerned with the production 
of aldosterone (Ayres et al*, 1956; Giroud et al*, 1956;
Ayres et al*t 1958; Giroud et al*, 1958)* and is thus separate 
in its function from the remainder of the cortex*
CUSHING* S SYNDROME
In 1952, Cushing described,in a classical exposition,
16 cases of the syndrome which carries his name. All the physical 
findings of this disease were recorded in its first description 
and Cushing ascribed the cause to a pituitary basophil adenoma* 
Albright (19^3) postulated that all the manifestations of the 
disease could be explained in terms of increased secretion of the 
adrenocortical hormones and this subsequently has been proved to 
be true. Between 50% to 60% of cases have been reported to be 
due to basophil adenomas of the pituitary (Thompson & Eisenhardt, 
19^3; Plotz et al», 1952) but more recently Jailer (1962) has shown 
that less than 10% are in fact of this aetiology. Doubt has been 
cast upon the type of cell involved in the pituitary tumours 
(Russfield et al., 1956) and chromophobe adenomas have been noted 
to develop following therapeutic bilateral adrenalectomy for 
Cushing’s syndrome (Nelson et al*, I960; Salassa et al., 1959)*
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The association of Cushing’s syndrome with acromegaly has been 
recorded in which an eosinophil adenoma of the pituitary was 
found (McCormack et al., 1951) and a few cases have been reported 
in which carcinomas of the adenohypophysis have been noted 
(Bergstrand, 1932*-; Cohen & Dible, 193&; Forbes, 19^7; Feirnig 
et al., 1953? Sheldon et al., 195^ 5 Haugen 8c Loken, 1959).
The pathology of the adrenal glands in Cushing’s syndrome 
may be due to either tumour or bilateral hyperplasia although the 
gland has been recorded as being of normal weight in several 
instances (Crooke, 1953; Kupperman, 1953; Soffer et al., 1955; 
Sprague et al., 1955). Between 25% and 30% of the cases have 
been reported as being due to tumours (Plotz et al., 1952;
Cope 8c Raker, 1955; Soffer et al., 1955; Sprague et al., 1955? 
Symington et al., 1958; Hurxthal 8c O’Sullivan, 1959). While 
benign tumours have been commoner in some series (Wilkins, 19^8; 
Cahill 8c Melicow, 1950; Potasse 8c Higgins, 1952; Sprague et al,, 
1955)i in others, malignant growths have predominated (Marks et al., 
19^0; Soffer et al., 1955). From reviews of adrenal tumours 
associated with Cushing’s syndrome, females were found to be 
affected more frequently and the disease tended to occur after 
the age of twelve years and especially between 30 and 50 years 
of age (Rapaport et al., 1952; Heinbecker et al., 1957; Lipsett 
et al,, 1963).
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Bilateral hyperplasia or ’’normal” adrenal glands have been 
noted in most patients with Cushing's syndrome (Plotz et al.,
1952; Cope & Raker, 1955; Soffer et al., 1955; Sprague et alM
1955; Symington et al., 1958; Hurxthal & O'Sullivan, 1959)* The
combined weight of the glands has varied from normal to 86 g. and
9^ f g. (Kcvach & Kyle, 1958; Kirschner et al., 196k), Micro­
scopically, some have been reported as normal, others as exhibiting 
hyperplasia of the zona fasciculata (Cohen et al., 1959; Carr 
et al., 196^ +). Loss of cortical lipid and cholesterol together 
with cellular atypism have been observed (Cohen et al., 1959).
Although the cause of tumours associated with Cushing's 
syndrome is unknown, considerable progress has been made in 
elucidating the aetiology of bilateral adrenocortical hyperplasia 
when not primarily due to a pituitary tumour. The hypothalamus 
was proposed as the site of the disturbance due to atrophy of 
the paraventricular nuclei (Heinbecker, 19^*0, but this has been 
shown to be effected by the high level of circulating corticosteroids 
(Castor et al., 1951)* The median eminence was invoked as a 
possible site of the primary abnormality due to the existence of 
a portal venous system by which a humoral substance could pass 
from this site to the adenohypophysis (Harris, 1955). Such a 
factor has been isolated and called the corticotrophin releasing 
factor (CRF) (Saffran et al., 1955; Royce & Sayers, 1958) and
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subsequent in vivo and in vitro studies have confirmed the ability 
of median eminence extracts to stimulate ACTH production by the 
anterior pituitary (Guillemin et al., 1957? Rumsfeld & Porter,
1959; McCann 8c Haberland, i960). Consequently high peripheral 
plasma levels of ACTH should exist in patients with Cushing's 
syndrome and be responsible for the increased corticosteroid 
secretion by the adrenal. Attempts to demonstrate this were 
negative (Sydnor et al., 1953; Paris et al., 195*0 hut further 
evidence favoured the concept that the ACTH secreting mechanism 
was at fault. Elevated ACTH values were found in the peripheral 
plasma of subjects who subsequently developed pituitary tumours 
following therapeutic bilateral adrenalectomy for Cushing's 
syndrome (Liddle et al., 1959; Salassa et al., 1959; Nelson et al., 
I960). In addition, resistance to the suppression of ACTH 
secretion was observed in patients with Cushing's syndrome due to 
bilateral hyperplasia (Liddle, I960). In I960, using different 
techniques, Davies and her associates found a two to threefold 
increase in the concentration of ACTH in the peripheral plasma 
in Cushing's syndrome due to adrenal hyperplasia.
Since the first report of the association of Cushing's 
syndrome with tumours of non-endocrine tissues (Brown, 1928) many 
further examples have been recorded, of which 58 were reviewed 
recently (Riggs & Sprague, 1961). Most were associated with
- 15
bronchogenic carcinoma, but cases with tumours of the thymus, 
pancreas, parotid and adrenal medulla have been recorded. ACTH 
or a polypeptide with similar biological activity has been 
demonstrated in some of these primary tumours and increased 
ACTH levels have also been detected in the plasma (Meador et al., 
1962; Liddle et al., 1963; Hallwright et al., 196*0.
THE ADRENOGENITAL SYNDROME
The adrenogenital syndrome has been a recognised entity 
since the days of Hippocrates (Keil, 19*1-9), and de Crecchio 
(I865) reported the physical and psychological findings in a 
typical case. In 1817, Cooke noted its association with an 
adrenal tumour, while bilaterally enlarged adrenals were observed 
in another instance (Fibiger, 1905)• Both benign and malignant 
tumours are associated with this syndrome, occurring more 
frequently in females than males and especially below the age of 
twelve years (Rapaport et al., 1952; Heinbecker et al., 1957)*
A fall in the output of urinary steroids with the administration 
of cortisone, cortisol or one of their synthetic analogues allows 
differentiation of tumours from bilateral adrenocortical 
hyperplasia (Wilkins et al., 1950). Bartter and his colleagues 
(1951) suggested that the aetiology of the cortical hyperplasia 
might be related to an inability to synthesise sufficient
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"corticoids” for the needs of the body. This was supported by 
the absence of a rise in the urinary steroid output following 
ACTH administration (Jailer, 1953) and confirmed by the reports 
of low cortisol production (Kelley et al., 1953; Bongiovanni 
et al., 195*f; Christy et al., 1955) and its failure to rise with 
ACTH (Christy et al., 1955). The aetiology of the low cortisol 
production has been shown to be due to an absolute or relative 
deficiency of one of three adrenocortical enzyme systems, the 
21-hydroxylase (Jailer et al., 1955; Bongiovanni, 1958), the 
llp-hydroxylase (Eberlein & Bongiovanni, 1956) or the A C“3P- 
hydroxysteroid dehydrogenase (Bongiovanni, 1961). Both the 
21-hydroxylase and the A ^-3P“hydroxysteroid dehydrogenase defects 
may be associated not only with virilism but also a tendency 
to salt loss when the enzyme deficiency is severe. Aldosterone 
secretion may be elevated, normal or low (Prader et al., 1955* 
Blizzard et al., 1959). Virilism and hypertension exist 
together when the defect is one of llp-hydroxylation. Genetic 
studies have revealed that each of the enzyme disorders is 
inhereted as an autosomal recessive characteristic, expressing 
itself in the homozygous state and breeding true in any one 
family (Childs et al., 1956).
Due to the negative feed-back mechanism exerted by cortisol 
upon the adenophypophysis, this disease with its low cortisol
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production is associated with elevated levels of blood ACTH 
(Sydnor et al., 1953) which are of a higher order than those 
found in Cushing's syndrome due to bilateral adrenocortical 
hyperplasia (Hamilton & Brush, 196*0 . The increased ACTH 
production leads to an increment in cortisol production, if a 
relative deficiency only of the particular enzyme at fault is 
present, by causing adrenocortical hyperplasia, but this is 
achieved at great metabolic cost due to the increased production 
of other steroids especially the androgens. The weight of the 
adrenal glands is always increased irrespective of age (Lowenthal 
et al., 1958; Landing & Gold, 1951; Scherz 8c Geppert, 1958). 
Contradictory reports with regard to the histopathology have been 
published. Blackman (19**6) noted hyperplasia of the zona 
reticularis, and that this was progressive with increasing 
duration of the disease and advancing age of the patiant. The 
hyperplasia was considered to be due to the presence of 
eosinophilic ’’compact” cells which ’’encroached” upon the zona 
fasciculata with a resultant decrease in its volume. Those 
’’compact” cells werethought to be derived from the foetal cortex. 
On the contrary, hyperplasia of the zona fasciculata (Tonutti 
et al., 1961) and hyperplasia of the zona reticularis with a 
normal zona fasciculata have been recorded (Seelen, I960)• The 
absence of the zona glomerulosa has been observed in cases
-  1ft -
associated with salt loss (Bonf^ovanmi & Moot* 19631•
A further histological variety of ©omgemtal adrenal 
hjpeiplasia due to an inability of the gpLamd to concert cholesterol 
to prehension© has been described (Prader & 'Sartaer* 1955) ia which 
the entire cortex was overstocked with lipid and cholesterol*
A particular variety of the adrenogenital syndrome eaosea 
feminization in the male* ihile this syndrome m y  be associated 
with mom-timiaoiaroiis adrenocortical hyperfassctiom (Perloff & liadd*
1957* Saferilove, 195^; Donald* 19611 Decourt £ ©aimet* 1962| 
Empperman# 1963) * the feminizing adrenogenital disorder is More 
commonly due to a tamour* Since the first reported cases 
(Bitterf * 1919; Parkes-Weber, 1926) 52 cases have been recorded 
and reviewed (Gabrilove et_al,, 1965) of which 50 were proved 
to be mail -s gm,ant by finding aefastases, fhey occur eost often 
between the ages of 25 and 50 years and have been proved, by 
in vitro incubation studies, to fora ©estrogens from suitable 
precursors (Baggett at al»» 1959* West et al.» 196% ; Gabrilove 
et al»« 1$:65)* Of great interest are the reports of the coexistence 
of Ciislsiiag,s syndrom,® and feminization in two patients (Picard et al»« 
1952? SabriXore et al** 1965)» *» this finding lends support to the 
Military concept of adrenocortical function expressed by SywdLngton
&960f 1962).
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COHN'S SYNDROME
The fourth and final clinical syndrome associated with 
adrenocortical hyperfunction is primary hyperaldosteronism*
This entity was first described by Foye and Feichtmeir (1955) 
its aetiology identified by Conn (1955)* although a similar 
syndrome associated with mineralocorticoid excess had been 
recorded previously in dogs (Ferrebee et al*, 19%l)• Most, 
but not all, cases are associated with a demonstrable hyper­
secretion of aldosterone (Conn, 1955? I960)* In vitro 
incubation studies with tumours causing this syndrome have 
revealed that they are capable of forming other corticosteroids 
apart from aldosterone (Bailey et al*, I960; Brode et al*, 1962; 
Fazekas & Webb, 1965). On this account together with the fact 
that not all cases show an elevated secretion of aldosterone, 
Conn*s syndrome may be a better name for this disease. When 
malignant tumours cause this syndrome, a rise in the 17-keto- 
steroids 17-hydroxysteroids or 17-ketogenic steroids can be 
detected (Foye & Feichtmeir, 1955; Brooks et al., 1957). The 
syndrome is most commonly due to a benign tumour of the adrenal 
cortex (Conn, 1963) indistinguishable from the "non-functioning” 
cortical adenoma found at autopsy (Biglieri & Forsham, 1961).
They occur more commonly in females than males especially between 
30 and 50 years (Conn, 1963). They are most frequently small
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in size and single although multiple tumours have been recorded 
(Conn, 1963). Bilateral adrenocortical hyperplasia, affecting 
the zona glomerulosa, the known site of aldosterone formation 
(Ayres et al., 1956; Giroud et al., 1956; Siebenmann, 1959) 
is rarely the basic pathological cause. It occurs predominantly 
in male children and is often associated with malignant hypertension. 
A congenital abnormality of the renal juxtaglomerular apparatus 
has been suggested as the aetiology of the increased aldosterone 
secretion (Conn 8c Conn, 1961; Conn et al., 196*0 • Although 
bilateral hyperplasia of the zona glomerulosa is seen in such 
cases (Symington 8e Jeffries, 1962), its association with ostensibly 
normal glands has also been recorded (Holten 8c Petersen, 1956;
Bartter 8c Biglieri, 1958; Conn 8c Conn, 1961) •
From the examination of hyperplastic and neoplastic adrenal 
glands associated with hypercorticalisoi, Symington and his 
colleagues (Symington et al., 1958; Symington 8c Jeffries, 1962; 
Symington, 1961-62) have been able to show that the alterations 
which occur in the adrenal cortex in association with its various 
diseases, accord with their views of a unitary functional concept 
for the zona reticularis and zona fasciculata. This present 
study of 127 lesions of the adrenal cortex associated with
21 -
hypercorticalism (Table I) was undertaken with a view to 
assessing whether all the adrenal abnormalities found after 
the initial reports accorded with the concept previously 
discussed. Although a considerable clinical overlap may be 
apparent in some cases, the pathological lesions, either 
hyperplasia or neoplasia, have been classified according to 
the predominant clinical signs as Cushing*s syndrome, Conn*s 
syndrome or the adrenogenital syndrome, including feminization.
TABLE I 
ANALYSIS OF 122 CASES OF 
ADRENOCORTICAL HYPERFUNCTION
Disease
Number
of
cases
Adrenal Pathology
Bilateral
Hyperplasia Adenoma Carcinoma
Cushing's 
Syndrome
80 69 5 6
Conn* s Syndrome 23 k 17 2
Adrenogenital
Syhdrome
(virilism)
17 7 6 k
Adrenogenital 
Syndrome 
(Feminization)
2 - - 2
- 22 -
MATERIAL AND METHODS
PREPARATORY TECHNIQUES
The histological investigations were performed on material 
obtained either at the time of surgery or at autopsy. The 
surgically removed suprarenal glands or tumours were placed in 
paLythene bags and kept on ice in a vacuum flask during transit 
to the laboratory. Of necessi ty. some of the lesions were 
kept on ice for periods of up to Zk hours when the operation was 
performed in areas of Great Britain other than Glasgow.
The adrenal glands and tumours were trimmed free of adherent 
tissues and weighed. Tumours were separated from the associated 
atrophic gland, when possible, prior to weighing. Post-mortem 
lesions were treated in a similar fashion following their 
removal.
Complete transverse sections were selected from the head, 
body and tail of each normal, hyperplastic or atrophic gland 
(Dobbie & Symington, 1965)* Representative portions of each 
tumour were obtained from its capsular, peripheral and central 
parts. Areas showing evidence of haemorrhage, necrosis, cyst 
formation or calcification were also included when observed.
HISTOLOGICAL AND HISTOCHEMICAL TECHNIQUES
Some of the selected portions of tissue were fixed in
- 23 -
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10% neutral formalin and subsequently embedded in paraffin or 
gelatine. Paraffin embedded material was sectioned at 6p, 
and stained with haematoxylin and eosin for general morphological 
purposes, or by Brachet's method for ribonucleoprotein (SM) 
(Brachet, 1953)* Lipid was demonstrated in gelatine embedded 
material sectioned at lOp and stained by haematoxylin and 
Sudan IV. Paraffin embedded tissue, previously fixed in a chrome 
dichromate solution, pH containing 2% osmic acid, was cut
and stained by Altman's aniline acid fuchsin method for 
mitochondria (Culling, 1963).
The remaining portions of tissue were used to study three 
enzyme systems. The distribution of acid and alkaline 
phosphatase was demonstrated using the techniques of Rutenburg 
and Seligman (1955) and Burgos and his colleagues (1955) 
respectively and the A^“3P“hydroxysteroid dehydrogenase by the 
method of Wattenberg (1958).
THE PATHOLOGY OF CUSHING'S SYNDROME
Cushing's syndrome accounted for 80 of the total 122 cases 
of adrenocortical hyperfunction composing this series* Sixty- 
nine of these cases were due to bilateral adrenocortical 
hyperplasia and 11 were caused by tumours. When the present 
series was totalled with the reports of Plotz (1952)i Sprague 
(1955)» and Soffer (1961) and their associates, non-tumourous 
involvement of the adrenal glands accounted for 7^*6% of 
307 cases, with benign and malignant tumours forming the 
remainder in almost equal proportions (Table II)#
BILATERAL ADRENOCORTICAL HYPERPLASIA
A detailed analysis of the 69 cases of bilateral hyperplasia 
is shown in Table III. While bilateral hyperplasia was the 
commonest entity, evidence of adenomatous hyperplasia was noted 
in 10 patients and in a further 8, Cushing's syndrome and 
bronchogenic carcinoma were found in association with one 
another. Irrespective of the type of hyperplasia, 73% of the 
cases occurred in females and the highest age incidence was 
between 20 and f^O years. The youngest patient was aged 3 months 
and only one further case occurred below the age of 10 years.
This accords with &he suggestion that bilateral hyperplasia is 
an uncommon cause of Cushing's syndrome in children. Only a
- 23 -
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TABLE III 
CUSHING*S SYNDROME 
Bilateral Adrenocortical Hyperplasia
Analysis of 69 Cases
Pathological Lesion Number of Cases
Hyperplasia 50
Hyperplasia with tuberculosis 1
Hyperplasia with bronchogenic carcinoma 8
Adenomatous hyperplasia 10
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few cases have been recorded (Chute et al«, 19*+9; Hubble 8c 
Illingworth, 1957; Goldblatt & Snaith, 1958; Silver & Ginsburgh, 
I960; Soffer et al,, 1961; Thursby-Felham & Crowe, 1961;
Perlmutter, 1962; O'Bryan et al., 196*0. As one might expect, 
almost all of the cases of Cushing's syndrome associated with 
bronchogenic carcinoma occurred in patients over *f0 years of 
age.
The weights of the adrenal glands removed surgically from 
50 patients, are recorded in Table IV. In 39 cases, the adrenal 
glands weighed less than 10 g. When the recorded weights in 
this series were summated with those of Sprague and his colleagues 
(1955), in 93 of the 119 cases, the glands weighed less than 
10 g» By separating the hyperplastic glands into two groups, 
namely bilateral hyperplasia and bilateral adenomatous hyperplasia, 
distinct differences in the weights of the gland were observed 
(Table V). Thirty-six of the *4-2 glands showing only bilateral 
hyperplasia weighed less than 10 g., while 3 of the 8 glands 
exhibiting bilateral adenomatous hyperplasia weighed more than
12 g.
Previous workers have reported the finding at operation of 
adrenal glands of normal weight in association with Cushing's 
syndrome (Plotz et al., 1952; Cope & Raker, 1955; Soffer et al., 
1955; Sprague et al., 1955; Hurxthal & O'Sullivan, 1959;
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Soffer et al., 1961). In these studies, the weight of the 
normal adrenal gland was adjudged to be 6.0 g. with an upper 
limit of 8.0 g. While these figures are true for autopsy 
specimens, the weight of a normal adrenal gland removed surgically 
without prior ACTH or steroid therapy, is *f.O g. with an upper 
limit of 6.0 g. (Studzinski et al., 1963). Consequently, of 
the bilateral hyperplastic glands in this series, only seven 
can be considered to fall within the normal range. These have 
been classified in detail (Table VI). Three patients are 
children of eleven years of age or younger. While this may 
explain the occurrence of glands of normal adult weight in those 
cases, the existence in adults of such glands is apparent.
However, their weights are outwith the narrow normal range of 
■^•01 - 0.02 g. found by Studzinski and his colleagues (1963)*
The concomitant occurrence of bronchogenic carcinoma and 
Cushing’s syndrome was observed in eight patients (Table VII), in 
one of whom (Case 8) none of the clinical stigmata of the disease 
was noted. Its urinary steroid biochemical abnormalities and a 
metabolic alkalosis were present. In sharp contradistinction to 
the sex incidence of Cushing's syndrome due to bilateral 
hyperplasia in general, seven of the eight patients were males. 
Apart from Cases 2 and ^ (Table VII.) , the glands were all 
examined at autopsy. In every instance, their weights were above
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TABLE VII
CUSHING'S SYNDROME
Non-endocrine Malignant Tumours in 
Association with Cushing's Syndrome
Case
Number
Age
Years Sex
Weight of Adrenal 
Glands (g.) at Autopsy
Left Right
1 33 M 12.60 11.30
2 46 M 11.70* 10.80"
3 4l M 19.0 13.60
4 M 19.10* 16.50*
5 49 F 30.</
6 M 32.(x
7 40 M 3^.0^
8 60 M 8.0 13.0
9 38 M 7.60* 11.0
* Operation specimen 
/ Weight of combined adrenal glands 
^ Details not available
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normal and in seven cases, the increment was severalfold 
approximating to the weight of adrenal glands found in the 
adrenogenital syndrome due to congenital adrenal hyperplasia.
The last case (Case 9» TableVII) is an example of the association 
of Cushing's syndrome and a malignant argentaffin tumour of the 
stomach. The difference in weights of the two adrenal glands 
found in this patient was due to the left gland being an 
operation specimen, while the right was weighed at autopsy.
Bilateral adenomatous hyperplasia was observed in the glands 
removed from 10 patients, of which 8 underwent therapeutic 
adrenalectomy (Cases 1-8, Table VIII). All but one were female. 
The age incidence ranged from 3 months to 47 years and without 
exception the adrenal glands were heavier than normal for the 
age of the patients and most were markedly increased in weight. 
Cases 9-12 are four previously reported instances of bilateral 
adenomatous hyperplasia (Mellinger & Smith, 1956; Hosier et al., 
I960; Silverman et al., 1963; Kirschner et al.» 1964). Mellinger 
and Smith (1956) and Kirschner and his colleagues (1964) have 
suggested that this type of pathological change occurs in patients 
who have suffered from Cushing's syndrome for many years. This 
is not apparent in the present series, especially with regard to 
Case 8 (Table VIII). This infant was of normal weight and 
appearance at birth, but by the age of 3 months, examination of
TAELS fill 
cusHiN&ts simmm
Bilateral Adenomatous Hyperplasia* Adrenal Glands Removed at Operation
Case
Humber Sex
Age
Years
Duration of
the Disease 
(years)
Weight of
Adrenal Glands g.
Response to 
ACTS Infusion
Response to 
Dexame t hasone 
Adaiai stration AuthorsLeft Right
1 F -/ - / 14.0 14.1 Hot performed Mot performed Present series
2 5* 42 - 4 13.2 Not performed Not performed Present series
3 M 4? 3-^ 17.50 r
. —
1
H O *
, 
o Not performed Not tiformed Present series
4 F 29 Over 2 8.30 8.80 No response No suppression Pi o & \t series
5 F 2? 2 6.?6 7.70 Exaggerated response Suppression 1 1 «>..*ut series
6 F 41 4 14.73 10,0 Exaggerated response Minimal
suppression
lit e k% series
7 F 40 2 20.97 22.97 Exaggerated response No suppression Present series
8 F 3/12 2-3/12 1.0 3.0 Not performed Not performed Present series
9 F 48 30 11.0 6.0 Exaggerated response Not performed Mellinger A* Gmrth* 1956
10 F 15 1 16.20/ No response No suppression* Moaier, Flynn* Will fc Turns*
I960
11 M 30 4 18.0 9.0 Exaggerated response No suppression Silverman* Marno11 * Sholiten, 
& Work, 1965
12 F 40 11 44.0 50.0 Exaggerated response No suppression Kirschner, Powell & Lipsett,
1964
/ Details not available 
/ Weight of both glands 
* 9a-fluorohydrocortisone
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both glands after surgical removal revealed evidence of 
adenomatous hyperplasia. Of interest is the failure of 
suppression of adrenocortical secretion with dexamethasone (Cases 
4, 6, 7, 10, 11 & 12; Table Vlli) This same response is found 
in cases of simple cortical tumour. It is therefore important 
to establish the precise pathological diagnosis as a bilateral 
adrenalectomy is necessary. This operation is curative in 
cases of adenomatous hyperplasia.
The right and left adrenal glands usually correspond closely 
in weight (Studzinski et al.t 1963). Of the 34 cases of 
bilateral non-tumourous involvement of the adrenal glands in which 
both adrenals were available for study, 23 pairs differed in 
weight by less than 1.0 g. and 5 further pairs by less than 2 g. 
(Table IX). Of the remaining six, discrepancy was due to 
adenomatous hyperplasia in three, intracortical calcification of 
unknown aetiology or an incomplete gland available for study 
in a further two.
Three points of importance emerge from a study of the 
weights of the adrenal glands associated with Cushing*s syndrome. 
First, the weight of glands in which bilateral hyperplasia is 
found is most often less than 10 g. Secondly, if the glands 
weigh more than 10 g., the pathological change may be either 
adenomatous hyperplasia or hyperplasia associated with bronchogenic
TABLE IX 
CUSHING'S SYNDROME
Weights of Both Hyperplastic Glands 
Removed at Operation in 3^ Cases
1...... ...... ... .
Weight Difference 
less than
Number
of
Cases Pathological Lesion
1*0 g* 23 -
2.0 g. 5 Adenomatous hyperplasia (2 cases) 
Hyperplasia (3 cases)
3«0 £• 2 Hyperplasia in association with 
bronchogenic carcinoma. 
Intracortical calcification
*f.0 g. 1 Hyperplasia - one gland incomplete
5*0 g. 2 Adenomatous hyperplasia 
Hyperplasia in association with 
bronchogenic carcinoma
8.0 g. 1 Adenomatous hyperplasia
-  37 -
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carcinoma. Finally, glands of normal weight (less than 6*0 g.) 
are extremely rare in adults suffering from Cushing's syndrome*
The hyperplastic gland in Cushing's syndrome is larger than 
normal, has rounded prominent edges and is yellow in colour. 
Where the gland is normal in weight, however, the macroscopic 
appearance is also normal. In cases of adenomatous hyperplasia, 
one or more prominent yellow nodules are noted on the surface 
of the gland, the remainder of which possesses a typical 
hyperplastic appearance. Occasionally, the nodules may be 
multiple or even wholly intracortical.
On section, the substance of the cortex consists of two 
distinct layers of similar proportions, the inner being brown 
in colour while the outer is yellow. The cut surface of adrenal 
glands found at autopsy presents a brown appearance extending 
outwards to, or almost to, the outer aspect of the glands. A 
similar appearance, often even broader in extent, is noted in 
the cortex.of those cases of Cushing's syndrome found in 
association with bronchogenic carcinoma.
The classical microscopic pattern of hyperplastic glands 
found at operation is shown in figure 6. The inner brown 
layer noted on gross examination corresponds to a prominent and 
broadened compact cell zona reticularis, while the outer yellow 
layer is caused by the clear cells of the zona fasciculata.
* ;wrjah>. t.i
Fig. 6.- Cushing's syndrome - bilateral hyperplasia. A broad 
compact cell zona reticularis is present and an undulating border 
separates it from the zona fasciculata. Large lipid containing 
spaces are noted in the zona reticularis. H & E xlOO.
- 39 -
The compact cells extend to one-third to one-half of the breadth 
of the cortex abutting abruptly upon the overlying clear cells* 
The dividing line between the two zones is undulating so that 
clear cells may extend deep into the cortex in one area and in 
another, the compact cells may reach out toward the capsule 
(Fig* 6)* The presence and distribution of RNA, mitochondria, 
acid and alkaline phosphatase and the A -3P-hydroxysteroid 
dehydrogenase correspond to the findings in normal clear and 
compact cells. Not only hyperplasia but also hypertrophy can 
affect the clear and compact cells more especially in glands 
which are over 12 g. in weight and which are associated with 
neither adenomatous hyperplasia nor bronchogenic carcinoma* 
Prominent nuclear pleomorphism can be seen in some of the compact 
cells in this type of gland (Fig, 7)•
Not infrequently, large adipose spaces occur in the 
hyperplastic zona reticularis or at its junction with the zona 
fasciculata (Fig. 6), In two patients, in both of whoa 
remission of their disease occurred, adipose tissue was found to 
replace the zona reticularis almost in its entirety. Two further 
patients were given courses of the drug otp»DDD with subsequent 
temporary remission of the syndrome. Following relapse, 
adrenalectomy was performed and the inner aspeot of the adrenal 
cortex was partly replaced by lipid containing apaoes. The
Fig. 7.- Cushing's syndrome - bilateral hyperplasia. A broad 
zona reticularis is present from which columns of hypertrophied 
compact cells pass outward toward the capsule. Foci of large 
clear cells remain between the compact cell columns. H & E xlOO.
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remainder of the cortex was composed of compact cells in some 
of which degenerative changes were present. Only the most 
peripheral part of the cortex contained clear cells (Fig. 8)•
The microscopic appearance of the glands whose weights are 
less than 6.0 g. reveals a broader and more prominent zona 
reticularis than normal, but not as broad as is found in the 
characteristic lesion. Moreover, cellular hypertrophy, nuclear 
pleomorphism or lipid infiltration of the zona reticularis is 
always lacking.
Small microadenomas composed more commonly of clear cells, 
but occasionally of compact cells, often occur not only in normal 
but also in hyperplastic glands. They can be situated either 
in the substance of the gland especially subcapsularly or in the 
surrounding adipose tissue of the gland. They are usually noted 
only on microscopical examination in contrast to the nodules of 
adenomatous hyperplasia which are obvious on gross inspection.
The nodules of this latter entity possess a peripheral capsule 
derived from the gland itself, but their component cells, 
predominantly clear in type, are contiguous with those of the 
typical hyperplastic cortex found in association (Fig. 9).
Adrenal glands removed from patients with Cushingis syndrome 
at autopsy exhibit the characteristic changes superimposed upon 
which are the morphological alterations which occur in response
m m .v y
m $ m
Fig. 8.- Cushing's syndrome - bilateral hyperplasia. 
Therapy - o,p-DDD. The inner aspect of the cortex is 
occupied by lipid containing cells while compact cells 
compose the central part. The outer aspect of the 
cortex consists of clear cells. H & E xlOO.
Fig. 9»~ Cushing's syndrome - bilateral adenomatous hyperplasia* 
A prominent nodule, composed principally of clear cells but with 
foci of compact cells, is projecting from one aspect of the 
associated hyperplastic cortex. H & E x5.
- 4 1 -
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to the stress of dying, so that the entire cortex consists of 
a unified zone of compact cells (Fig. 10).
A similar appearance, except that the cortex is usually 
broader, is seen in the gland removed from patients who also 
suffered from bronchogenic carcinoma. However, foci of clear 
cells often occur in the substance of the cortex or cap the 
columns of compact cells (Fig. 11), Both cell types frequently 
are hypertrophied. If metastases from the primary tumours 
involve the adrenal gland, they are noted first in the zona 
glomerulosa, the medulla or the cortical lymphatics.
The distribution of the zona glomerulosa is normal in the 
majority of hyperplastic glands causing Cushing*s syndrome. A 
few, mostly those associated with pre-operative hypokalaemia, 
show a slight degree of hyperplasia of the zona glomerulosa.
TUMOURS OF THE ADRENAL CORTEX
The aetiology of autonomous functioning neoplasms of the 
adrenal cortex causing Cushing’s syndrome would appear to be 
unrelated to the trophic hormone ACTH or the hypothalamo- 
pituitary axis. Such tumours may cause either a pure or a 
mixed type of Cushing’s syndrome, in the latter virilism being 
an added feature. Both benign aid malignant growths may 
cause the disease, their relative incidence being shown in Table
II.
Fig. 10.- Cushing's syndrome - bilateral hyperplasia 
(autopsy specimen). Compact cells compose the entire 
cortex so that the zona reticularis and fasciculata 
form a unified zone. H & E x75.
m m
8 ®' m m
H V v  IT 'w m&W v *?-'>> v  ■ • '
;'*!?*•• SAfta*'
■ F f y
Fig. 11.- Cushing's syndrome - bilateral hyperplasia 
due to bronchogenic carcinoma. Compact cells, some of 
which are hypertrophied, others showing degenerative 
changes, compose the cortex, with large clear cells 
forming foci, either in the substance or in the peripheral 
parts of the cortex. H & S xlOO.
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Benign Tumours.
Five benign adrenocortical tumours were studied in the 
present series (Table X)• All except Case 1, were associated 
with the pure form of the syndrome. The preponderance of 
females and the age incidence of benign growths paralleled the 
findings in Cushing’s syndrome due to bilateral hyperplasia. The 
clinical details of Case 5 (Table X) could not be traced. All 
the tumours weighed less than 40 g. and possessed well formed 
capsules by which they were attached to the associated thinned 
and atrophic adrenal cortex.
On sectioning these oval or spherical lesions, a yellow 
appearance is seen in which small dark brown foci are apparent.
Areas of haemorrhage and necrosis are also observed, especially 
in Cases 2 and 5 (Table X).
Microscopic examination reveals that the predominant 
cell type is the clear lipid-laden cell, slightly larger in size 
but morphologically and histochemically similar to normal clear 
cells (Fig. 12). The cellular arrangement is in the form of 
small alveoli, cords or columns separated from one another by 
fibrovascular trabeculae which arise from the capsule. The small 
brown coloured foci noted on gross inspection consist of cells 
with an eosinophilic granular cytoplasm, resembling the compact 
cells of the zona reticularis of the normal adrenal cortex (Fig. 12)•
Fig. 12.- Cushing’s syndrome - adenoma. The 
predominant component cells are clear in type with foci 
of compact cells. They are arranged in alveoli 
separated by a fibrovascular stroma. H 8c E xlOO.
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These cells are arranged in similar patterns as the clear cells 
and with increasing size of the tumour constitute more of its 
structure. The nuclei of both the clear and compact cells 
may be normal in size but nuclear pleomorphism with bizarre types 
may be present. Mitoses are absent or minimal. Haemorrhage 
and necrosis tend to be absent from the smaller tumours, and even 
in large ones are infrequent.
Malignant Tumours.
Table XI demonstrates the relative data concerning six 
malignant tumours all of which were associated with Cushing’s 
syndrome of the mixed type. The preponderance of females is 
again apparent. There is a wide age and weight distribution.
The weights of the tumours in Cases 2 and 5 (Table XI) were not 
recorded. Both were stated to be ’’large”. The two tumours 
weighing 3*000 g» and 4,040 g. measured 27*5 x 22 x 12.5 cm. and 
30 x 25 x 10 cm. respectively. A well formed capsule was 
present in each of the tumours in which the entire specimen was 
available for study. The thinned remains of the adrenal gland 
were stretched over the tumours.
The cut surface of these growths presents a fleshy rather 
brown colour with irregular lobulations (Fig. 13). The tissue 
may be rather soft and friable especially in the larger lesions, 
in which areas of haemorrhage and necrosis are frequent.
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Fig. 13»- Cushing’s syndrome - carcinoma (weight 139 g.). 
The tumour is encapsulated and divided into irregularly 
shaped lobules. It is soft and fleshy and shows areas of 
necrosis.
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The carcinomas are composed of cells of the compact type, little 
lipid being demonstrable in their eosinophilic cytoplasm. While 
neither acid nor alkaline phosphatase can he stained in these 
cells, the A - 38-hydroxysteroid dehydrogenase is present in 
trace amounts as judged histochemically. RNA is apparently 
absent and mitochondria are sparse. The cells are arranged in 
alveoli of varying size and shape (Fig. 14) although cords and 
columns of cells may be seen in some areas. A consistent feature 
in each tumour is the presence of enlarged vesicular ovoid or 
round nuclei which possess a finely stippled interior in which 
one or more nucleoli are present (Fig. 13)• Although uniformity 
of cell and nuclear size and shape can be observed in some areas, 
most zones exhibit cellular and nuclear pleomorphism. Giant 
forms occur, but mitotic figures are not prominent in any of the 
lesions. Areas of necrosis are obvious in each of the malignant 
tumours especially the tumours of Cases 4 and 6 (Table XI). The 
necrosis involves large numbers of cells in contrast to the 
individual cell necrosis seen in growths which subsequently 
behave in a benign manner (Fig. 16). Haemorrhage, both recent 
and old, the latter containing cholesterol clefts and haemosiderin 
laden macrophages, is seen in several of the tumours.
Each tumour possesses a well formed capsule from which 
fibrous trabeculae carrying blood vessels arise to divide the
Fig. 14.- Cushing's syndrome - carcinoma. The tumour cells 
are arranged in alveoli of varying size, separated by trabeculae 
in which dilated vascular spaces are present. H & E x95»
Fig. 13»- Cushing’s syndrome - carcinoma. The alveolar
arrangement of the cells is more obvious. The tumour cells are 
compact in type, but are larger than normal compact cells. Their 
nuclei are vesicular in character and exhibit pleomorphism.
H & E x240.
V* 'ij£
Fig. 16.- Cushing's syndrome - carcinoma. The alveolar 
arrangement of the compact cells is seen together with 
an extensive area of necrosis. H & E xlOO.
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tumours into lobules. Many dilated vascular channels are 
present in these tumours (Fig. 14) but in none is there any 
evidence of vascular invasion by the malignant cells.
Local invasive infiltration occurred in each of the lesions 
examined at autopsy. In one patient (Case 4, Table XI) the 
tumour extended from the bed of the right adrenal gland through 
the diaphragm to the pleura. Lymph node metastases occurred in 
three patients (Cases 2-4, Table XI) and in five, pulmonary 
metastases were noted. The liver and brain were involved in two 
cases (Cases 2 Sc 4, Table XI) (Fig. 17)* Case 6 is included as 
a malignant tumour in the absence of proved metastases on the 
strength of extensive necrosis and large prominent vesicular 
nuclei. These two features are the only consistent histological 
guides to malignancy shared by the five cases of carcinoma in 
which malignancy was proved by the capacity to metastasise.
The Associated Adrenal Cortex.
Evidence of cortical atrophy is observed in the associated 
adrenal cortex found in conjunction with functioning benign: 
and malignant tumours. The capsule of the gland is broad and 
oedematous and the cortex consists of a narrow zone of clear cells 
only (Fig. 18).
p l ^
CMS,
Fig. 17.- Cushing's syndrome - carcinoma. Metastases 
involving the liver.
Fig. 18. - Cushing's syndrome - adrenal gland found in 
association with benign or malignant tumours. The associated 
adrenal gland shows evidence of steroid induced atrophy, with 
the cortex composed solely of clear cells. The capsule of the 
gland is thickened and oedematous. H & E x65.
THE PATHOLOGY OF THE ADRENOGENITAL SYNDROME
A. VIRILISM
The adrenogenital syndrome accounted for 17 of the total of 
122 cases of hypercorticalism (Table I). Ten of these patients 
had benign or malignant tumours of the adrenal cortex, while seven 
were due to bilateral hyperplasia. The relative incidence in this 
series gives a false indication of incidence of the two pathologies 
in general. Between 1943 and 1962, 433 cases of congenital 
adrenal hyperplasia were reported (Bratand 8c Thompson, 1943;
Bentwick et al., 1952; Russell, 1954; Wilkins, 1962), whereas over 
a 25 year period, only 113 adrenal tumours causing the adrenogenital 
syndrome were found in a review of the literature (Rapaport et al., 
1952; Heinbecker et al., 1957)* Doubtless, due to the simplicity 
of effective therapy for congenital adrenal hyperplasia, many more 
cases remain unrecorded. This pathological entity is due to 
a congenital anomaly inherited as an autosomal recessive 
characteristic which manifests itself as a deficiency of one of the 
enzyme systems involved in the biosynthesis of cortisol.
BILATERAL ADRENOCORTICAL HYPERPLASIA
All seven cases of congenital adrenal hyperplasia in the 
present series occurred below the age of thirteen years, and all
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but one were females, two of whom were sisters* The remaining 
patients were unrelated*
The weights were recorded only in the glands removed from 
two patients. In one, a female aged twelve years, they weighed 
21.8 g. and 20.0 g. In the other patient, only one gland was 
examined and it was found to weigh 7»5 g* This small increment 
in weight was due to the patient having received therapeutic 
suppressive doses of cortisone pre-operatively.
Macroscopically, the adrenal cortex is lobulated and the 
surface is thrown into a series of convolutions. The edges are 
rounded and the cut surface is uniformly brown in colour, 
resembling the gross appearance of the zona reticularis of the 
normal gland.
Histological examination of these glands reveals the presence 
of a diffusely broadened cortex composed exclusively or almost 
exclusively, of compact cells. Those cells exhibit the same 
histochemical enzymic properties as the compact cells of the 
normal gland and similarly have abundant mitochondria and 
stainable RNA. This cellular pattern extends from the inner border 
of the cortex to the zona glomerulosa (Fig. 19). In a few focal area 
the columns of compact cells are capped by a few clear cells.
The zona glomerulosa is prominent and hyperplastic in all but one 
of the glands of this series. It is present around the entire
Fig. 19.- Adrenogenital syndrome - bilateral hyperplasia. 
A prominent, hyperplastic zona glomerulosa is present. 
Compact cells compose the remainder of the cortex and 
form a unified zone. H & E x!50.
w m m
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periphery of the cortex and is between two and four times its 
normal width (Fig. 19)*
TUMOURS OF TEE ADRENAL CORTEX
The adrenogenital syndrome when caused by adrenocortical 
tumours occurs particularly before the age of twelve years and more 
frequently in females than males (Goldstein et al.t 1946;
Rapaport et al., 1952; Heinbecker et al., 1957; Symington & 
Jeffries, 1962). Both benign and malignant tumours may cause 
the syndrome and from the review series published by Rapaport 
(1952) and Eeinbecker (1957) and their colleagues, malignant 
lesions appear to occur at least twice as frequently as benign 
ones.
Benign Tumours.
Adrenocortical adenomas were responsible for six cases of 
the syndrome in this series (Table XII). Although the sex 
distribution was equal, four of the tumours were found in patients 
less than twelve years of age. The range of recorded weights 
of the growths showed a wide scatter and in the larger tumours 
found in Cases 3 and 4 (Table XII), difficulty was encountered in 
deciding whether they were benign or malignant.
All the adenomas are surrounded by a well formed capsule 
to which the associated atrophic adrenal cortex is attached.
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Fig. 20.- Adrenogenital syndrome - adenoma (228 g.). The 
tumour is encapsulated. It is soft in consistency and shows 
areas of recent haemorrhage.
4Fig. 21.- Adrenogenital syndrome - adenoma. The cells are 
compact in type and are arranged in small alveoli or cords.
Little nuclear or cellular pleomorphism is present. H & E x220.
; »• v,*.v;;“ r u , L ; » p . A » - »  .
Fig. 22.- Adrenogenital syndrome - adenoma. Both clear and 
compact cells are present in this lesion, the latter predominating. 
They are arranged in alveoli or cords. Some nuclear pleomorphism 
is seen. H 8c E x225.
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Fig, 23»- Adrenogenital syndrome - adenoma (228 g.).
The cells are compact in type and are larger than normal. 
Nuclear pleomorphism is prominent and many of the nuclei are 
enlarged and vesicular in character. Dense pyknotic nuclei 
are present in some cells, the cytoplasm of which is 
eosinophilic and homogeneous. H & E x2k0.
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absent or minimal in all the tumours, and necrosis which is 
confined to individual cells in the smaller growths tends to 
be more extensive.in the larger tumours of Cases 3 and ^ (Table 
XII). Fibrovascular trabeculae, which are derived from the 
well formed capsules, divide the tumour into lobules and surround 
each of the alveoli (Fig. 21)•
It is not clear whether the tumours from Cases 3 and k 
(Table XII) are benign or malignant. The histological picture 
is complicated by the presence in both tumours of large areas 
of necrosis and the presence of larger vesicular nuclei in 
Case k (Table XII). This child shows no evidence of recurrence 
30 months after the removal of the tumour, but the outcome 
must be awaited before a final decision can be reached. In 
Case 3 (Table XII), although necrosis is prominent in the tumour, 
the nuclei are small and not enlarged so that the diagnosis of 
a benign growth can be made with more certainty.
Malignant Tumours.
All the patients in whom carcinomas of the adrenal gland 
were responsible for the development of the adrenogenital 
syndrome were females (Table XIII). Benign and malignant tumours 
associated with this syndrome shows a considerable overlap,
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in weight (Tables XII & XIII). Two of the lesions (Cases 2 &
Table XIII) were proved malignant by the presence of metastases. 
Apart from local involvement of the tumour site and the presence 
of a morphologically similar tumour in the opposite adrenal gland, 
no metastases were found at the autopsy of Case 5 (Table XIII).
No clinical evidence of secondary tumour was noted in Case 1 
(TABLE XIII) apart from its recurrence at the original site.
The carcinomas are all well encapsulated and on sectioning, 
the cut surface presents a fleshy appearance in which areas of 
necrosis and haemorrhage are prominent particularly in the larger 
lesions (Fig. 2k). The associated adrenal glands are noted in 
relation to one pole of the tumour and are stretched over their 
surface.
The cell component common to all of those tumours is the 
compact type of cell in which lipid is absent from or sparse in 
the cytoplasm. The cells are larger than the compact cells of the 
zona reticularis of the normal gland and marked pleomorphism is 
present with the formation of giant cells in some areas (Fig. 25). 
The nuclei are also enlarged and their vesicular character is a 
prominent feature (Fig. 26). One or more nucleoli are noted in the 
nuclei which also have a well marked nuclear membrane. Mitoses 
are not frequent in any of the lesions. In some areas, particular1; 
in the tumour removed from Case 1 (Table XIII), a remarkably
Fig. 2k,- Adrenogenital syndrome - carcinoma (1,250 g.) 
The tumour is encapsulated and divided into lobules.
Areas of haemorrhage and necrosis are prominent.
Fig. 25«- Adrenogenital syndrome - carcinoma. The compact 
cells are larger than normal and are arranged in alveoli 
separated by fibrovascular trabeculae. Nuclear pleomorphism
is marked and giant forms are present. H 8c E x240.
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Fig. 26.- Adrenogenital syndrome - carcinoma. The component 
compact cells possess prominent vesicular nuclei, in which one 
or more nucleoli may be seen. Pleomorphism is also present.
H & E x950.
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uniform nuclear and cellular pattern can be observed in which the 
cells are very similar to the normal compact cell and in which 
the nuclei are round and small. Eistochemical demonstration of 
the A -3(3-hydroxysteroid dehydrogenase enzyme in the tumour of 
Case 3 (Table XIII) yields negative results. The cellular 
arrangement differs not only between the tumours but also in any 
one tumour. The formation of alveoli can be less conspicuous 
than in the benign tumours of this syndrome, and cords or 
syncitial groups of cells may be more apparent. Extensive areas 
of necrosis involving many groups of cells are apparent and 
haemorrhagic zones are also seen. Dilated vascular sinusoidal 
spaces are prominent and lie in close apposition to the tumour 
cells. In none of these malignant growths is there evidence of 
vascular invasion. Although the tumours have a lobular structure, 
fibrovascular trabeculae are not prominent among the syncitial 
cell areas, but can be seen surrounding the alveolar structures.
The Associated Adrenal Cortex.
The appearance of the associated adrenal cortex is similar 
to that occurring in association with Cushing’s syndrome due to 
autonomous functioning tumours (Fig. 18), except that a prominent 
hyperplastic zona glomerulosa is observed in the atrophic cortex 
attached to the tumour removed from Case 4 (Table XII).
-  57 -
B. FEMINIZATION
Feminizing tumours of the adrenal cortex are the least 
common manifestation of the adrenogenital syndrome, a total of 
32 cases having been recorded and reviewed by Gabrilove and his 
colleagues (1965)• Of these, 10 appeared to be benign, while 
of the remainder, 30 were proved to be malignant by the presence of 
metastases at autopsy.
TUMOURS OF THE ADRENAL CORTEX
Two male patients of the present series of 122 examples of 
hypercorticalism presented with symptoms and signs of feminization. 
Both were due to tumours, one of which has been found to be 
malignant (Table XIV).
Both tumours are encapsulated and divided into lobulas of 
differing size and shape. Areas of haemorrhage and necrosis are 
conspicuous. The tissue is soft and is brown to pink in colour.
A remarkable similarity exists between the two tumours in 
cell type and structure. The neoplastic cells are compact but are 
larger than normal. They are arranged in sheets or cords with 
little intervening fibrovascular stroma. The nuclei are large 
and vesicular with prominent nucleoli and nuclear membranes (Fig. 27) 
Mitoses are rare. A minimal degree of pleomorphism is present
U% &  m * {f t
* w  w  - * -w f  «■ - •  jr ' « % ♦ * « * *  1
' & & & (  W * P -  * '  ■ "_ ■•••Vs-;£*. ‘ir./.V
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Fig. 27»~ Feminization - carcinoma. The cells are 
compact in type and have enlarged vesicular nuclei. 
Little cellular or nuclear pleomorphism is present! 
Many cells possess pyknotic nuclei and an homogeneous 
eosinophilic cytoplasm. H & E x390.
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in both lesions. Although prominent areas of necrosis are seen, 
individual cells in many foci also show degenerative changes and 
necrosis (Fig. 27).
Due to the similarity of the two tumours, particularly with 
regard to the enlarged vesicular nuclei and the prominent areas of 
necrosis, the tumour from Case 2 (Table XIV) is regarded as a 
malignant growth despite both the lack of metastases at present 
and the lack of pleomorphism and mitotic activity.
THE PATHOLOGY OF COHN’S SYNDROME
Conn’s syndrome accounted for 23 of the total of 122 cases 
of hypercorticalism, of which 19 were due to adrenocortical tumours* 
Two of the tumours were malignant.
Since the first description of this disease in 1955 (Conn,
1955i Foye & Feichtmeir, 1955)» its recognition has increased 
sharply. In 1964, Conn and his colleagues reviewed 145 cases 
due to adrenal tumours reported in the literature and they were 
aware of the existence of at least 70 other unreported similar 
lesions. Consequently, at present, it is still too early to assess 
the true incidence of aldosterone secreting tumours in patients 
with hypertension. The syndrome can also be caused by bilateral 
adrenocortical hyperplasia. This entity occurs more commonly in 
young males who present with malignant hypertension (Conn & Conn, 
1961).
BILATERAL ADRENOCORTICAL HYPERPLASIA
The existence of bilateral hyperplasia of the zona glomerulosa 
was suspected in 4 patients in the present series. Two of the 
cases occurred in young male children in whom bilateral 
adrenalectomy produced clinical improvement. Only one gland was 
removed from each of the remaining two cases, one a male, the 
other a female, both aged 40 years. Their post-operative courses
- 60 -
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are being studied at present as the adrenalectomies were performed 
on an empirical rather than scientific basis.
All the glands are normal in appearance and weight. In the 
two children, the zona glomerulosa is hyperplastic. It is 
present around the entire periphery of the cortex forming a broad 
zone several cells in depth (Fig. 28) from which occasional tongue­
like projections may be sent into the zona fasciculata. Focal 
hyperplasia of the zona glomerulosa is seen in the gland removed 
from the 40 year old male subject, while a relatively narrow zona 
glomerulosa with focal areas of hyperplasia is present around the 
periphery of the gland removed from the fourth case.
The cells of the zona glomerulosa in cases of Conn's syndrome 
due to bilateral hyperplasia are identical with those of the 
normal gland. They are small in size, possess dense hyperchromatic 
nuclei and finely granular eosinophilic cytoplasm in which lipid is 
demonstrable. Neither mitoses nor pleomorphism are apparent. The 
presence of the -hydroxysteroid dehydrogenase can be noted
histochemically.
The zona fasciculata and zona reticularis are normal in 
appearance in these glands (Fig. 28).
TUMOURS OF THE ADRENAL CORTEX
A detailed analysis of the 19 patients in whom tumours of the 
adrenal cortex were responsible for their developing Conn's syndrome
iraf e ^ ^ g p  ‘V)
Fig. 28.- Conn's syndrome - bilateral hyperplasia. 'The 
zona glomerulosa forms a broad hyperplastic zone immediately 
below the capsule of the gland. The zona reticularis and 
fasciculata are normal in appearance. H & E xl40.
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is presented in Table XV. Cases 1 to 17 were caused by benign 
tumours while the remaining two patients had malignant growths, that 
of Case 18 being proven by the development of metastases post- 
operatively. This case has been the subject of a previous report 
(Brooks et al., 1957) and only 4 other malignant tumours have been 
recorded in the literature (Foye & Feichtmeir, 1955; Zimmerman et al., 
1959; Conn et al., 1964; Leutscher, 1964).
The preponderance of females in this series closely corresponds 
with the incidence in general. Fourteen of the present cases 
occurred in women and from the published reports of Conn (1963) 
and Leutscher (1964), 126 of the cases were found in the female 
sex. The highest age incidence was between 31 and 50 years into 
]' which group fell 15 of the l8 patients in whom the weight of the 
tumour is known. In Table XVI, the present series is summated 
with 157 other patients and of the total of 1?5» 132 cases were 
found to occur in this age group. This age incidence applied 
equally to men and women. A predilection for affecting the left 
adrenal gland was noted in women not only of the present series 
but also from the reviewed material (Table XVII). In males, on 
the othei^hand, the tumours occurred equally on either side when 
single tumours were studied but in cases where multiple growths 
were observed, the right gland was more often involved (Table XVIII).
Whereas tumours causing the adrenogenital or Cushing's syndrome
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tended to weigh more than 20 g., 10 of 15 tumours of this series 
were less than this weight and six of them were less than 6 g. 
in weight. When a total of 85 tumours were examined including 
this series, 52 were found to weigh less than 6 g. (Table XIX)*
Benign Tumours
Benign tumours are usually small in size and attached at 
one pole by their well formed capsules to the associated adrenal 
glands, the appearances of which are normal* Generally the 
growths are ovoid or spherical and their cut surface presents a 
golden yellow to yelloxv-brown colour. The very small tumours 
found in Cases 2, 5 and 7 (Table XV) are wholly contained within 
the associated gland and only become apparent on cutting it*
Areas of necrosis and haemorrhage are noted only in the larger 
tumours and are relatively prominent at one pole of the lesion 
weighing 79 g. (Case 11, Table XV).
Several different histological cell types and patterns 
compose these tumours. The commonest cell type is morphologically 
similar to the clear cells of the zona fasciculata of the normal 
gland (Fig* 29). They resemble such cells in size, in their 
nuclear-cytoplasmic ratio and high lipid content of the cytoplasm. 
Stainable RNA is absent or minimal, but the A^~3P“hydroxysteroid 
dehydrogenase is present as judged by histochemical techniques.
These cells are arranged in small cords or acini which are separated
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FiK- 29.- Conn's syndrome - adenoma. The component cells 
are similar to the clear cells of the zona fasciculata of the 
normal adrenal cortex. They are arranged in small alveoli or 
cords, separated by a fine fibrovascular stroma. Nuclear 
pleomorphism is minimal. H & E x240.
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by fine connective tissue trabeculae in which a few capillaries 
can be seen (Fig. 29). The nuclei of these cells are more 
vesicular than those of normal clear cells and both nuclear and 
cellular pleomorphism can be seen in most of the tumours, but 
they seldom become prominent features.
Cells of the zona glomerulosa type are noted in several of the 
tumours, forming solid trabeculae or alveoli. They occur more 
commonly immediately below the tumour capsule (Fig. JO) but are 
also demonstrable in the more central areas of the lesion. The 
nuclear:cytoplasmic ratio of these cells is high and their scanty 
eosinophilic cytoplasm contains variable amounts of stainable 
lipid and SNA. Their nuclei which may show pleomorphism, are 
vesicular in character with prominent nucleoli.
Small groups of cells, morphologically similar to the compact 
cells of the zona reticularis of the normal gland are observed in 
a few tumours. They occur in association with the clear and 
glomerulosa-type cells or they may form small micro-adenomata.
Clear cells alone or in conjunction with cells of the 
glomerulosa and reticularis type composed all but two of the 
benign tumours. In four of these another morphologically distinct 
type of cell is apparent. Its nuclear:cytoplasmic ratio is similar 
to cr higher than that of the zona glomerulosa, but its cytoplasm 
is filled with lipid and similar in appearance to the cells of i
Fig. JO.- Conn's syndrome - adenoma. Three different types 
of cells are seen in this figure. Cells of the zona glomerulosa 
type are present especially subcapsularly, while large clear 
cells are noted on the right and the hybrid type of cell on the 
left of the figure. H & E x9J*
- 70 -
the zona fasciculata. They are referred to as “hybrid cells”
(Fig* 30).
Two tumours in the series (Cases 6 & 11$ Table XV) are formed 
almost exclusively by zona glomerulosa type cells (Fig. 31)» with 
only a few foci of clear cells. In most areas of the lesion, the 
arrangement of the cells is similar to the previous description, 
but in other zones, the trabeculae, cords or acini are noted to 
be separated by a myxomatous Schiff-negative stroma (Fig. 32).
These tumours possess well formed capsules from which narrow 
trabeculae arise and divide the lesions into a lobular pattern 
more especially in the larger growths.
Malignant Tumours
Both the malignant tumours are larger than the benign lesions 
in this series (Cases 18 8c 19, Table XV) and their cut surfaces 
reveal a lobular pattern and areas of necrosis and haemorrhage 
(Fig. 33).
The morphological appearance of both tumours is very similar. 
The component cells are ovoid or round and large in size. They 
possess a finely granular vacuolated cytoplasm in which sparse 
amounts of lipid are demonstrable. The nuclei are large and the 
nuclear:cytoplasmic ratio approximates to that of the “hybrid” cell 
found in some benign lesions (Fig. 3*0. Many of the nuclei are 
vesicular in character and possess a finely stippled interior in
9 $ $ B
* # « WW^mmir-rd v* “T v\
Fig. 31»~ Conn's syndrome - adenoma. The component 
cells are of the zona glomerulosa type and they are 
arranged in small alveoli. Some nuclear pleomorphism 
can beseen. H & E x2k0.
Fig. 32*- Conn’s syndrome - adenoma. Cells of the zona 
glomerulosa type are arranged in short cords or columns, 
separated by an oedematous, Schiff-negative stroma.
H & E x2^0.
Fig, 33.- Conn's syndrome - carcinoma (weight 1,400 g.). The
tumour is encapsulated and divided into irregular lobules. The
cut surface is soft and areas of necrosis are noted. The
associated, normal sized, adrenal gland is attached at one pole
of the growth.
igSi V-4 •';> *«f>
^  -Vt*
‘*4 t*3^.jksr
,  r  v ! * ?
/* * - .__v __^  > » . M _ ■ *.
Fig. 3^»- Conn's syndrome - carcinoma. The cells, which are 
of the "hybrid" type, are arranged in large alveoli surrounded 
by prominent vascular spaces. Their nuclei are vesicular in 
character and also show pleomorphism. H & E x2k0.
Fig. 33.- Conn’s syndrome - adrenal gland found in association 
with benign or malignant tumours. The associated adrenal gland 
shows a prominent, broadened zona gloraerulosa. The zona 
reticularis and fasciculata are normal in appearance.
H 8c E x90.
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and contains prominent blood filled capillaries. The zona 
reticularis and zona fasciculata are normal in appearance in many 
glands, but occasionally evidence of focal lipid depletion is 
seen.
DISCUSSION
It is dubious whether the incidence of the various 
pathological lesions associated with hypercorticalism in this 
survey is an accurate reflection of their true incidence. This 
is due perhaps to two factors. First, there is considerable 
selection of lesions referred to the Department of Pathology at 
the Glasgow Royal Infirmary, the rarer ones in particular being 
submitted for opinion. Secondly, with the development of 
adequate medical therapy for congenital adrenal hyperplasia, glands 
from these patients are no longer available for study except at 
autopsy. Thirdly, Conn's syndrome is a relatively new entity, 
and its true incidence in hypertension and in relation to the other 
adrenal disorders remains to be clarified.
The histological patterns noted in bilateral adrenocortical 
hyperplasia associated with Cushing’s syndrome, Conn's syndrome 
and the adrenogenital syndrome are distinct and diagnostic, but 
histological differentiation of tumours causing Cushing’s syndrome 
and both the virilising and feminizing adrenogenital syndromes is 
impossible. In Conn's syndrome, the diagnosis of aetiological 
tumours can be made on histological grounds, provided function of 
the tumour was proved during life.
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BILATERAL ADRENOCORTICAL HYPERPLASIA
The zona glomerulosa is the site of aldosterone biosynthesis 
both in man (Ayres et al., 1958; Siebenman, 1959) and animals 
(Ayres et al., 1956 ; Giroud et al., 1956), so that bilateral 
hyperplasia of this zone in cases of Conn’s syndrome not due to 
adrenal tumours is the expected finding. Although the external 
appearance and weight of such glands are normal, the reports of 
histologically normal glands may have their foundation upon 
failure to appreciate the focal nature of the zona glomerulosa in 
the normal human adrenal cortex. In both cases where there were 
urinary steroid analyses to support the clinical diagnosis of 
Conn's syndrome, the zona glomerulosa exhibited prominent 
hyperplastic changes. In these cases in which estimations of 
the urinary aldosterone titre. were not made, the hyperplasia was 
less marked and focal in type. This latter histological pattern 
is not diagnostic of Conn's syndrome; it may occur in cases of 
essential hypertension, especially in its malignant phase. 
Consequently, although the histological pattern may suggest the 
diagnosis of Conn’s syndrome due to bilateral adrenocortical 
hyperplasia, evidence of raised aldosterone levels compajtable with 
this disease must be established before the diagnosis can be made 
with certainty.
The aetiology of bilateral hyperplasia of the zona glomerulosa
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is unknown but it has been noted to occur in two distinct groups 
of patients* In one, the disease occurs most frequently in 
young subjects especially males and is associated with malignant 
hypertension, while in the other, benign hypertension is found 
in adults particularly females between the ages of 30 and 30 years. 
The disease has been reported to be due to both hyperplastic and 
normal glands in both groups (von Buchem et al., 1956; Holten & 
Petersen, 1956; Bartter & Biglieri, 1958; Conn 8c Conn, 1961). 
Bilateral adrenalectomy fails to cure the hypertension in the older 
patients, but succeeds in the younger age group. However, the 
latter still exhibit hypersensitivity to mineralocorticoids followii 
operation (Conn et al., 196*0 and the suggestion has been made that 
their disease is due to a congenital anomaly of the renal 
juxtaglomerular apparatus (Conn & Conn, 1961).
The hyperplasia of the zona glomerulosa found in association
with adrenal tumours causing Conn’s syndrome would appear to be
paradoxical. It may be related, however, to the potassium loading 
which these patients receive pre-operatively to raise their serum 
levels to normal.
The changes which occur in the adrenal cortex in response to
ACTH depend upon its dose and type (Symington et al., 1956;
Studzinski et al., 1963). In bilateral adrenocortical hyperplasia 
associated with Cushing's syndrome and the adrenogenital syndrome,
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the morphological changes are consistent with an elevation in the 
circulating ACTH concentration. The normal plasma level of ACTH 
was found to be 0.75 milliunits/100 ml. by Davies and her 
colleagues (i960) and it was found to be raised to between 2 and 
3 milliunits/100 ml. in Cushing’s syndrome due to bilateral adrenal 
hyperpiasia^CDavies et al., I960). Using the same method, a 
value of 5*71 milliunits/100 ml. has been reported in a case of 
congenital adrenal hyperplasia (Hamilton & Brush, 1964). The 
compact cell zone found in the hyperplastic adrenals is not as 
broad in Cushing's syndrome as it is in the adrenogenital syndrome. 
Thus the appearances are consistent with those plasma ACTH levels.
In the adrenogenital syndrome, this increased secretion of 
ACTH results from a reduced level of circulating cortisol, the 
biosynthesis of which is impaired by a deficiency in the adrenal 
enzyme systems (Jailer et al., 1955; Eberlein & Bongiovanni, 1956; 
Bongiovanni, 1958; Bongiovanni, 1961). The low cortisol level 
releases the anterior pituitary from its inhibitory effect. The 
elevated ACTH values in bilateral adrenal hyperplasia in Cushing's 
syndrome, not due to pituitary tumours, would appear to be a primary 
pituitary or hypothalamic effect, the latter mediated perhaps by 
the corticotrophin releasing factor (CRF). The hypothalamo- 
pituitary axis is deranged in this disorder not only in its 
increased ACTH secretion, but also in its unresponsiveness to
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suppression by normal levels of blood cortisol, the feed-back 
mechanism working at an abnormally high level (Williams et al., 19&1) 
so that large doses of suppressant cortisol analogues are 
required (Liddle, i960). A loss in the diurnal rhythm of ACTH 
secretion has been postulated (Williams et al., 1961). Pituitary 
tumours cause Cushing's syndrome due to their increased secretion 
of ACTH but none of the present patients have been found to 
possess such lesions either before or after therapeutic 
adrenalectomy.
It may be possible to explain the occurrence of glands 
morphologically hyperplastic but of normal weight in Cushing's 
syndrome on the basis of the secretion of different types of ACTH.
An adrenal weight factor, described by Stacke-Dunn and Young (1951) 
has been demonstrated in the plasma in some patients with Cushing's 
syndrome (Christy et al., 1957)- From their studies with crude 
and purified forms of ACTH, Studzinski and his colleagues (1963) 
showed that the degree of hyperplasia occurring in normal glands 
removed from patients with metastatic breast carcinoma was related 
to the type of ACTH administered. Using the crude preparation 
containing both a steroidogenic and a weight factor, a 115% increase 
in adrenal weight was achieved, whereas little or no increa® in 
weight occurred with the more highly purified ACTH preparations, 
equal in steroidogenic potency. Consequently, both factors
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may be elevated in Cushing’s syndrome when the gland weighs over 
6.0 g., while only the steroidogenic factor is elevated in patients 
with the smaller glands. The occurrence of a marked increase 
in weight and hypertrophic cellular changes in Cushing's syndrome 
due to bilateral hyperplasia may be due to the predominance of- the 
mght factor, as similar weight and morphological alterations 
were noted in response to crude ACTH preparations (Symington 
et al., 1956).
The increased secretion of ACTH has also been implicated in 
the causation of bilateral adenomatous hyperplasia in Cushing's 
syndrome (Kirschner et al., 1964). As two of the four previously 
reported patients with this condition (Cases 9 & 12, Table VIII) 
suffered from the disease for a long time prior to treatment, the 
suggestion was made that prolonged exposure to increased 
concentrations of ACTH might be responsible. However, this is 
not apparent in the patients of the present series, particularly 
the three month old female child (Case 8, Table XIII) and some 
other factor must be responsible for the change.
The importance of this disorder lies in the nedd to differenti 
it from an adenoma causing Cushing's syndrome. All functioning 
adrenocortical tumours causing Cushing's syndrome are found in 
conjunction with atrophy of the associated and contralateral glands, 
whereas adenomatous hyperplasia is associated with hyperplasia of
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the non-adenomatous areas of the cortex. Moreover as 
adenomatous hyperplasia is a bilateral condition, both glands 
require surgical treatment, whereas removal of a unilateral 
functioning tumour is curative.
Further difficulty occurs in the differentiation of 
adenomatous hyperplasia from an adenoma as the former entity can 
simulate a benign functioning tumour in its response to the 
infusion of ACTH and suppression with dexamethasone. An 
exaggerated response to ACTH was found in five cases of adenomatous 
hyperplasia of either the present or previously reported cases 
(Table VIII) and failure to suppress with dexamethasone or a 
similar pharmacological agent in six. These responses can also 
be obtained in cases of Cushing’s syndrome caused by adenomas 
(Liddle, i960) so that some degree of autonomy is possessed by 
either the adenomatous nodule or the hyperplastic gland. It is 
presumed that the response to ACTH is elicited due to their content 
clear cells. Thus diagnostic confusion may occur leading to 
inadequate surgical treatment if this feature is not known.
Recent studies in Cushing's syndrome found in association with 
tumours of "non-endocrine" tissues have suggested that ACTH or 
a polypeptide with similar biological and chemical properties is 
elaborated by these tumours and is responsible for the changes 
in structure and function of the adrenal cortex (Meador et al.,
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1962; Nichols et al., 1962; Liddle et al., 1963; Marks et al.,
1963; Scholz et al., 1963; Hallwright et al., 196*0, Since the 
first published case of this association (Brown, 1928), many 
further reports have confirmed its existence. Fifty-eight cases, 
mostly due to oat cell carcinomas of bronchus were reviewed in 
1961 (Riggs 8c Sprague, 1961), Carcinomas of the thymus v/ere 
the first type of tumour to establish the relationship with certainty 
(Leyton et al., 1931; Duguid 8c Kennedy, 1933; Hubble, 19*1-9;
Sprague, 1950; Soutter et al., 1957; McCullagh 8c Tretbar, 195$;
Scholz 8c Bahn, 1959; Camus et al., 1961; Mucic 8c Arsenijevic, 1963). 
Of 13 cases of the syndrome reported by Liddle and his associates 
(1963), nine occurred in patients with oat cell carcinomas of the 
bronchus. Carcinomas of the islet cells of the pancreas, the
\
^mediastinum and the parotid and a phaeochromocytoma were found in 
each of the remaining four cases. The association with tumours 
of the pancreatic endocrine (del Castillo et al., 1950; Howard 
et al., 1950; Rosenberg, 1956; Balls et al., 1959; Farrant 8c 
Insley, I960; Meador et al., 1962) and exocrine tissues (McLetchie 
8c Scott, 19*1-3; Crooke, 19*1-6; Peart et al., 1963) has been noted 
by other workers and argentaffin tumours of the pancreas 
(Hallwright et al., 196*0 and bronchus (Sscovitz 8c Reingold, 1961) 
have been found in causal relationship.
While a definite association exists between those entities
- 8 1 -
and adrenal hyperplasia, the co-existence of the syndrome in 
patients with carcinomas of the colon (Warren, 19**5)» prostate 
(Webster et al., 1959), gall-bladder (Brickner et al., 1961), 
testis (Di Ferranti etal., 1951) and ovary (Parsons & Rigby, 1958) 
may be fortuitous.
Bronchogenic carcinoma was found in each of the 8 cases of 
this series. The adrenal glands tended to be larger and heavier 
with the exception of Case 8 (Table VIII) than those of other 
cases of bilateral hyperplasia in Cushing’s syndrome. The 
histological pattern resembles the hyperplasia found in congenital 
adrenal hyperplasia with the exception that clear cells cap the 
columns of compactcells in some glands. These clear cells may 
be responsible for the positive response to the infusion pf ACTH 
noted in some patients (Werk & Sholeton, I960; Christy, 1961;
Meador et al., 1962; Marks et al., 1963). In their absence, 
no response to ACTH is obtained (Meador et al., 1962; Marks e t al., 
1963)• Of interest is the lack of suppression of the secretion 
of corticosteroid by dexamethasone (Meador et al., 1962; Liddle 
et al., 1963; Marks et al., 1963; Friedman et al., 1965). These 
tests serve to differentiate the disease from bilateral hyperplasia 
but fail to do so in patients with bilateral adenomatous hyperplasi 
or a functioning cortical adenoma.
The ninth case (Case 9, Table VII) in this series was
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associated with a malignant argentaffin tumour of the stomach.
The morphological picture of both glands was in keeping with 
bilateral hyperplasia due to an hypothalamo-pituitary defect of 
ACTH secretion rather than to the secretion of ACTH by the tumour 
itself.
Clinical evidence of Cushing's syndrome may be absent 
(Hudson & Evans, 1962; Marks et al., 1963; Meador et al., 1963; 
Scholz et al., 1963; Cohen et al., 1964; Friedman et al., 1965) 
and only the steroid biochemical aberrations present. This was 
seen in one of the patients of this series (Case 8, Table VII) 
but hypokalaemic alkalosis and pigmentation often serve to 
attract attention. The former is due to the increased cortisol 
levels (Christy 8c Larague, 196l) and not to an increase in 
aldosterone secretion (Scholz et al., 1963) while the latter is 
caused by the secretion of MSH by some of these primary tumours 
(Hallwright et al., 1964).
In 16 cases, the presence of ACTH or a similar polypeptide 
has been demonstrated not only in the primary but also the 
secondary tumours (Meador et al., 1962; Nichols et al., 1962; 
Liddle et al., 1963; Marks et al., 1963; Hallwright et al., 1964). 
Increased plasma ACTH levels (Liddle et al., 1963; Scholz et al., 
1963) and a low concentration in the adenohypophysis (Nichols 
et al., 1962; Liddle et al., 1963; Marks et al., 1963) have also
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been described. These findings could be interpreted as being 
the result of increased ACTH production by the adenohypophysis and 
its subsequent storage by the tumour. However, the clinical 
and biochemical manifestations of Cushing's syndrome recede 
following surgical removal of the primary tumours (Liddle et al., 
1963; Micic 8c Arsenijevic, 1963) so that these tumours appear to 
be responsible for the elaboration and secretion of ACTH or a 
structurally similar protein (Liddle et al., 1963). The presence 
of metastases in the median eminence of the brain was shown in 
Case 7 (Table VII), but not in a further two cases (Cases 2 & 3* 
Table VIII) (Dobbie, personal communication). Although this 
may represent another method whereby increased amounts of ACTH 
may be produced through the agency of CRF, its absence in other 
cases makes it an unlikely cause.
Two further aspects of adrenocortical hyperplasia merit 
consideration. Remissions occur rarely in Cushing's syndrome, 
but were noted in two cases of this series, one of which was 
induced by radiotherapy. Lipid infiltration of the zona 
reticularis was noted to occur. Lipid laden cells occupying the 
site of the zona reticularis with hyperplastic changes outwith 
this zone was observed in two patients in whom remission with 
o'p’DDD was obtained, but a relapse developed subsequently.
The hyperplasia of the zona glomerulosa noted in five of
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the six cases of congenital adrenal hyperplasia probably represents 
a reactive change as the biosynthesis of aldosterone requires the 
enzymes found to be deficient in this syndrome. However, the zona 
glomerulosa has been noted to be absent (Blackman, 1946;
Lewis et al., 1950) or hyperplastic (Bernhiem et al., 1954) in 
other glands. Normal aldosterone levels have been found in 
cases of congenital adrenal hyperplasia due to a 21-hydroxylase 
defect unassociated with salt-loss, while low levels occurred 
in association with salt loss (Degenhart et al., 1965). The 
relation of these values to the appearance of the zona glomerulosa 
remains to be elucidated.
An appreciation of the morphological changes which occur in 
the human adrenal cortex due to stress or the administration of
ACTH, enables a correct interpretation of the distinctive
hyperplastic patterns found in Cushing's and the adrenogenital 
syndromes. As the zona glomerulosa is the site of aldosterone 
biosynthesis, only this zone is affected in Conn's syndrome due 
to bilateral adrenocortical hyperplasia.
TUMOURS OF THE ADRENAL CORTEX
If the concept is accepted of the compact cell of the zona
reticularis being responsible for most of the production of
corticosteroids with the exception of aldosterone, the androgens
- 85 -
and the oestrogens required by the body from day to day, then 
it is possible to understand why the morphological appearance of 
tumours causing Cushing’s syndrome and the adrenogenital syndrome 
are identical. Since both benign and malignant tumours consist 
exclusively, or almost exclusively, of compact cells, it is not 
possible on histological grounds alone to distinguish between 
those of differing endocrine capacity. The exception to this is 
the small tumour, usually weighing less than 7° g*» associated with 
the pure form of Cushing's syndrome in which admixtures of clear 
and compact cells occur, the former predominating.
Small cortical adenomas are commonly found at autopsy, the 
majority being apparently non-functioning in vivo. Histological 
examination gives no information on the functional capacity of 
these tumours and both they and the uncommon non-functioning 
carcinoma may be composed of compact or clear cells. In the 
latter event, distinction from the tumours of Conn's syndrome may 
be imxoossible. Some of the non-functioning clear cell adenomas 
respond to the stress of dying with transformation of some of the 
clear cells to compact cells. Their resemblance to the small 
benign tumours causing Cushing's syndrome is readily apparent.
A suggestion has been made recently, that an enzyme defect, 
possibly the A ,_-3p-hydroxysteroid dehydrogenase, is present in 
some non-functioning tumours, the reason for the lack of
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symptomatology being due to the failure fo form physiologically 
active steroids (Fukushima & Gallagher, 1963)*
The incidence of adrenocortical tumours in Cushing's syndrome 
would appear to be of the order of 25% (Table II) benign and 
malignant tumours occurring almost equally. An accurate assessment 
of the incidence of malignancy is difficult due to the different 
criteria used by different investigators. Benign tumours have 
been reported more frequently in some reports (Wilkins, 1948;
Cahill & Melicow, 1950; Poutasse & Higgins, 1952) and malignant 
lesions in others (Weinberg, 1941; Markes et al., 1940; Soffer 
et al., 1961). From the 117 cases of Cushing's syndrome due to 
tumours collected by Rapaport and his colleagues (1952), 73 were 
stated to be malignant and 35 benign. In 9 cases, the pathological 
diagnosis was of "adrenal tumour". Tumours occurred more 
frequently in females and especially after the age of 12 years 
(Rapaport et al., 1952; Heinbecker et al., 1957)* The present 
series conforms to these observations.
The adrenogenital syndrome due to virilising tumours occurs 
more often below the age of 12 years, but like Cushing's syndrome 
more commonly in females (Rapaport e t al., 1952; Heinbecker etal., 
1957). These frequencies occur in this series. As in Cushing's 
syndrome, the incidence of malignancy in tumours causing the 
adrenogenital syndrome is difficult to guage, but of the 71 cases
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reported by Rapaport and his co-workers (1952) 46 were malignant*
Feminizing tumours of the adrenal cortex occur most frequently 
between the ages of 25 and 50 years (Gabrilove et al., 1965)» 
although they have been found in children from the age of 5 years 
(Wilkins, 1948; Snaith, 1958) and in adults up to the age of 
66 years (Case Records, Massachusetts General Hospital, 1955)*
Of the 52 feminizing tumours reviewed by Gabrilove and his 
colleagues (1965), 4l were diagnosed as carcinomas of which 30 
subsequently developed metastases. Of the 10 tumours diagnosed 
as adenomas, only a few of the patients have been followed for 
sufficiently long periods for this diagnosis to be accepted. Those 
include the cases reported by Ostergaard (1947), Wilkins (1948), 
Mortensen and Murphy (1951), Dostal (1955), Hosier and Goodwin 
(1961) and Dempsey and Hill (1963)• The follow-up periods range 
from 2 to 14 years. Long periods of reappraisal are essential 
before a benign tumour can be established, as the development of 
metastases has been known to be delayed for as long as seven years 
(Roholm and Teilum, 1942; Kerr & Gordan, 1952; Myhre, 1952;
Dohan et al., 1953; Landau et al., 1954; Wallach et al., 1957)* 
Feminizing tumours vary greatly in weight from 10 g.
(Snaith, 1958) to over 2 kilogrammes (Roholm & Teilum, 1942;
Myhre, 1952; Higgins et al., 1956). While benign tumours tend to 
be lighter and smaller (Mortensen 8c Murphy, 1951; Dostal, 1955;
- 88 -
Snaith, 1958; Hosier & Goodwin, 1961), a considerable overlap 
occurs (Hall, 1950; Luft & Sjogren, 1949; Dohan et al*, 1953?
Fontaine et al*, 1954; Dempsey & Hill, 1963). This has also been 
observed in virilising adrenal tumours (Fordyce & Evans, 1929)* 
Consequently all feminizing tumours must be regarded with 
suspcion. Both tumours in this series showed similar histological 
patterns, and one was found to have metastasised (Case 1, Table XIV ) 
the other lesion must be regarded as possibly malignant.
Conn's syndrome is most commonly due to tumours, the majority 
of which are benign (Conn, 1963). They occur particularly in 
adult life, between the ages of 31 and 50 years. The present 
series corresponds closely with the other reported cases and the 
morphological appearance of the tumours present distinct and 
diagnostic patterns. However, tumours which are composed of only 
clear cells, although they often exhibit pleomorphism, cannot be 
distinguished histologically from the non-functioning adenomas 
composed of clear cells unless in vivo function has been demonstrated 
The relative infrequency of cells of the zona glomerulosa 
type is difficult to understand as these tumours have been found 
to be capable of aldosterone biosynthesis in vitro (Ayres etal., 
1958; Bailey et al., I960; Davignon et al., 196I5 Pasqualini, 1964; 
Fazekas & ?/ebb, 1965). Moreover they can also form cortisol and 
corticosterone (Davignon et al., 1961; Louis & Conn, 1961;
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Brode et al., 1962; Fazekas & Webb, 1965).
Zona glomerulosa cells of the normal adrenal gland lack the 
17<x-hydroxylase system but possess an "l8-oxidase" required for 
the production of aldosterone, whereas the cells of the normal 
zona fasciculata lack the "l8-oxidase", but possess the 
17a-hydroxylase required for the formation of cortisol. Brode 
and his colleagues (1962) studied three tumours causing Conn's 
syndrome and by histological control of the incubated tissue noted 
that while the cells of glomerulosa type produced similar steroids 
as normal zona glomerulosa cells, the clear cells of the tumour 
produced steroids characteristic of both normal clear and 
glomerulosa cells. For this reason these clear cells are referred 
to as "hybrids". The subsequent finding in other tumours of 
morphologically "hybrid" cells confirms the biochemical observation. 
Consequently, all the clear cells of these tumours appear to be 
hybrid in type as judged biochemically and this helps to explain 
why other workers have also noted the predominant or sole content 
of clear cells in aldosterone producing tumours (Ross, 1959;
Bailey et al., I960; Conn& Conn, 1961; Davignon et al., 1961;
Conn, 1963).
The histological patterns noted in the tumours removed from 
cases 6 and 11 (Table XV) presents diagnostic problem. The weight 
of the tumour removed from Case 6 is unknown, but the lesion from
- 90 -
Case 11 weighed 79 g. This is more in keeping with malignant
than benign tumours. The histological pattern in both tumours
which consisted of cords of zona glomerulosa type cells separated b 
an oedematous stroma, is similar to the histological description 
of the malignant tumour described by Foye and Feichtmeir (1955)* 
However, both patients in this series are alive and well and 
9 years post-operatively•
Only five malignant tumours have been reported previously 
(Foye & Feichtmeir, 1999; Brooks et al., 1997; Zimmerman et al,, 
1999; Conn et al., 196^ -; Luetscher, 196^ -). Case 18 (Table XV) 
is the patient reported by Brooks and his colleagues (1997).
Case 19 (Table XV) presented with signs and symptoms of both 
Conn's syndrome and Cushing's syndrome. These two tumours are 
similar. The cell type is compatible with the appearance of the 
"hybrid" cell, and this accords with the finding not only of 
elevated urinary aldosterone levels, but also raised urinary 
17-hydroxy, 17-ketogenic and 17-ketosteroids (Foye & Feichtmeir, 
1999; Brooks et al., 1997; Case 19» Table XV). The histological 
appearance of these two growths is distinctive and allows 
diagnosis of malignant tumours causing Conn's syndrome but in view 
of the histological pattern noted by Foye and Feichtmeir (1999)i 
not all malignant tumours in this group are similar morphologically 
As with other endocrine tumours, it is often difficult to
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determine whether adrenocortical tumours are benign or malignant. 
This has been observed by other workers particularly Symington 
and Jeffries (1962) and Lipsett and his colleagues (1963)* The 
usual criteria of malignancy cannot be applied. Mitotic figures 
can be observed not only in malignant tumours but also in benign 
lesions and, furthermore, they may be absent in proved 
metastasing carcinomas (Symington & Jeffries, 1962; Lipsett et al., 
1963)• Invasion of the tumour capsule has been proposed as 
being most suggestive of carcinoma, but this feature and apparent 
venous invasion have been found in non-malignant endocrine tumours. 
Importance has been attached to the size of the tumour, but a 
considerable overlap in weight has been observed not only in this 
series but also by others (Fordyce 8c Evans, 1929; Hall, 1930; Luft 
8c Sjogren, 19^ +9; Rapaport et al., 1932; Dempsey 8c Hill, 1963).
Thus, although extremes in weight are helpful, the larger tumours 
being more likely to be malignant, this cannot be used as a reliabl 
criterion.
Several features which have been found to occur in the maligna 
tumours of this series appear to be relatively reliable. The 
presence of enlarged, vesicular nuclei with prominent nucleoli was 
noted in every malignant tumour and was also present in the 
metastases examined at autopsy. When extensive areas of necrosis 
involved the tumours, the lesion almost always behaved in a maligna
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fashion. When marked nuclear pleomorphism is observed in 
association with enlarged vesicular nuclei and extensive necrosis, 
this feature would appear to serve as a guide to malignancy. 
However, if pleomorphism is found alone, then the tumour can 
behave as a benign or a malignant growth.
The finding of enlarged vesicular nuclei with or without 
pleomorphism and with extensive areas of cellular necrosis is the 
most reliable index of malignanqfavailable at present. These 
features can occur alone or in association with the usual criteria 
for the histological diagnosis of malignancy. Nevertheless, the 
only absolute criterion of malignancy is the detection of distant 
metastases, so that careful follow-up over long periods is required 
in every instance.
SUMMARY
A review of 122 cases of hypercorticalism has been presented. 
The pathological features of the lesions associated with the 
various syndromes have been submitted to a critical reappraisal 
based upon the observations of the effects of stress and ACTH 
upon the normal human adrenal cortex.
Cushing's syndrome was the most frequent entity and bilateral 
adrenocortical hyperplasia its most common pathology. Almost all 
patients suffering from Conn's syndrome were found to have tumours 
of the adrenal cortex. Similarly the adrenogenital syndrome was 
caused principally by adrenal tumours.
The pathological problems associated with the diagnosis of 
these conditions have been discussed in detail and the difficulties 
encountered in deciding whether a particular tumour was benign 
or malignant have been outlined.
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P A R T  II 
THE IN VITRO BIOSYNTHESIS OF ADRENAL ANDROGENS
INTRODUCTION
GENESIS OF THE SECRETIONS OF THE ADRENAL CORTEX 
Historical Account.
The earliest demonstrations of the vital nature of the 
adrenal cortex were made by Rogoff and Stewart (1927) and Swingle 
and Pfiffner (1930) in the United States. Following bilateral 
adrenalectomy in dogs and cats respectively, they found that 
extracts of the adrenal glands were capable of maintaining the 
animals in a relatively normal state of health for long periods 
whereas the control untreated animals died within seven to ten 
days. This "life-maintaining” function was thought to be due 
to a unitary type of adrenocortical secretion, named "cortin” 
(Hartman et al., 1928), which was found to reside in the lipid 
soluble fraction of the extracts (Swingle & Pfiffner, 1931).
Systematic chemical studies of adrenocortical extracts were 
undertaken by three groups of workers in an attempt to isolate 
the active principle. Four crystalline compounds were found by 
Wintersteiner and Pfiffner (1936) but none appeared to possess 
any biological activity. Also in the United States, Kendall and 
his associates isolated five compounds, one of which possessed 
biological activity (Mason et al., 1936a, 1936b). This substance 
referred to as Kendall’s compound E, was subsequently shown to be 
cortisone. By 1936, Reichstein, working in Switzerland, had
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isolated six compounds from extracts of beef adrenal glands and 
had made preliminary observations upon their chemical nature 
(Reichstein, 1936)•
These isolation studies culminated in the structural 
identification of twenty-eight crystalline steroidal substances 
in 19^3 (Reichstein & Shoppee, 19^3)* so ending the confusion that 
existed due to their designation by different letters of the 
alphabet. Cortisone, for example, had been found by all three 
groups of workers and was variously referred to as Kendall's 
compound E, Wintersteiner*s compound F and Reichstein’s substance 
FA.
The magnitude of the problem in .'identifying these steroids 
can only be appreciated when it is realised that from the extracts 
of both adrenal glands, of 20,000 cattle, 200 mg. of cortisone 
(Reichstein Sc von Suw, 1936)1 3^ Gig. of cortisol (Reichstein, 
1937a, 1937b), 300 mg. of corticosterone (Kendall, 1937) and 
6 mg. each of 11-deoxycortisol and 11-dehydrocorticosterone 
(Reichstein 8c von Euw, 1938) only were isolated.
From the preliminary extracts, crystalline steroids were 
found which possessed progestational,androgenic and oestrogenic 
biological activity (Reichstein Sc Shoppee, 19^3). In addition, 
a non-crystalline portion of the extract, called the "amorphous 
fraction", was found to contain the majority of the biological
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activity required to maintain life in adrenalectomised animals 
(Kendall, 19^2; Reichstein & Shoppee, 19^3; Kendall, 19^8). From 
this fraction, the steroid hormone, aldosterone, was eventually 
recovered and identified (Simpson et al., 1952; 1953)*
Vogt (19^3), in her classical experiments with dogs, 
demonstrated that the steroids present in adrenal venous blood 
were in higher concentrations than could be isolated from the 
cortex of these animals. This was a landmark in the investigation 
of the products of the adrenal cortex, but no detailed follow-up 
of these observations was possible at that time due to the 
inadequate techniques available for microchemical work. With 
the development of paper chromatographic systems by Zaffaroni anefe 
his colleagues (Zaffaroni & Burton, 1951; Burton et al., 1951) 
and by Bush (1952) a significant new research field was pioneered. 
These techniques together with the development of infra-red 
spectrophotometry (Jones & Dobriner, 19^9) and sulphuric acid 
chromagens (Zaffaroni, 1950) for the identification of steroids 
led to an upsurge in the investigation of the adrenal cortex which 
was necessitated by the discovery of the possible therapeutic 
application of cortisone (Hench et al., 19^8).
Under the direction of Hechter and Pincus working in the 
Worcester Foundation for Experimental Biology, the isolated beef 
adrenal gland was perfused in vitro and from these experiments,
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Following the in vitro perfusion of bovine adrenal glands
with C labelled acetate and cholesterol, Zaffaroni (1951) and
Hechter and their colleagues (1953) isolated both radioactive
corticosterone and cortisol. This has been confirmed using
different in vitro techniques for the incubation of other animal
adrenal glands (Haines, 1952; Heard et al., 195^5 Bligh et al.,
1955)• Cholesterol was the more efficient substrate for steroid
hormone production in most of these experiments, indicating its
more proximal position in the biosynthetic pathway from acetate.
However, from a comparison of the rates of incorporation of labelled
acetate and cholesterol into cortisol and corticosterone by perfused
bovine adrenal glands in the presence of ACTH, a path?/ay for the
formation of these hormones seemed to exist which bypassed
cholesterol (Hechter et al., 1955). This was confirmed in the hog
when radioactive corticosteroids were isolated following in vitro
"l*fincubation with acetate-1- C but the tissue cholesterol isolated 
possessed no radioactivity (Bligh et al., 1955).
The use of the in vitro perfusion technique of cattle adrenal 
glands was largely responsible for the delineation of the 
biosynthetic pathways from cholesterol. Using pregnenolone, 
progesterone, l?a-hydroxyprogesterone and 11-deoxycortisol as 
substrates, the isolation of cortisol was achieved in each experimen 
(Hechter et al., 1951; Levy et al., 1953; Levy, 195*0. Similarly
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corticosterone was found to be formed from pregnenolone,
progesterone and deoxycorticosterone (Hechter et al., 1951;
Hechter & Pincus, 195*0 • Similar findings were reported for the
biosynthesis of cortisol and corticosterone using homogenates
of animal adrenal glands (Plager & Samuels, 1952; Plager & Samuels,
1955; Dorfman et al., 1953; Samuels, 1953).
Cortisol, corticosterone and cortisone have been extracted
from human adrenal glands (Neher, 1958) and shown to be produced
in vitro from endogenous substrates (Cooper et al., 1958;
Dyrenfurth et al., I960). Using suitable steroid precursors,
normal and hyperplastic human adrenal glands and neoplastic
human adrenal tissue were found to be capable of the oxidation of .
the hydroxl group at position 3, and hydroxylation at positions
17, 21 and 11 (Hayano 8c Dorfman, 1952; Lombardo et al., 1956;
Lombardo & Hudson, 1959; Goldstein et al., I960; Roversi et al.,
1963). In vivo, the administration of cholesterol, doubly 
1*flabelled with C and tritium, resulted in the isolation of
cortisol and its metabolites in urine as well as some 17-keto-
'\k 3
steroids labelled with the same ratio of C: H as the administered 
substrate (Werbin 8c Le Roy, 195*t; Wabin 8c Le Roy, 1955) •
Cholesterol has been converted to pregnenolone and progesterone 
in vitro (Saba et al., 195**-? Lynn et al., 1955; Staple et al..
1956)• 20a-hydroxycholesterol was thought to be the intermediary
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(Lynn et al., 1955; So1 g» oh e t  aj.t 1956 ) and ACTH has been shown 
to have a stimulatory effect upon the utilization of not only 
cholesterol but also 20a-hydroxycholesterol in cell free enzyme 
preparations of bovine adrenal homogenates (Shimizu, 1963). 
A^-cholestenone has been found not to serve as a precursor of the 
steroid hormones (Hechter et al., 1953; Kowal et al., 196*fa) •
Although the reaction steps are not elucidated in full, 
cholesterol is established as a major precursor of the hormones in 
both man and animals. Following the formation of progesterone, 
it has been postulated that an orderly sequence of hydroxylations 
of progesterone occur at positions 17, 21 and 11 to form cortisol 
or positions 21 and 11 to form corticosterone (Hechter & Pincus, 
195*+; Samuels, I960). This appears to be true but other 
alternative routes for the formation of cortisol have been 
demonstrated recently.
Cortisol is the major steroid produced by both bovine and 
human adrenal glands (Pincus & Romanoff, 1953), yet using 
progesterone labelled with C, a greater net synthesis of 
corticosterone than cortisol was achieved (Eichhorn & Hechter, 1957 
Berliner et al., 1958) and the specific activity of the isolated 
corticosterone extracted after the incubation of human adrenal 
glands with progesterone was higher than that of cortisol 
(Mulrow & Cohn, 1961)• This suggested the existence of a
- 102 -
pathway for the formation of cortisol which did not include 
progesterone. Pregnenolone was found to be converted to 
17a-hydroxy pregnenolone, which was subsequently oxidised to yield 
17a-hydroxyprogesterone (Cox, i960) and it was noted that 17a- 
hydroxypregnenolone served as a substrate for the production of 
cortisol by normal human , rat and guinea-pig adrenal glands 
(Lipsett 8e Hokfelt, 1961) and by hyperplastic human adrenal glands 
removed from patients with Cushing’s syndrome (Mulrow et al., 1962). 
The in vitro incubation of a tumour causing Cushing's syndrome 
was shown to utilize 17<x-hydroxypregnenolone more efficiently 
than progesterone for the formation of cortisol (Weliky & Engel, 
1962). Pregnenolone was converted via 17a-hydroxypregnenolone to 
cortisol by a human hyperplastic gland at a higher rate than was 
progesterone when incubated concurrently (Weliky & Engel, 1965) »
but, although they suggested that progesterone served as a 
precursor primarily for the formation of corticosterone, other 
in vitro studies with human glands (Mulrow et al., 1962) indicated 
that, to the contrary, progesterone was the favoured substrate 
for cortisol formation when compared with 17a-hydroxypregnenolone. 
Progesterone has been found to inhibit the conversion of 
pregnenolone to progesterone by acetone powder preparations of 
bovine adrenal glands (Kowal et al., 196^ -b) and this may explain
the variation in the pathway to cortisol noted by Weliky and Engel 
(1963).
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21-hydroxypregnenolone has been isolated from human urine 
following the administration of ACTH (Dobriner 8c Lieberman, 1952) 
and this substance is known to be formed from pregnenolone by the 
adrenal of rats and rabbits (Pasqualini et al., 1964). This 
steroid has been found to be converted to deoxycorticosterone by 
bovine adrenal glands (Berliner et al., 1962; Kowal et al., 1964a) 
and to deoxycorticosterone and corticosterone by hyperplastic 
human glands (Pasqualini et al., 1964). Similarly, 17a,21- 
dihydroxypregnenolone can be metabolised to 11-deoxycortisol 
and cortisol (Pasqualini et al., 1964) and 17a,21,ll(3-trihydroxy- 
pregnenolone to cortisol (Kowal et al., 1964a). Consequently 
the action of the A^-3(3-hydroxysteroid dehydrogenase-isomerase 
system responsible for the formation of the A^-3ketosteroids 
can be delayed until the hydroxylations at positions 17,21 and 11 
have been completed in part or whole. Apart from the pathway 
involving the rate of conversion of 17a-hydroxypregnenolone to 
17a-hydroxyprogesterone, the relative importance of these routes 
compared with those involved in the formation of progesterone 
remains to be elucidated. However, the original concept of an 
orderly hydroxylation sequence folloxving the oxidation of 
pregnenolone would require but slight modification.
The principal adrenal androgens are testosterone, 
dehydroepiandrosterone (DHA), androstenedione, llfj-hydroxy- 
androstenedione and adrenosterone. DHA is produced in greater
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amounts than the remainder, between 15 and 25 mg, per day
(Vande-Wiele & Lieberman, I960), but most occurs as the sulphate
ester in both plasma and urine.
Both acetate and cholesterol serve as precursors of the
adrenal androgens. In humans, acetate has been converted to DHA
in vivo (Ungar Sc Dorfman, 1953) and to DHA, androstenedione and
ll(3-hydroxyandrostenedione by the in vitro incubation of slices of
the human gland (Bloch et al., 1956; Bloch 8c Benerischke, 1959)*
The formation of androstenedione and ll{3-hydroxyandrostenedione
from the precursor has also been shown in animals (Bligh et al.,
1955; Bryson 8e Sweat, 1962)*
Cholesterol has been noted to be an in vivo precursor of
DHA in a case of adrenal carcinoma (Ungar 8c Dorfman, 1953) and
in vitro in several "human adrenal adenomas (Burstein 8< Dorfman,
1962; Gual et al., 1962; Goldstein et al., 1963), and in the
foetal adrenal gland (Villee et al., 1959)*
ll|3-hydroxyandrostenedione has been extracted from normal
human adrenal glands (itfeher, 195$) while DHA and testosterone
have been found in adrenal tumours (Anliker et al., 1956; Plantin
/
et al., 1957) and androstenedione and adrenosterone in animal 
glands (Reichstein, 1936; Reichstein 8c Ewu, 19^1). Only 11£- 
hydroxyandrostenedione has been found to be formed in vitro from
endogenous substrates (Cooper et al., 1955; Cooper et al., 1958;
- 105 -
Dyrenfurth et al,, I960).
In 1953, Lieberman and Teich suggested that the conversion of 
pregnenolone to 17a-hydroxypregnenolone might represent the first 
step in the formation of androgens. Both steroids are good 
substrates for the formation of DHA, androstenedione and 
llj3-hydroxyandrostenedione in vitro by normal and pathological 
human adrenal glands (Goldstein et al., I960; Solomon et al., i960; 
Roberts et al., 1961; Bernstein & Dorfman, 1962; Gual et al., 1962; 
Weliky & Engel, 1962; Cohn et al., 1963; Weliky 8c Engel, 1965)* 
but only in the testis of the human and of the rat has 17a- 
hydroxypregnenolone been found to be converted to testosterone 
(Carstensen, 1961)• The extra-adrenal formation of DEA from both 
pregnenolone and 17a-hydroxypregnenolone has been suggested as a 
function of striated muscle (Oertel Sc Eik.-Nes , 1959). Both 
DHA and androstenedione have been produced on incubation of human 
adrenal tissue with 17a,21-dihydroxypregnenolone (Pasqualini et al. 
196*0 .
Although pregnenolone appears to be an obligatory intermediate 
in the synthesis of cortisol and corticosterone, its formation is 
not a prerequisite for the production of the adrenal androgens,
the formation of 17a,20a-dihydroxycholesterol as the only 
intermediate between cholesterol and DHA has been reported
•* 1
(Bernstein & Dorfman, 1962; Gual et al., 1962).
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Cholesterol may also be bypassed in the formation of androgensby
the hog adrenal (Bligh et al., 1955)» but recently another pathway
from cholesterol to DHA has been discovered. DHA as the sulphate
ester, has been found to be formed by homogenates of human normal
adrenal glands and tumours(Adams, 1963; Cohn et al., 1963; Migeon,
1963; Wallace & Lieberman, 1963; Adams, 1964; Bostrom et al., 1964;
Killinger & Solomon, 1965) and DHA-sulphate has been isolated from
the adrenal venous blood of a patient harbouring an adrenal tumour
(Baulieu, 1962). A recent study by Calvin and his colleagues
35(1963) demonstrated that pregnenolone sulphate - S could be
35metabolised in vivo to S labelled DHA-sulphate. The conversion
of pregnenolone sulphate to 17a-hydroxypregnenolone sulphate has
been reported in an incubation of hyperplastic adrenal tissue
(Calvin & Lieberman, 1964), but although pregnenolone was converted
to pregnenolone sulphate, 17a-hydroxypregnenolone sulphate and
DHA-sulphate by an homogenate of a normal human adrenal gland,
pregnenolone sulphate was not metabolised under these in vitro
conditions (Killinger & Solomon, 1965). The demonstration of the
presence of cholesterol sulphate in beef adrenal glands (Drayer
et al♦, 1964) and the in vivo conversion of cholesterol-7a-^H- 
35sulphate- S to DHA containing both isotopes in a case of adrenal 
carcinoma has revealed the presence of another biosynthetic route 
for the formation of androgens (Roberts et al., 1964). As
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DHA-sulphate and DHA are freely interconvertible (Roberts et al.,
1961), the supply of biologically active androgen may be regulated 
by such a mechanism. However, as DHA-sulphate can also be converted 
to oestrogens (Siiteri & MacDonald, 1963; Baulieu & Dray, 1963)$ this 
metabolic pathway may provide not only a reserve pool of androgen, but 
also be part of a general biosynthetic pathway.
Adrenal androgens, with the exception of DHA, may also be 
formed by a route involving progesterone. This steroid can be 
converted to 17a-hydroxyprogesterone and subsequent side chain 
cleavage by a desmolase to yield androstenedione as was first 
demonstrated in the rat by Savard and his colleagues (1956) and 
Slaunwhite and Samuels (1956). This pathway has been shown to 
occur in other animals (Rao & Heard, 1957s Kushinsky, 1963) and in 
human adrenal, tissue, normal, hyperplastic and neoplastic 
(Solomon et al., 195S; Kase and Kowal, 1962; Villee et al., 1962; 
Weliky & Engel, 1962; Roversi et al., 1963; Ward & Grant, 1963)*
By a double isotope technique, Kase and Kowal (1962) 
demonstrated that the yield of androstenedione and testosterone 
from the incubation of a normal human adrenal gland was greater 
from progesterone than 17a-hydroxyprogesterone. This accords 
with the finding of a biosynthetic pathway from progesterone to 
testosterone with testosterone acetate as the intermediate in 
Cladosporium resinae (Fonken et al., I960) and in human testes
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and ovaries (Dorfman, 1962), so that the formation of 17a- 
hydroxyprogesterone from progesteron may not be an obligatory 
step. Testosterone may also be formed from DHA via 
A^-androstenediol, thereby omitting androstenedione as an 
intermediate (Baulieu et al., 1963b),
DHA itself may serve as an intermediate in the in vitro 
(Meyer et al., 1955; Kosenfeld et al., 1955; Rubin et al., 1961? 
Bloch et al., 1962; Rubin et al., 1963) and in vivo (Mahesh & 
Greenblatt, 1962; Dorfman et al., 1963) formation of the 
A^-3-&etosteroid C ^  androgens.
Consequently, seven different pathways for the formation of 
adrenal androgens exist. Most recent evidence tends to point 
to cleavage of the C ^  side chain of the A,_-3p-hydroxy-pregnenes 
as being the most important method of their formation with the 
subsequent action of the A^-30-hydroxysteroid dehydrogenase systems 
upon DHA (Baulieu et al., 1963a; Cohn & Mulrow, 1963)*
CORTICOSTEROIDS AND ANDROGENS PRESENT IN ADRENAL VENOUS BLOOD
The biosynthetic schemes of the adrenal cortex have mainly 
been established by the study of in vitro one step transformations. 
By using radioactive substrates, many products have been detected, 
but such experiments give no indication as to which steroids 
represent the physiological secretions. This depends upon the
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demonstration that a given steroid appears in the adrenal venous 
blood or plasma in a concentration higher than that found in 
peripheral blood or plasma.
Cortisol and corticosterone are quantitatively the most 
important C ^  steroids present in the human adrenal effluent, in 
which they have been detected in patients with normal adrenal 
function (Romanoff et al., 1953; Hudson & Lombardo, 1955; Sweat, 195 
Grant et al., 1957; Lombardo et al., 1959; Short, I960) with 
either virilism (Bush et al., 1956) or Cushing’s syndrome (Sweat, 
1955)* Cortisol is always the major component of normal adrenal 
function and is present usually in ten times the concentration of 
corticosterone although the ratio is variable (pincus & Romanoff, 
1953). In vivo cortisol and corticosterone secretion rates 
confirm these findings (Petersen & Wyngaarden, 1955; Ayres et al.,
1957)• Although the level of both cortisol and corticosterone is 
elevated in Cushing's syndrome, only the level of cortisol rises wit 
the administration of exogenous ACTH (Hudson Sc Lombardo, 1955;
Grant et al., 1957).
Progesterone, 17a-hydroxyprogesterone, 11-deoxycortisol and 
cortisone also have been detected in normal adrenal venous blood 
but always in trace amounts (Lombardo et al., 1959; Touchstone 
et al., 1959; Short, i960), so that they have not been found in 
every sample assayed (Lombardo et al., 1959). However, after
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the administration of ACTH, the amounts of these substances are 
increased in the adrenal blood (Short, i960).
llp-hydroxyandrostenedione has been detected in adrenal 
venous plasma of normal (Romanoff et al., 1953; Sweat, 1955»
Grant, et al., 1957; Lombardo et al., 1959; Short, i960) and 
virilised patients (Bush et al♦, 1956), so that it was thought to 
be the major secreted androgen (Bush & Kahesh, 1959)* Trace amoun 
of androgtenedione have also been isolated (Sweat, 1955; Short, 
I960). However, testosterone has only recently been demonstrated 
in the peripheral blood and shown to be elevated 
due to adrenal adenomas (Dorfman et al., 1963).
The magnitude of the amount of DHA present- in normal urine 
has been appreciated only since i960 (Vande-Wiele Sc Lieberman, i960 
Almost all occurs as the 3-sulphate ester (Munson, et al., 1944) 
and it has been found in both peripheral and.adrenal venous blood 
in this form (Migeon & Plager, 1954; Clayton et al., 1955;
Baulieu, 1962). Trace quantities of free DHA do occur in the 
peripheral (Cohn et al., 1961) and adrenal venous blood of normal 
and virilised patients (Dorfman & Ungar, 1953; Bush et al., 1956; 
Bush & Mahesh, 1959; Iiirschmarfl et al. , I960; Short, i960) . The 
adrenal gland itself secretes DHA-sulphate as mentioned above and 
as has been shown by in vitro techniques (Cohn et al., 1963;
Migeon, 1963; Wallace 8c Lieberman, 1963; Bostrom et al., 1964).
A further C steroid, 7-keto-DHA has been isolated from normal 
19
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and pathological human urines (Fukushima 8c Gallagher, 1957) 
and as 7-keto-DHA-sulphate from the adrenal venous blood in a 
case of an adrenal tumour (Baulieu, 1962)•
ADRENOCORTICAL BIOSYNTHETIC ENZYME SYSTEMS
The most important positions of the steroid molecule which 
are hydroxylated by the adrenal glands of both man and animals 
are those at carbon atoms 17,21 and 11 of the steroid nucleus*
The 21 and 17<x-*hydroxylases are located in the soluble fraction 
of the cell (Plager 8c Samuels, 1955)* while the site of the 
lip-hydroxylase activity is in the mitochondria (Sweat, 1951*
Hayano 8c Dorfman, 1955). All three enzyme systems require reduced 
NADP and the llp-hydroxylase also uses molecular oxygen 
^Hayano et al., 1956). The original hypothesis was that the 
hydroxylations of the progesterone molecule occurred in positions 
17, 21 and 11 in that order (Hechter 8: Pincus, 1954; Eichhorn 8c 
Hechter, 1957). Once 21-hydroxylation has occurred, an effective 
block to 17a-hydroxylation became apparent. Similarly, when an 
oxygen function was substituted at the lip-position, no further 
hydroxylations occurred. However, the conversion of 11p— 
hydroxyprogesterone to further hydroxylated steroids by tissue of 
the zona glomerulosa of the human adrenal cortex has been observed 
(Grant, 1962). The possibility that more than one Up-hydroxylase
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exists has been raised (Erode, 1962; Sweat, 1962) and recent 
evidence obtained from a study of the urinary products, found in 
cases of congenital adrenal hyperplasia, postulated the presence 
of different 21-hydroxylase systems (Degenhert et al., 1965)*
Only one 17cc-hydroxylase appears to be present in human adrenal 
tissue.
Hydroxylations may occur at other positions of the steroid 
structure. With the exception of those occurring at positions 
16 and 19, no biological significance can as yet be attached to 
their presence.
Two mitochondrial enzyme systems capable of causing 
hydroxylation in either the 6a or 6j3 positions have been reported 
(Meyer et al., 1955)• Both 6a-hydroxyandrostenedione and 
6a,lip-dihydroxyandrostenedione have been found in adrenal tissues 
and a 6(3-hydroxy group has been shown to be added to progesterone, 
l?a-hydroxyprogesterone, androstenedione, deoxycorticosterone, 
corticosterone and cortisol (Hechter et al., 1951; Haines, 1952; 
Hayano & Dorfman, 1952; Meyer et al., 1955; Neher & Wettstein, 
1956; Howaczynski et al., 1962; Goldstein et al., 1963;
Pasqualini et al., 1964).
l6a-hydroxylation can occur in both animal (Rao 8c Heard,
1957; Wettstein et al., 1959) and human adrenal glands (Villee 
et al., 1962; Weliky 8c Engel, 1963). In one instance,
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l6a-hydroxyprogesterone was the major product from the incubation
of a hyperplastic human adrenal gland with progesterone-V* C
as substrate (Weliky & Engel, 1963) 5-pregnene-3a»l6a,20a-triol
has been isolated from the urine of a patient who had an adrenal
carcinoma (Fukushima et al., 1961)*
Incubation and. perfusion techniques have shown the presence
of a 19-hydroxylating enzyme system, located in the mitochondria
and shown to affect androstenedione, deoxycorticosterone and
11-deoxycortisol (Hayano & Dorfman, 1953? Kahnt et al., 1955*
Levy & Kushinsky, 1953? Meyer, 1953a).
The importance of this enzyme system may well be as an
intermediate step in the formation of adrenal oestrogens in that
incubation of adrenal tissue with 19-hydroxyandrostenedione
yielded oestrone (Meyer, 1955b), while that of the l6a-hydroxylase
system may be involved in the conversion of oestrone to oestriol
by the adrenal (Engel, 1962).
The presence of an adrenal enzyme system capable of converting
both and Ac;-3p-hydroxysteroids to those with a
d 1 1? 3
A^-3-ketone grouping was demonstrated by Samuels and his 
associates (1951). This Aj_-30-hydroxy steroid dehydrogenase 
system (A^-3f3HSD) was shown to required NAD (Samuels et al., 1951), 
to be a lipoprotein, and to be located in all cell fractions, 
but appeared in highest concentrations in the microsomes
-  I l k  -
(Beyer & Samuels, 1956). It was thought that this system 
effected both the oxidation ofthe p hydroxyl group at position 
3 and the shift in the double bond from the 5-6 to the k-5 position. 
Working with the micro-orgamism Pseudomonas testosteroni,
Talalay and Wang (1955) showed the presence of a separate 
isomerase component, effecting only the change in the position of
the double bond from ring B to ring A. A direct transfer of a
proton from position 4 to 6 on the enzyme surface without exchange 
with the media was also demonstrated. Isomerase activity 
could be shown to be present in rat liver and human peripheral 
plasma.
Beyer and Samuels (1956) used pregnenolone as the substrate 
for this enzyme system, measuring its activity by the isolation 
of the formed progesterone. However, the A,_-3p-hydroxy 
17-ketosteroid, DHA, was subsequently found to be utilized at a
higher rate (Rubin 8c Dorfman, 1957; Kowal et al., 196*fa) •
This enzyme system is important physiologically as its 
action is necessary for the formation of the C^  and 
A^-3-ketosteroids. In 1961, an impetus to further research into 
itsfunction was received by the finding of a deficiency of the 
enzyme in a small number of cases of congenital adrenal hyperplasia 
associated with virilism and a marked tendency to salt loss 
(Bongiovani, 1961). A deficiency of the 21-hydroxylase or
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llp-hydroxylase occur more commonly in this disorder, but of the 
aetiology of virilism due to adrenocortical tumours, little or 
nothing is known. A deficiency of the A^-3|3HSD has been 
reported in such tumours histochemically in tissue sections 
(Roversi et al., 1963; Goldman et al., 196*0, by the incubation of 
tissue (Rubin et al., 1963; Goldman et al., 196*0 and by urinary 
studies (Lipsett & Wilson, 1962). Other enzyme abnormalities 
have been noted in adrenal tumours by the study of the urinary 
steroids or their in vitro activity. Deficiencies of the 21 
and lip-hydroxylases have been recorded in some tumours (Lipsett 
& Wilson, 1962) and an increased activityof the 17a-hydroxylase 
of the tumour with subsequent desmolase action in another 
(Roversi et al., 1963).
Initially, only one A^-3pHSD system was thought to exist 
acting upon both C ^  and C ^  <d^-3|3-hydroxysteroids. In an 
incubation of an hyperplastic adrenal gland, Weliky and Engel 
(1962), using a double isotope technique, noted the absence of the 
A^-3f3HSD for pregnenolone, yet they isolated cortisol from the 
medium. They proposed that multiple substrate-specific 
A^-3{3HSD systems may exist in the gland. This was substantiated 
by the reports that not only did pregnenolone and DHA serve as 
substrates, but also 17a-hydroxypregnenolone, 21-hydroxypregnenolon 
17a,21-dihydroxypregnenolone, 11(3,17a, 21-trihydroxypregnenolone
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and ^_-androstenediol (Berliner et al., 1962; Baulieu et al.,
5 -----
1963b; Kowal et_al., 1964a; Pasqualini et al., 1964).
Biochemical evidence has now accrued confirming the existence 
of more than one A^-3f3HSD system. This has been shown 
histochemically in the mouse testis also (Baillie & Griffiths, 1964)
Mammalian isomerase activity appeared to differ from that 
found in bacterial preparations (Werbin & Chaikoff, 1963) and two 
substrate specific A -3-ketosteroid isomerase, each 
distinguishable from the A^-3p-hydroxysteroid dehydrogenase, 
were shown to exist in bovine adrenals (Ewald et al., 1964a).
The enzymes were named A^-pregnene-3i20-dione isomerase and
A^-androstene-3»20-dione isomerase according to the appropriate 
substrate utilized. Both isomerases were found to be associated 
with the microsomal and mitochondrial fractions of the cells 
(Ewald et al., 1964b; Kruskemper et al., 1964), but the 
Aj.-pregnene-3»20-dione isomerase was more tightly bound to the 
cell components then the A^-androstene-3,20-dione isomerase. 
Neither isomerase showed any coenzyme requirements (Kruskemper 
et al., 1964)•
In a further investigation of the Aj.-3£HSD system in bovine 
adrenal glands, Kowal and his colleagues (1964b), using acetone 
powder preparations, noted that both DHA and more especially 
androstenedione, inhibited the conversion of pregnenolone by
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inhibiting the A ^ -pregnene-3i20-dione isomerase. This same effect 
was noted with all the C ^  A ^-3p-hydroxysteroids tested, so that 
one system appeared to exist capable of acting upon all pregnene 
derivatives. Progesterone itself also inhibited the conversion 
of pregnenolone but did so by acting upon the dehydrogenase 
component of the A -3j3HSD system and not the isomerase. No
inhibition of the conversion of DHA to androstenedione was 
achieved with any C ^  A^-3p-hydroxysteroid or C^  A^-j3-ketosteroid 
tested, thus illustrating the presence of a separate system for 
DHA. These authors have postulated that the inhibitory effect 
of DHA, androstenedione, 110-hydroxyandrostenedione and 
testosterone upon the A^-33HSD systems for the pregnenes may 
explain the low or normal cortisol production in patients 
possessing virilising adrenal tumours. However, this does not 
explain the occurrence of Cushing*s syndrome and virilism due to 
adrenal tumours.
The inhibitory effect of progesterone upon the conversion 
of pregnenolone to progesterone was progressively decreased by 
subsequent hydroxylation at positions 17* 21 and 11. Consequently, 
there may be an in-built self-regulatory mechanism to control the 
concentration of cortisol produced by the adrenal cortex.
Only one dehydrogenase system has been found so far for 
the A^-3p~hydroxysteroids, but a separate dehydrogenase does exist
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for the saturated 30-ol compounds (Kowal et al., 1964b).
The conversion of a A^-3-alcohol to the corresponding
A^-3-ketone by bovine adrenal homogenates never goes to
completion (Samuels, 1933)* This may be due to the reversibility
of the A^-3pHSD system as was demonstrated using acetone powder
preparations of sheep adrenal microsomes (Ward 8c Engel, 1964).
In 1961, when the present work was commenced, little was
known about the A -38HSD system in the human adrenal cortex.
Using histochemical techniques, its distribution had been outlined
to be predominantly in the clear cells of the outer zona
fasciculata (Wattenberg, 1958; Dawson et al., 1961).
A technique was evolved by Rubin and her colleagues (1961)
which allowed measurement of the activity of the A -3J3HSD
3
system by the in vitro incubation of adrenal tissue using DHA 
as substrate and determination of the amount of androstenedione 
formed. The system was shown to be present in the adrenal glands 
of both man and animals.
Consequently, it appeared of interest to study in more 
detail the occurrence of the A^-3pHSD system in normal and 
pathological human adrenal tissues and to see if the administration 
of ACTH or cortisol or one of its synthetic analogues affected 
the activity of this enzyme system.
MATERIAL AND METHODS
The following trivial names have been used in 'the text.
Trivial Name
ACTH
adrenosterone
aldosterone
A._-androstenediol
3
androstenedione
cholesterol
corticosterone
cortisol
cortisone
dehydroepiandrosterone (DHA) 
deoxycorticosterone (DOC) 
11-dehydrocorticosterone 
11-deoxycortisol 
11-deoxy,19-hydroxycortisol
6a-lip-dihydroxyandrostenedione
Substance 
adrenocorticotrophic hormone 
A^-androstene-3fll»17-trione 
A^-pregnene-llp,21-diol-l8-al- 
3*20-dione
A^-androstene-3P,17P“diol
A^-androstene-3,17-dione
A_-cholestene-3p-ol
3
A^-pregnene-lip,21-diol-3,20-dione 
A^-pregnene-llp,17a,21-triol-
3,20-dione
A^-pr e gne ne-17a,21-diol-3,11$ 20- 
trione
A_-androstene-3P*"Ol-17-one
3
A^-pregnene-21-ol-3,20-dione 
A^-pregnene-21-ol-3,11,20-trione 
A^-pregnene-17«* 21-diol-3,20-dione 
A^-pregnene-17ot» 19 »21-triol-3,20- 
dione
A^-androstene-6a,llp-diol-3»17” 
dione
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Trivial Name 
17<x, 20a- di hy dr oxy ch ole s t e r ol 
17a, 21 - di hy d r oxyp r e gne noLo n e 
6p,17a-dihydroxyprogesterone 
6a-hydroxyandrostenedione 
7a-hydroxyandrostenedione 
7a-hydroxy-DHA 
7a-hydroxy-ll-deoxycortisol
7a~hydroxyoestrone
7tt-hydroxypregnenolone
l6a-hydroxyprogesterone
17(X-hydroxypregnenolone
17a-hydroxyprogesterone
20a-hydroxycholesterol
6p-hydroxyandrostenedione
6p-hydroxycorticosterone
6p-hydroxycortisol
6p-hydroxydeoxycorticosterone 
6 p-hydr oxyp ro ge s t erone
Substance
A -cholestene-3P»17a,20a-triol
5
A_-pregnene-3P117a, 21-triol-20-one 
3
A^-pre gnene-6 p,17a-di ol-3 * 20-dione
A^-androstene-6a-ol-3,17-dione
A^-androstene-7a-ol-3,17-dioae
A,--androstene-3p 17a-diol-17-one 
3
A^-pre gnene-7a,17a,21-triol-3,20- 
dione
A1 ^ ^^10^-estration-3P,7a~diol- 
17one
A^-pregnene-3p-7a-diol-20-one
A^-pregnene-l6a-ol-3»20-dione
A^-pre gnene-3 P,17a-diol-20-one 
3
A^-pre gnene-17a-ol-3,20-dione
A,.-cholstene-30»2Oa-diol
3
A^-androstene-6p-ol-3,17-dione 
A^-pregnene-6p, U p , 21-triol-3 » 20- 
dione
A^-pregnene-Sp,lip ,17a,21-tetrol-
3,20-dione
A^-pre gnene-6p,21-diol-3 »20-dione 
A^-pregnene-6p-ol-3,20-dione
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Trivial Name 
70-hydroxy-DHA 
70-hydroxypregnenolone 
110-hydroxyandrostenedione 
19-hydroxyandrostenedione
19-hydroxydeoxycorticosterone 
21-hydroxypregnenolone 
7-keto-DHA 
NAD 
NADP
pregnenolone
progesterone
testosterone
17a,21,110-trihydroxy-
pregnenolone
TISSUE PREPARATION
Substance
A_-androstene-30,70-<*iol-17-oEe P
A_-pregnene-30,70-diol-2O-one 
P
A^-androstene-110-ol-3»17",dione 
A^-androstene-19“Ol-3»17",dione 
A^-pregnene-19»21-diol-3 * 20-dione 
A^-pregnene-3P»21-diol-20-one
Ac.-androstene-30“Ol-7»17“<iione
P
nicotinamide adenine dinucleotide 
nicotinamide adenine dinucleotide 
phosphate
A,--pregnene-3P-ol“20-one
P
Aj^-pregnene-3,20-dione
A^-androstene-17p-ol-3-one
A_-pregnene-30,110,17a,21-tetrol-
P
20-one
Human adrenal glands were removed surgically from patients 
with metastatic mammary carcinoma or various adrenal disorders, 
and placed in polythene containers on ice for transit to the 
laboratory.
Bovine glands were obtained from Walter Black and Company
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Limited, Glasgow, Mouse adrenal glands were obtained from the 
Animal House of the Glasgow Royal Infirmary Pathology Department,
INCUBATION PROCEDURES
The adrenal glands were freed of connective tissue and fat,
weighed, chopped and minced in a Latapie Mill, The resultant pulp wa
homogenized in a hand piston-type glass homogeniser with a small 
volume of the appropriate medium, and diluted to a final concentration 
(W/V) of 100 mg,/ml., 200 mg/ml, or 300 mg/ml.
The homogenates were incubated in a Gallenkamp metabolic 
shaker at 37°C in air, or in an atmostphere of 95$> oxygen and 3% 
carbon dioxide when Krebs’ Ringer bicarbonate medium was used,
MEDIA
Three different media were employed,
(a) Equal volumes of 0.15^M sodium chloride and 0,1M phosphate 
buffer, pH 7*^» the latter being prepared from monopotassium and 
disodium phosphates.
(b) Krebs’ Ringer phosphate, pH 7*^
(c) Krebs’ Ringer bicarbonate, pH 7«^
Glucose and nicotinamide were added to both the Krebs* Ringer 
phosphate and bicarbonate media to a 0.01M final concentration.
- 123 -
SUBSTRATES
Dehydroepiandrosterone (DHA) (L. Light & Co.) was dissolved 
in propylene glycol to give a concentration of either 20 mg/ml. or 
50 mg/ml.
14 1 4Pehydroepiandrosterone-4- C (DHA-4— C) (New England Nuclear
Corporation, 141.0 pc/mg; Amersham, 117.0 pc/mg.) was diluted to
between 0.45 pc/mg. and 4.84 pc/mg. with unlaballed DHA.
14Androstenedione-4-j C (Amersham, 121.7 pc/mg.) was diluted 
with unlabelled androstenedione (L. Light 8c Co.) to give a final 
specific activity of pc/mg.
Pregnenolone-l6T (Amersham, 4.97 mc/mg.) was diluted with 
^Labelled pregnenolone (L. Light 8c Co.) to 0.5 mc/mg.
17a-hydroxypregnenolone-7T (New England Nuclear Corporation; 
44.3 mc/mg.) was diluted with unlabelled 17a-hydroxypregnenolone 
to give a final specific activity of 21.3 pc/mg.
Paper chromatography of these four substrates revealed only 
one zone of radioactivity.
14Progesterone-4- C (Amersham, 83*0 pc/mg.) was used with the 
supplied specific activity. Paper chromatography was not carried 
out to ensure a single radioactive zone.
14Cholesterol-4- C (Amersham 50.0 pc/mg.) was diluted with 
authentic cholesterol (L. Light 8c Co.) to give a specific activity 
of 4.8l pc/mg.
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COFACTORS
Diphosphopyridine nucleotide (NAD) (L. Light 8c Co.) was 
dissolved in 0.154M sodium chloride to give a concentration of 
30 mg./ml.
SOLVENTS
All solvents were of BDH ’’Analar” quality and were redistilled 
before use.
EXTRACTION PROCEDURES
All the incubates were extracted thrice with 5 volumes of 
either ethyl acetate for low concentrations of tissue, or three 
times with 5 volumes of benzene:chloroform (6:1) with large amounts 
of tissue. The pooled extracts were evaporated to dryness under 
a stream of air at 45°C.
COLUMN CHROMATOGRAPHY
Silica Gel Davison (USA) Grade 12 (L* Light & Co.) was used 
without further activation.
Aluminum oxide, BDH ’’for chromatography” grade was employed, 
also without prior activation.
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PAPER CHROMATOGRAPHY
Whatman No. 1 paper for chromatography was used throughout.
The paper was washed in a soxhlet extractor with chloroform, 
benzene, ethyl acetate and methanol prior to use.
The paper chromatographic systems used were those of 
Zaffaroni (Zaffaroni & Burton, 1951; Burton et al., 1951)>
Savard (1953) and Bush (1952).
SPECTROPHOTOMETRY
A Unicam SP500 spectrophotometer was used to determine the 
absorption of light at 225 mp, 240 mp and 255 mp by steroids absorbii 
in the ultra-violet. The criterion of a reliable curve was the 
finding of an optical density at both 225 mp and 255 mp which was 
approximately half the optical density at 240 mp. Steroids 
possessing a 17-ketone group with or without a A^-3-ketone 
structure, were determined by the Zimmermann reaction (Zimmermann 
1935; Fotherby, personal communication).
DETECTION AND QUANTITATION OF RADIOACTIVE STEROIDS
Radioactive steroids were located on paper chromatograms 
using a windowless gas-flow Nuclear Chicago 4 Jf Actigraph II.
Samples for quantitation were plated at "infinite thinness” 
and counted by an Isotope Development Limited (IDL) end-window
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automatic solid sample counting 601*f system, operating at 6%
5efficiency for carbon-1^- (1,32 x 10 cpxq/iic- C), A Ti?acer-Lab 
SC16, windowless gas-flow solid sample counting system connected 
to a Panax Scaler (T300) was used for tritium, operating at 32% 
efficiency (7.04- x 10 cpm/iic - tritium). Constancy of specific 
activity of the isoJ^ed steroids was considered established if 
the variation in the specific activity of the steroid and any 
derivatives made was within the 5% standard error of net activity 
(Calvin et al., 19^9)•
FORMATION OF STEROID DERIVATIVES 
Acetylation.
Acetylation was performed by dissolving the steroid in 
pyridine and adding an equal volume of acetic anhydride, and 
leaving overnight at room temperature (DeCourcy et al,, 1933)* 
Saponification,
The steroid acetates were hydrolysed using 0,k% methanolic 
potassium bicarbonate according to the method of Meyer (1953)•
This method was found to be unsuitable for the complete hydrolysis 
of 3P-acetoxyl groups for which a method using methanolic sodium 
hydroxide was substituted (Bush, 1961),
Oxidation.
The oxidation of certain side chains to give 17-ketones was
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performed using acetic acid and a 2% (W/V) aqueous solution of 
chromium trioxide according to the method of Lieberman and his 
colleagues (1953)*
ASSAY OF THE A..-3 8-HYDROXYS TEROID DEHYDROGENASE 
SYSTEM UTILIZING DHA
METHODS
The assay procedure is a modification of that proposed hy 
Rubin and her associates (1961), 1*6 ml. of a 20% (V//V) homogenate
prepared in equal volumes of 0.15*+M sodium chloride and 0.1M 
phosphate buffer (pH 7**0 » were added to each flask containing 
6 mg. NAD and 500 p-g* DHA for a final volume of 1.80 ml. A 
tissue blank with a similar amount of tissue and equal NAD 
concentration was also prepared. In all the experiments, at 
least duplicate incubations were undertaken. Following incubation 
in air at 37°C for 30 minutes, the media were diluted with 3 volumes 
of distilled water and extracted three times with 5 volumes of 
ethyl acetate. The pooled extracts were taken to dryness.
Attempts to determine the concentration of A^-3~ketosteroids 
formed by direct ultra-violet spectrophotometry of the extracts 
against the tissue blank extract, as recommended by Rubin and her 
colleagues (1961) were unsatisfactory. Therefore, the method 
was modified to include a '’preparatory" silica gel column.
1*5 g* silica gel columns, slurried in benzene, were set up!.
The extracts were added to the column with two 10 ml. washes 
of benzene and the steroids were eluted by stepwise increments 
of ethyl acetate:benzene as outlined in Table XX and Figure 37.
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TABLE XX
SILICA GEL COLUMN CHROMATOGRAPHY 
Standard Protocol
Fraction
number
% Ethyl acetate 
in benzene ml. collected
1 100% benzene 30
2 5% 20
3 10% 20
k 20% 20
5 50% 20
6 100% ethyl 
acetate
20
ju
g.
 
D
H
A
 
gg
. 
A
N
D
R
O
S
T
E
N
E
D
I
O
N
E
17-5
15g. SILICA GEL C O L U M N  
STANDARD A N D ROSTENEDIONE
150
7-5
5 0
650 3 41 2
FRACTION N U M B E R S
1-5g. SILICA GEL C O L U M N  
\  S T A N D A R D  DHA
12-5
10-0
5 0
2 5
0 1 52 3 4 6
FRACTION N U M B E R S
Fig. 37.- Silica gel column chromatography.
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No separation of DHA from androstenedione was achieved, but a  
satisfactory measurement of A^-3-ketosteroids could always be 
obtained when read against the tissue blank. The recovery of 
standard DHA and androstenedione from the columns averaged 90%•
The recovery of androstenedione, added to a suitable tissue blank 
and processed in the same manner as the incubation samples, 
averaged No correction of the results is made for the
losses incurred during extraction and chromatography.
The results are expressed as y,g. U.V. absorbing steroid formed 
per minute per mg. nitrogen. The nitrogen content of the 
homogenate was determined by the method of Nayyar and Glick (195*0*
RESULTS
Seven human adrenal glands, removed from patients with 
metastatic mammary carcinoma with normal adrenocortical function, 
were assayed (Table XXI). The results show g. wide scatter 
from 1.36 to 2.50 p,g. steroid formed per minute per mg. nitrogen.
The assay of eight hyperplastic glands associated with Cushing's 
syndrome also reveals a broad spectrum of results (Table XXII).
The mean rate of production by normal glands is 1.83 - 0.*f6 as 
opposed to 1.9*f - 0.^1 p,g. per minute per mg. nitrogen for the 
glands found in Cushing's syndrome (Table XXIIl). The statistical 
difference between the two means is not significant (P = <0.7 ,>0.6).
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TABLE XXIII 
A^-3fi-HYDR0XYSTER0ID DEHYDROGENASE ASSAY 
Comparison of Normal and Hyperplastic Glands
The data recorded in this Table are 
derived from Tables XXI and XXII
Type of 
adrenal gland
Total number 
of glands
pg UV absorbing 
steroid formed per 
minute per m^. nitrogen 
mean - SD
Normal 7 1.83 * 0.46
Hyperplastic 8 1.94 - 0.41
t test P <T 0.7 } 0.6
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In Cushing^ syndrome associated with bilateral adrenocortical 
hyperplasia, an increase in the plasma concentration of ACTH has 
been reported (Davies et al., I960). Thus each hyperplastic 
gland has been exposed to high blood levels of ACTH for varying 
periods of time. Consequently, ACTH of endogenous origin does 
not appear to alter the activity of the enzyme system measured 
in vitro under the experimental conditions used here. Moreover, 
the administration of ACTH pre-operatively, in pharmacological 
doses, also fails to elicit any change in the activity in either 
normal or hyperplastic glands. (Glands 1 and 3* Table XXI and 
Gland 14, Table XXII).
Prednisone, a synthetic analogue of cortisone, causes no 
change in the activity (Gland 7i Table XXI).
ALTERATION OF THE ASSAY TECHNIQUE
An ideal assay for such an enzyme system is one which not
only gives reproducible results, but also requires a small amount
of tissue. With these requirements in view, a further modification
of the method of assay of the A^-3PHSD system for DHA was 
undertaken.
METHODS
0.3 ml. of a 10% (W/V) homogenate, prepared in equal volumes
- 135 -
of 0,154m sodium chloride and 0.1M phosphate buffer (pH 7*4), 
was added to each flask containing 6 mg. NAD and 200 p,g. DHA, 
giving a final volume of 0,7 ml. At least triplicate incubations 
were prepared, together with a suitable tissue blank similar in 
all respects except lacking the addition of the substrate DHA,
The incubations were performed for 30 minutes in air at 37°C 
and following dilution with 4 volumes of distilled water, they 
were extracted three times with 5 volumes of ethyl acetate.
The pooled extracts, following evaporation to dryness, were 
submitted to silica gel chromatography as previously outlined
(p. 128).
The results are expressed as p,g. U.V. absorbing steroid formed 
per minute per mg. nitrogen as before.
RESULTS
Direct comparison of the two methods is outlined in Table 
XXIV, The activity of the enzyme system, expressed in y,g. steroid 
formed per minute per mg. nitrogen, is increased bya factor of 
between 2 and 2.5 using 50 mg. of tissue compared with the 
incubation of 320 mg., in both normal and hyperplastic glands.
This is most probably related to the relative increase in the 
concentration of NAD present in the incubates of smaller tissue 
amounts, the A^-3(3HSD having been shown to be NAD dependent
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(Samuels et al,, 1951)* No further experiments were made to 
determine the optimal requirements for NAD in human adrenal glands 
by the A^-3PHSD system. The concentration of NAD used in the 
initial experiments was that reported to be optimal under similar 
conditions to the present (Rubin et al., 1961)•
Of the eight glands studied by this method, only two were 
associated with normal in vivo function. The pre-operative 
administration of ACTH or prednisone did not appear to alter the 
activity of the enzyme system (Table XXV).
Five hyperplastic glands associated with Cushing's syndrome 
(Table XXVI) showed activities ranging from 4*0 to 4.98 ]xg. per 
minute per mg. nitrogen with a mean of 4.57 - 0.40 mg. Although 
there would appear to be a tendency towards higher activity in 
Cushing's syndrome due to bilateral hyperplasia, statistical 
confirmation could not be obtained due to the small sample of 
normal glands. However, glands 18 and 19 (Table XXVI) fall 
within the activity level found in normal tissue so that it is 
possible that there is no real difference. The adenoma causing 
Cushing's syndrome (Gland 23, Table XXVI) exhibits an enzyme 
activity in the upper range of that found for hyperplastic glands. 
This is probably related to their high content of clear cells 
which show a high A,--3£HSD system activity histochemically 
(Wattenberg, 1938; Dawson et al., 1961) and by the in vitro
>
H
am
a
►H
<m
co
<
to
C5O
PES«
WH
ft
ft
HO
EH
CO
fx
XO
§
N
WI
co.
K\
Iin
Sh
0*H
<H
SJ
,0
0
-p
0ja
ftn
o
rH
a
.S3 id
ft <0
10 a
T 3 s  © 3 ••$3 H P rH 0
0 •  cd o 0
rH o  a > cd
o o .S3
rt3 bO pH ft
H S3 O  Cd 1
cd <d g  a 10
a O  -H cd
o> ©  rd ft o
u ts
TS •H
<4 Sh { >
o  \
a H  ?S
cd .S3
a o
aS o3.
W a o0 H •
H •H &0 •
cd t J ch  • ; ±  ®
a O  O  bO 0
sh co a O  P
o • O
s £  H V O OJ S3a 
in
pH m  ft
* * <A0 0 3
•H
•* a
W O p m
a 0
S3 S3
•H 0
t3 0
0 •H
S EH
bO
S3 TS Sh
•H 0 0  S3
a ft ©
Sh Sh bO
O o 0  O
0 -P  Sh o m
3  P rH OJ
cd 'cs S3 -H • •
•H •H S3 J * -3 -
> O g
b Sh •
0 Sh bO
• P © a
bO 0 ft
?1
S3
0
bO «H 0
O O -P
Sh 0
P •  S3 vo c\i
■H r-j 0 rH in
S3 a  bo 
o
•
rH
•
pH
• u a
bO 0 o
a ft H3
faO
S3 TS
•H 0
p  a
u u
o o
0  «H ON ON
P • •
© T3 rH VO
•H O - ON
>  o
b  Sh
0
• p
bO 0
0 .
>>
0TS
\
>» •
0 0 bO
> T3 a
•rH \
P  >> • O
0 ft f t m 0
Sh cd • si
0  Sh H  0 © p
f t  0 S3 S3
0 Si
1 p
Q  0 
-if TS
O
0
O
a
0 •d
S-t '■ -4 ' S3 m
ft f t ■0
EH Sh
o  o
0
Sh
Sh
o
«aj ch ft ^
p
•0 .S3 O IN
S3 bO • rH <\J
cd •H bO • •
rH 0 VO OJ
O =!
Sh
Ti 0
S3 S> VO o-
0 a rH iH
H as
O  S3
a
So
d
©
T3
<
rH
Ctf
o
•H
-P
dO
OO
d
a>
d
T3
<«!
d
<< d fc>
03 x
03 'd x
d
d ©
pq rH
03 d X
< •H dS3 ra Eh
P3 d
CD rH d
O ft •H
p s d
o © w
HI X ft d
W >3
X W w ra
ft d
H o
pq « d •H
i-l M o -Ppq O •H •rl
< PS -P
EH pq d d
EH O o
03 o oo
M d dO © o
PS d •Ho T5 -PX < d
w X1 rH dca d o
m d d
l © H
lf\ -p 
<1 drH
•rl
pq
I
a>
S
o
d
T3
d5^03
ra
"k
d
•rlJ4
ra
do
Ti
g
. 
UV
 
a
b
s
o
rb
in
g
 
s
te
ro
id
 
fo
rm
e
d
 
p
er
 
m
in
u
te
 
p
e
r 
m
g.
 
n
it
ro
g
e
n
o
H
.
O•
m
ON
•
-3"
O
in
•
J -
00
ON
•
-d"
ON
in•
-d"
H
O•
in
ovo
•
-d*
d
© «H ©
bO O -P
o  d
d • d ON VO o in n - o
•p H © H LfN o H m OO VO O
•H S bo . • • • • • • •
d  o H H CM H H H H CM
d  a
• © o
bO f t .d
a
bO
d  ts
•H ©
. f t  a
d  d
O O
ra «h NO O m O oO O O O
X • • . • • • • •
d  h m -dh 00 H O CM m 00
•H tN ON •d- IN o m CM m
>  o H H H H H
ft> d©
• -P
bo ra
d-
©
>
•H
-P
d f td d© d 1 i I 1 1 1
f t  ©
o  X
1 -P
©
d
f t
+> o O O CO O
•d X O KN m CM -d- m
d  bO • • • • • . •
d  -H bo n - OO oo O- CO oo
H  © H
CD 5
dH ©
d  . f t *
d a 00 ON o H CM tn
H  d H H CM CM CM CM
CD d
*0
©
-P
d
.ft
d
o
d
•H
ra
d
o
*H
-P
d
O
f t
©
-P
d
d
d
f t
©
ra 1
© ON
© m
d H
X
•ft 1
1
d
S
o
d
©
T3
d
H
d
o
•rl
-P
d
O
O
O
d
©
d
<X5
<
*
- lAo -
incubation of clear cells with DHA as substrate (Grant, 1962).
The results are summarised in Table XXVII. The finding 
that variation in the in vivo level of ACTH does not alter the 
overall activity of the enzyme system when determined by either of 
the described techniques accords with the reports that neither 
hypophysectomy in rats (Samuels & Helmreich, 1956) nor cobalt 
irradiation of guinea pig pituitary glands (Rubin & Dorfman, 1957) 
altered the activity of the A,_-33HSD system utilizing DHA.
Cortisol or its synthetic analogues was without effect upon 
the enzyme in animal adrenal glands (Rubin & Dorfman, 1957) and 
was found to be without effect in the two normal human adrenal 
glands of the present series.
Although the values obtained from both normal and hyperplastic 
tissue varied from gland to gland, individual values found for 
any one homogenised gland, using duplicate or triplicate assays, 
were within 6%. This variation in activity has been demonstrated 
by other workers in rat, mouse and beef adrenal glands (Samuels, 
1953; Rubin et al., 1961) and even between paired glands from the 
same animal (Rubin et al., 1961). This variability, consequently, 
would appear to be inherent in the assay of the enzyme system by 
these procedures in the various species cited, including man.
The value of 1.83 - 0.46 ;xg U.V. absorbing steroid formed per 
minute per mg. nitrogen is much lower than that reported in
TABLE XXVII
A -3 P -H YDROXYSTERQID DEHYDROGENASE ASSAY
Comparison of Normal and Hyperplastic Glands
The data recorded in this Table are 
derived from Tables XXV and XXVI
Type of 
gland
Total number 
of glands
Hg. UV steroid 
formed per minute 
per mg. nitrogen 
mean - S.D.
Normal 2 4.18
Hyperplastic 5 4.37 - 0.40
- l4l -
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normal human glands by Rubin (1961) and Bloch (1962) and their 
colleagues. They found 3*9 and 8.2 jig androstenedione to be 
formed per minute per mg. nitrogen under similar conditions.
In an adenoma associated with Cushing's syndrome, values of 2.2 
9.3» 28.0 and 31.6 p,g. androstenedione formed per minute per 
mg* nitrogen were reported for four separate areas of the same 
tumour. Apart from the broad scatter of these figures, these 
higher values are difficult to reconcile with either of the 
present series. However, in these published experiments, the 
U.V. steroids formed were measured spectrophotometrically against 
a tissue blank directly after extraction. This procedure was 
never satisfactory in the present series and never yielded 
satisfactory U.V. absorption curves.
The use of a preparatory column and extraction procedures 
did not entail losses greater than 22%. Consequently, the 
difference between the reported results and those of the present ser 
may be due to the relatively higher purity of the steroids 
measured spectrophotometrically following column chromatography.
Four tumours have been assayed for their content of the 
Aj_-3{3HSD system for DHA (Table XXVIII) • Gland 24 was removed 
at operation from a patient suffering from Cushing's syndrome 
and virilism ("mixed" Cushing's syndrome) and the enzyme activity 
was much lower than normal. Under similar conditions, Rubin and
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her co-workers (1963) studied a carcinoma associated with 
Cushing's syndrome and also noted that it possessed a lower 
enzyme activity than normal.
Of the three tumours associated with the adrenogenital 
syndrome, two (Glands 26 & 27» Table XXVIII) did not possess 
measurable A^-3pHSD activity. This accords with the reports of 
an absence of the enzyme system in virilising tumours as was shown 
on ift vitro incubation by Goldman and his colleagues (l96*f) and 
histochemically by Roversi and his associates (1963).
However, not all virilising tumours exhibit an absolute 
deficiency of this enzyme system, but can show lower than normal 
activities (Gland 25» Table XXVIII; Rubin et al., 1963;
Goldman et al., 196^ -) •
The relative deficiency of the A^-3£HSD system demonstrated 
here in a tumour causing Cushing's syndrome and one causing 
the adrenogenital syndrome gives no indication as to whether the 
activity of each cell is low or whether some cells lack the 
enzyme completely, while others possess it in normal amounts.
The histochemical studies reported in the first part of this 
thesis favour the former hypothesis that all cells possess a 
lowered enzymic activity; however, Goldman and his associates (I96*f) 
demonstrated histochemically that the enzyme was only present in 
certain focal areas of one tumour, associated with virilism, 
studied by them.
ASSAY OF THE A_-33-HYDROXYST2ROID DEHYDROGENASE ------------  5 —c------------------------- ----
•ik
SYSTEM UTILIZING DHA-^f- C
The assay of the A^-3PHSD system using unlabelled DHA as
substrate allows comparison of the activity of this enzyme system
between various types of human adrenal glands, but it contributes
no information as to the number and relative proportions of
steroids formed from DHA. Nor does it ensure that androstenedione
the expected product is the only U.V. absorbing steroid formed.
Moreover, it is possible that androstenedione may be formed from
other endogenous sources which may vary in proportion from gland
to gland. Consequently, to ensure that the assay technique
gave a valid measure of the activity of the enzyme system, it
*] A-was decided to substitute DHA-^ f- C for the unlabelled DHA, used 
previously, as the substrate and to estimate the radio-active 
steroids formed by such incubations and to determine whether all 
the androstenedione formed was derived only from the added 
substrate,
METHODS
The standard assay procedure, using 0,5 ml, of a 10% (W/V) 
homogenate prepared in equal volumes of 0,13^ - M sodium chloride and 
0,1M phosphate buffer with 6.0 mg NAD added, was retained, 200 pig,
«lZf
of DHA- f^- C were added to each flask in 0,01 ml, propylene glycol.
-  Ik5 -
- 1^6 -
The specific activity of the labelled substrate varied from 
60 cpm/y,g. to 6k0 cpm/Vg., but was constant within each 
incubation. The incubates were extracted with 5 volumes of 
ethyl acetate after a 30 minute incubation as previously described.
Alumina column chromatography was substituted for the silica 
gel column procedure, 7*5 £• alumina columns were established 
in 0.225% ethanol in benzene, and the extracts were eluted with 
stepwise increments of ethanol in benzene, 32 fractions being 
collected. The standard alumina column protocol is shown in 
Table XXIX.
From Figure 3&a it may be seen that good separation of the 
authentic standard steroids, androstenedione, DHA and llp-hydroxy- 
androstenedione, was achieved, the average recovery of each 
compound being 90%. However, llj3-hydroxyandrostenedione could 
not be separated from adrenosterone or testosterone by this column 
procedure.
Ultra-violet absorbing steroids were measured spectro­
photometrically at 2*f0 my, and DHA was estimated by the Zimmermann 
reaction (Zimmermann, 1935; Fotherby, personal communication). 
Aliquots of each column fraction were assayed for radio-activity 
and the specific activity of each isolated steroid was determined. 
Constancy of specific activity was achieved by repeated paper 
chromatography in several of the systems of Bush (1952) without
rHOOO
-P
ou
CU
r&u
«5
t3
S
trS
•p
CQ
T3 
<D 
-P 
• O
H  © 
S H
o
CM 20 20 20 oCM 20 20 20 20 oCM 20 20 20 20 20
O
IA
O
O
%
 
e
th
a
n
o
l 
in
 
b
e
n
ze
n
e
LA
CM
ON
•
O
o
LA
ON
•
o
IA
A-
cr\
•
O 1
.0
!
o•
CM 3
.0 O•
-4"
o
.
LA 6.
0 O•
A-
o•
oo
0*01 20
.0
o•
3
o•
o
LA
0*001
F
ra
c
ti
o
n
n
u
m
b
e
r
17 ooH
ON 
r-!
o
CM
H
CM
CM
CM
IA
CM
-3"
CM
LA
CM
vO
CM
A-
CM
oo
(M
ON
CM
O
fA
rH
fA
CM
IA
T3 
© 
-p  
• o
H  ©
a  h
o
fA
O
lA
o
IA
LA LA O
IA
O
IA OIA
o
CM
O
CM
O
CM
O
CM
OCM
O
CM
O
CM
O
CM
o
O
©
rH
O ©
«  N
a  s
X l © 
-P X  
©
LA
CM
CM•
O
O
LA
CM•
O
LA
A-
CVJ
•
O
LA
A-
CM
•
O
O
o
IA
•
O
O
O
IA
«
O
O
O
-d"
.
o
O
o
IA•
O
O
o
VO•
o
O
o
A -
•
O
O
LA
A -•
O
O
O
OO.
o
LA
CM
00•
O
O
LA
OO•
O
I A
A -
00•
o
O
O
ON
•
O
-H
F
ra
c
ti
o
n
n
u
m
b
er
rH CM fA -4- L A vO A- oo ON o
pH 11
CM
rH
IA
rH
-*
rH
LA
rH
VO
rH
I
A --d-H
I
Tc
pm
 
x 
10
'3 
H°
- 
s
t
e
r
o
i
d
600
500
ANDROSTENEDIONE
11 {3-HYDROXY - ANDROSTENEDIONE
DHA
7-5g. ALUMINA C O L U M N  
STANDARD STEROIDS
100
3 6 9 12 15 16 21 24 27 30 32
FRACTION N U M B E R S
B
70
60
7 5 g. ALUMINA C O L U M N  
INCUBATION EXTRACT
III
50
30
2-0
IV
1-0
3 6 9 12 15 18 24 27 30 32
FRACTION N U M B E R S
Fig. 38." Alumina column chromatography.
- 148 -
the addition of carrier steroid. Acetylation of DHA and 
subsequent hydrolysis were performed in the initial experiments 
to confirm its identity. Androstenedione was rechromatographed 
with authentic carrier androstenedione for its identification. 
Constancy of specific activity from columns and several paper 
systems was considered to be sufficient identification.
The results are expressed as ]xg. U.V. absorbing steroid 
formed per minute per mg. nitrogen of the original homogenate.
No correction for extraction and column recoveries is made.
RESULTS
Alumina column chromatography of extracts of the incubates 
revealed the presence of five radio-active peaks (Fig. 38b). 
Peaks I and II corresponded to authentic androstenedione and 
DHA respectively. A prominent shoulder to peak II was 
observed in a few assays possibly representing trace amounts 
of lip-hydroxyandrostenedione, adrenosterone and testosterone, 
while peaks III, IV and V did not match the mobility of any of 
the following authentic steroids: ll{3-hydroxyandrostenedione,
6p-hydroxyandrostenedione, 19-hydroxyandrostenedione.
The steroid corresponding to peak III absorbed U.V. light 
and gave a positive Zimmermann reaction with dinitrobenzene.
Its identity at this time was unknown, but it was assumed to be
- 1^9 -
a 17-ketosteroid possessing a A^-3-ketone grouping in Ring A of 
the steroid molecule* In no instance did the steroid peaks IV and 
V, eluted from the columns, give U.V. absorption curves* This 
was assumed to be due to their being either A^-3P”hydroxysteroids 
or A^-3>-ketosteroids present in only trace amounts*
Consequently under the present conditions, the assay of the 
Ap.-3PHSB using DHA-*4— C as the substrate revealed two principal 
products which absorbed U.V* light, one of which was identified 
as androstenedione and the second of unknown structure*
Two normal adrenal glands, removed surgically from patients 
with metastatic mammary carcinoma, and five hyperplastic glands 
removed at operation from patients with Cushing’s syndrome, were
it
assayed using this procedure. Tables XXX and XXXI show the 
Tig. of DHA recovered and the y,g. of androstenedione and of the 
unknown steroid (peak III) formed by the incubations of these 
glands* Each value represents the results of a single assay with 
the exception of gland in which three separate assays of the 
same homogenate were examined. In each assay, the specific 
activity of both isolated steroids lies within 10% of the 
substrate DHA-4- C isolated after incubation, this figure being 
within the 5% standard error of net activity used (Calvin et al*, 
19^9; p«126).
TABLE XXX
A^-3ftHYDR0XYSTER0ID DEHYDROGENASE ASSAY
Normal and Hyperplastic Human Adrenal Glands
Medium; 0.154m sodium chloride and 0.1M phosphate buffer (lsl) 
Tissue; 0.5 ml. of 10% (W/V) homogenate
Additions; NAD, 6.g mg. Final Volume 0.7 ml.
Substrate; DHA-4- C, 200 jig., specific activity varying from
60 cpm/|Lg. to 640 cpm/p-g.
Incubation Time; 30 minutes. Gas-phase; air.
Gland
number
Type of 
gland
Gland
weight
g*
Isolated Steroids
DHA (peak II)* Androstenedione (peak I)*
Pg.
Specific activity 
' cpm/vig. VS*
Speoific activity 
cpm/p,g.
28 Normal 3.84 122 71 34 72
29 Normal 3.50 93 60 21 61
30 Hyperplasia 8.30 61 640 71 662
31 Hyperplasia 7.78 98 216 36 214
32 Hyperplasia 8.30 101 234 37 233
33 Hyperplasia 8.48 92 480 66 468
34 Adenomatoushyperplasia 10.0
76 167 59 155
90 107 30 105
’■So ' 162 30 153
* see Fig. 38b.
/ counts per minute
- 130 -
TABLE XXXI
Ar- -3 & -HYDROXY S TERQID DEHYDROGENASE ASSAY 
Normal and Hyperplastic Human Adrenal Glands
Incubation conditions as in Table XXX
Isolated Steroids
Gland
weight
g.
DHA (peak I)* Peak III*
Gland
number
Type of 
gland ^g.
Specific activity 
'cpm/p.g. Tig.
Sepcific activity 
' cpm/ng.
2 8 Normal 3.84 122 71 27 73
29 Normal 3.50 95 6 0 53 6 0
30 Hyperplasia 8.30 6 1 64o 54 620
31 Hyperplasia 7.78 98 2 1 6 39 210
32 Hyperplasia 8 . 3 0 101 234 46 243
33 Hyperplasia 8.48 92 48o 1 8 435
76 1 6 7 38 1 8 6
34 Adenomatoushyperplasia 10.0 90 1 0 7 59 107
8 0 1 6 2 65 154
* see Fig, 38b.
/ counts per minute
- 151 -
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Thus both steroids are derived only from DHA under these
conditions. The sums of the A^-3“ketosteroids formed from the
substrate are expressed as p.g U.V. absorbing steroids formed
per minute per mg. nitrogen and are shown in Table XXXII.
The mean rate of production - SD of U.V. absorbing steroids
1 +in hyperplastic glands is 4.79 - 0.51 per minute per mg. nitrogen,
Considerable variation in the activity of this enzyme system is
apparent between individual hyperplastic glands. This may be
related to variable amounts of compact cell tissue from the
zona reticularis, which givds anegative histochemical reaction
for the A.--30HSD, included in the homogenates from individual 
5
glands. An explanation of the varying amounts of formed 
androstenedione and the unknown steroid found in the same 
homogenate from gland 3^ Is difficult to explain. Although 
androstenedione composed between 32% and 6l% of the total steroid 
formed by the incubation of this gland, less than 5% difference 
was detected between these three homogenates in their production 
of total steroid (i.e., the sum of androstenedione and the
14unknown steroid) from DHA-4- C.
The average rate of formation of U.V. absorbing steroids by 
the tv/o normal glands studied was 4.0 jig. per minute per mg. 
nitrogen and of the f ive hyperplastic glands 4.79 - 0.51 jig.
There seems to be a slight increase in hyperplastic glands, but
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no statistics can be applied due to the small number of normal 
glands for comparison. A similar problem in interpretation 
existed when unlabelled DHA was used as the substrate (Table 
XXVII), but some of the values found in those hyperplastic glands 
also fell within the normal range. However, the possibility 
exists that there is an increase in the activity of the A^-3PHSD 
system for DHA in hyperplastic glands.
Two further steroid peaks were eluted on alumina column 
chromatography of the incubation extracts (peaks IV and V)• In 
glands 28 and 31 (Table XXXIII), neither was demonstrable, but 
in the remainder they composed between 1.^1% and 16.6% of the 
utilized substrate, peak IV always containing more radio-activity 
than peak V. No reliable ultra-violet absorption curves were 
obtained in the corresponding fraction upon spectrophotometry 
of these fractions. It was concluded that they did not possess 
the A^-3-ketone chromophore grouping absorbing at 2^0 mp. and 
consequently were not steroids formed by the action of the 
A^-3PHSD system upon the substrate DHA.
Attempts to isolate C-labelled lip-hydroxyandrostenedione, 
adrenosterone or testosterone by paper chromatography of the 
appropriate column fractions after the addition of authentic 
carrier steroids were unsuccessful in each assay. No radioactivity 
could be detected in carrier steroids after the paper chromatographic 
step.
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Table XXXIV compares the activity of the A^-3PHSD system 
for DHA as measured by the silica gel and alumina column procedures. 
It can be seen that the difference of the two means, found for 
hyperplastic glands, is just statistically significant 
(P-£ 0.5 >0**0, indicating a somewhat higher steroid recovery 
with alumina chromatography.
To establish further this apparent difference, three separate 
incubation extracts, two with DHA-^ f- C as substrate, one of which 
contained 732 ?ag. of androstenedione added to the incubate as a 
trap, and one with unlabelled DHA as substrate, all from the 
same gland, were chromatographed initially using the silica gel 
column technique and the combined fractions eluted from this 
column were rechromatographed on an alumina column.
The results obtained are tabulated in Table XXXV. The 
apparent losses incurred when the results of the silica gel and 
alumina columns are compared are probably due to the fact that 
the recovery of standards from an alumina column is only 90%
In addition losses would occur due to combining the silica gel 
column fractions and to plating one fortieth of each sample for 
counting.
As the total cpm and the total U.V. absorbing steroids 
recovered after the two procedures closely match one another 
(Table XXXV) it can be concluded that there is no true difference
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TABLE XXXV
A_-33-HYDROXYSTEROID DEHYDROGENASE ASSAY 
~0   ------
Comparison of results obtained by Silica Gel and Alumina Column Chromatography
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
0.15^M sodium chloride and 0.1M phosphate buffer (1:1) 
1,6 ml, of 20% (W/V) homogenate-
NAD, 6 mg.
Assay 1 - DHA-4-.7C, 130 pg.,
Assay 2 - DHA-4- C, 130 pg.,
Assay 3 - DHA, 130 pg.
30 minutes.
Final Volume 1.8 ml. 
specific activity k79 cpm/pg.
specific activity k79 cpm/pg. with added androstenedione, 732 p,g. 
Gas-phase: air.
Assay
sample
number
Silica Gel Column Chromatography Alumina Column Chromatography Percentage UV 
absorbing steroid 
recovered from 
alumina column
---------------- [
Percentage Tcpm 
recovered from 
alumina colum
Total TJV absorbing 
steroid pg. Tcpm eluted
Androstenedione
Tig.
Peak III 
Tig*
Total UV absorbing 
steroid pg. Tcpm eluted
1 6^.9 55,07^ l*f.2 kl.O 5^.2 ifif,826 83 81
2 727.7 ^9,398 550.5 23.3 573.8 35,550 79 7**
3 66.2 - 39.5 12.3 51.8 - 78 -
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between the two methods. However, the use of an alumina 
column is preferable due to its greater resolution in the 
separation of the formed steroids. The two steroids measured 
by the silica gel column procedure are mainly androstenedione 
and that of peak III of the alumina colomn.
UNKNOWN STEROID (PEAK III) ELUTED FROM
ALUMINA COLUMNS
Almost all the experiments reported in this thesis were 
conducted before the identity of this steroid was established.
Due to the small quantities of the steroid produced in each 
incubation, unequivocal identification of the substance by infra-* 
red spectrophotometry could not be achieved until several hundred 
p.g* were collected from a number of separate incubations.
As the steroid absorbed U.V. light and gave a positive 
dinitrobenzene reaction (Zimmermann chromagen), it was inferred 
that the substance was a 17-ketosteroid possessing a A^-3-ketone 
grouping and thus probably arising in the androstenedione formed 
from the DHA of the assay procedure. In addition, the specific 
activity of this substance calculated from either the U.V. 
absorbancy or from the Zimmermann chromagen was identical.
Although peak III was eluted from an alumina column in a more
polar effluent fraction than was authentic lip-hydroxyandrostenedione, 
it was thought that this represented its most probable identity.
When carrier ll(3-hydroxyandrostenedione, testosterone, and 
adrenosterone were added to this radio-active unknown steroid and
chromatographed in the A system of Bush, the radio-activity did
not separate from authentic 1^-hydroxyandrostenedione. No
radio-activity was detected in the well-separated paper spots of
- 160 -
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either testosterone or adrenosterone (Table XXXVI).
However, in the and system of Bush, separation of the 
radio-activity from carrier lip-hydroxyandrostenedione was readily 
achieved, all of the radio-activity being located as a discrete 
zone more polar than the ll{3-hydroxyandrostenedione.
further attempts to characterise this steroid were made in 
the Bush B^ system but it separated from each of the following 
carrier steroids: 6{3~hydroxyandrostenedione, l6a-hydroxy-
androstenedione, 19-hydroxyandrostenedione (Table XXXVI), which 
were considered to be the hydroxylated androstenedione derivatives 
most likely to be formed.
The steroid was acetylatable with acetic anhydride and 
pyridine (Bush, 1961) and the acetate thus formed possessed a 
chromatographic mobility similar to the acetates of both DHA and 
testosterone in the Bush A system and ligroin-propylene glycol 
system of Savard* This indicated the presence of at least one 
easily acetylatable hydroxyl group. A positive result was obtained 
using the soda fluorescence technique for A^-3-ketones on paper 
by a sample of the free steroid after paper chromatography.
All of this evidence agreed with the interpretation that the 
unknown compound was a 17-ketosteroid possessing a A^-3-ketone 
group with at least one acetylatable hydroxyl group.
Its absorption spectrum was determined in ethanol-sulphuric
<•—>.
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acid (Smith 8c Bernstein, 1963). Authentic androstenedione, 
testosterone and ll|3-hydroxyandrostenedione scanned concurrently 
gave absorption spectra which were identical with those reported 
by other workers (Smith 8c Bernstein, 1963)* The absorption 
spectrum of the peak III substance was - X  maximum, 288 mp, 
and 360 mp,; X  minimum, 310 mp, and *f00 mp,. These values did not 
correspond with any other hydroxylated androstenediones reviewed 
(Smith 8c Bernstein, 1963) *
It was decided that only infra-red spectrophotometry would 
establish its identity. Further incubations were necessary to 
accumulate sufficient steroid for this characterisation and in 
the course of these incubations, the unknown compound was found 
to be formed not only from DHA-4- C, but also, in small amounts, 
from androstenedione-^- C and unlabelled androstenedione.
400 pg. of the unknown compound were amassed from these experiments 
and the combined steroid sample submitted, derived from both DHA 
and androstenedione, showed only one zone of radio-activity as 
judged by column and paper chromatography.
The infra-red spectroscopy was kindly conducted by Dr. K.D. 
Roberts and Dr. S. Lieberman of the Departments of Biochemistry and 
of Obstetrics and Gynecology, College of Physicians and Surgeons, 
Columbia University, New York.
The infra-red spectrum of the unknown steroid is shown in
-  16k -
Figure 39* It is identical to that of a sample of authentic 
7-keto-dehydroepiandrosterone (7-keto-DHA) tested concurrently.
The presence of a A^-7-ketone grouping explains the finding 
of its absorbing U.V. light, and giving a positive soda fluorescence 
reaction (Bush, 1961). As it is a 17-ketosteroid it would give 
a positive dinitrobenzene reaction (Zimmermann chromagen) and by 
having a {3-hydroxyl group at position 3* it would yield a mono­
acetate on acetylation with acetic acid and pyridine.
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UNKNOWN STEROIDS (PEAKS IV & V) ELUTED FROM ALUMINA COLUMNS
The compounds corresponding to peaks IV and V of the alumina 
columns may represent either intermediates in the formation of 
or further derivatives of 7-keto-DHA or androstenedione. Neither 
absorbs U.V. light, but the steroid (peak IV) gave a positive 
dinitrobenzene reaction (Zimmermann chromagen) while the steroid 
composing peak V did not,
STEROID CORRESPONDING TO PEAK IV
The compound was highly polar and possessed an Rf of O.Vf 
in the Bush system (cortisol, Rf. 0.25), This corresponds 
closely' to the Rf value of 0.^ +2 reported by Starka and Katova* (1962) 
for 7a-hydroxy-DHA in this system.
The unknown steroid was easily acetylatable using the 
conditions of DeCourcy and his colleagues (1955)i following which, 
the steroid had a paper chromatographic mobility similar to 
that of DEA-acetate. The 7oc-hydroxy group is also acetylated 
under these conditions (Burnstein et al., 1959)• Saponification 
of the acetate(s) using methanolic potassium bicarbonate failed 
to release the free steroid, but this was achieved with methanolic 
sodium hydroxide. Since similar observations have been noted 
when saponification of DHA-acetate is attempted, this may indicate 
the presence of a 30-hydroxy group. Being capable of forming a
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Zimmermann chromagen the substance is probably a 17-ketosteroid and 
when considered in relation to the polarity of other steroids in 
the Bush system, it is possible that this substance is 
7a-hydroxy-DHA. Definitive proof must await the availability of 
an authentic standard (in preparation) and the amassing of 
sufficient material from further incubations for an infra-red 
spectrum to be obtained,
STEROID CORRESPONDING TO PEAK V
This compound failed to move from the starting line in the 
Bush B_ system, but was easily acetylatable, following which it 
possessed an Rf of 0,33 in this paper system (Cortisol, Rf, 0,25)* 
Saponification failed using methanolic potassium bicarbonate, but 
with methanolic sodium hydroxide, two products were obtained, 
one of which had a paper chromatographic mobility similar to the 
steroid corresponding to peak IV (0.^), The second product 
possessed an Rf, of 0,60 in the Bush Bj_ system. The identity of 
this compound (peak: V) is completely unknown, but it may be a 
17-hydroxylated steroid with a A,_-30-hydroxy group due to the 
negative Zimmermann reaction, no U.V. light absorbtion at ZkO my. 
and the failure to saponify with methanolic potassium bicarbonate.
RBIHTERPRETATION OF THE RESULTS OF THE ASSAY OF THE
A,.-3P-HYDROXYSTEROID DEHYDROGENASE USING DHA-*<— C
In the light of finding that the unknown steroid (peak III) is
7-keto-DHA and not a A^-3-ketosteroid, a reappraisal of the results
of the various assays of the A^-3pHSD system for DHA is essential#
Using this experimental model, two principal products are formed
*1 ^
by human adrenal glands in in vitro incubations using DHA-^f- C 
as substrate, namely androstenedione and 7-keto-DHA# The formation 
of androstenedione represents a true assessment of the activity of 
the A,--3(3HSD system. The formation of 7-keto-DHA by adrenal 
tissue has not been shown previously under in vitro conditions.
The relationship of the 7-keto-DHA formation to the A_-3|3HSD 
system is not clear#
The modified results are tabulated and summarised in Table 
XXXVII. The activity of both enzyme systems remains very variable 
not only between glands but also in any one gland (Gland 3^ -, Table 
XXXVII). Gland 29 (Table XXXVII) shows a very low level of 
androstenedione formation and a high level of 7-keto-DHA formation. 
However, despite the variation in the figures from the other normal 
gland (Gland 28) the recovery of total cpm added, isolated as 
DHA,androstenedione, and 7-keto-DHA was 85%. Of interest is the 
finding that the sum of the amounts of androstenedione and 
7-keto-DHA formed in each incubation of the same homogenate of
- 167 -
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gland 3^ (Tables XXXII & XXXVII) fall within the same range 
despite the variation in the proportion of the two steroids formed.
The Aj--3pHSD activity in hyperplastic glands is 2.38 - 0.66 p,g. 
androstenedione per minute per mg. nitrogen, whereas in normal 
tissues, it is 1.69 Tig. (Table XXXVII). Statistical evaluation 
of these results cannot be performed due to the small normal sample 
but due to the overlapping of the values, it is doubtful whether 
any difference in the activity of this enzyme system exists between 
normal and hyperplastic tissues. Similarly, the activity of the 
enzyme system(s) leading to the formation of 7-keto-DHA from 
DHA is similar in both types of tissue.
This is the first demonstration of the formation of 7-keto-DHA 
in vitro by the human adrenal cortex. Biochemical assay of 
the human adrenal A^--3^HSD system has been performed by 
others using similar incubation conditions to that in the present 
investigation and with DHA as substrate (Rubin e t al., 1961;
Bloch et al., 1962; Rubin et al., 1963). Assays of normal
and neoplastic adrenals have been made and the results have 
been expressed as p,g. androstenedione formed per minute 
per mg. nitrogen. These results were obtained by direct 
spectrophotome trie comparison of incubates against tissue 
blanks. It seems possible that not only androstenedione but also 
7-keto-DHA have been measured and included in the figures for
- 170 -
A^-3PHSD activity. These reported results are all higher than 
those presented here, but they also show considerable variation 
between one gland and another (Rubin et al., 1961; Bloch et al., 
1962; Rubin et al., 1963).
7-keto-DHA was isolated in small amounts from the urine of 
both normal patients and those with a variety of adrenal 
hyperfunctional disorders (Lieberman et al., 19^8) and characterised 
subsequently (Fukushima et al., 195^ )• Gallagher (1958) suggested 
that it may represent a product of adrenal biosynthesis rather than 
a peripheral metabolite of DHA, and he showed that it occurred in 
elevated amounts in two patients with adrenal carcinomas causing 
Cushing’s syndrome. Baulieu (1962) found 7-keto-DHA sulphate 
in adrenal tumours associated with both virilism and Cushing’s 
syndrome and noted its occurrence in elevated concentrations in 
the peripheral plasma and in the urine. Because adrenal venous 
plasma contained the sulphate ester of 7-keto-DEA in higher 
concentrations than peripheral plasma, he concluded that it was 
indeed a product of the adrenal gland. Ho free 7-keto-DHA 
was demonstrated in any of the tumours, in plasma or in urine, 
so that conjugation appeared to occur in the adrenal itself*
The 7-keto-DHA, isolated in the present experiments is the 
free unconjugated steroid. Between 83% and 95% of the total cpm. 
added as substrate DHA were recovered after column chromatography.
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Never more than 1% of the total cpm. added as substrate DHA 
were found in the aqueous residue of the incubation remaining 
after extraction. Thus no significant sulphation occurred 
under the assay conditions.
MECHANISM OF 7-KETQ-DHA FORMATION
Despite the evidence presented on page 169» for the active 
formation of 7-keto-DHA by the human adrenal cortex, the possibility 
that it represents an auto-oxidation product of DHA must be 
excluded* 7-keto-cholesterol and the 7a and 7f3-hydroxycholesterols 
have been shown to be products of the non-enzymatic oxidation of 
cholesterol (Wintersteiner & Bergstrom, 19^1; Bergstrom, 19^3)* 
Cholesterol may also be oxidized to 7-keto-cholesterol when exposed 
in thin films to air and irradiated with U.V. light (Windaus et al., 
19^1) or when present in aqueous solutions and exposed to X-rays 
(Keller & Weiss, 1930, Weiss & Keller, 1930). To ensure that 
7-keto-DHA occurred as a true biosynthetic product of DHA, the 
following experiment was performed*
METHODS
A 10% (W/V) homogenate of a human autopsy adrenal gland was 
made with equal volumes of 0.15^M sodium chloride and 0,1M phosphate 
buffer. 30 mg. of NAD and 372*f mg. of DHA-^ f- C (specific 
activity 6k.& cpm/p,g) were added to each of three flasks. 10 ml. 
of medium alone were pippetted into one flask. 10 ml. of 
the 10% (W/V) homogenate added to a second fl^ isk and to the 
final flask, 10 ml. of the 10% (W/V) homogenate which had been 
boiled.
The incubates were shaken in air at 37°C for 60 minutes.
- 172 -
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2 volumes of acetone were added to each flask and the resultant 
clear supernatent, following filtration and removal of the acetone 
in vacuo, was extracted three times with 5 volumes of benzene: 
chloroform (6:1). The pooled extracts were taken to dryness and 
submitted to alumina column chromatography. The appropriate 
column fractions corresponding to the polarity of 7-keto-DHA 
were combined and rechromatographed on paper in the Bush system.
RESULTS AND DISCUSSION
No evidence of the formation of 7-keto-DHA in any of the 
incubates could be detected by alumina column chromatography 
(Table XXXVIII) or by paper chromatography. No peak of radio­
activity or U.V. light absorption could be found in the areas 
corresponding to the polarity of 7-keto-DHA. Thus the formation 
of 7-keto-DHA can be assumed to be the result of a biosynthetic 
process of the adrenal cortex.
Micro-organisms have been shown to be capable of converting 
DHA to 7a and 70-hydroxy-DHA and 7-keto-DHA (Dodson et al., 1959); 
cholesterol to 7-hydroxycholesterol (Kramli & Horvath, 19^ +8, 19*f9) 5 
and pregnenolone to 7a and 7p-hydroxypregnenolone (Epstein et al., 
1956). A^-3-l^etosteroids can also serve as substrate for bacterial 
hydroxylation at C-7 in that 7a-hydroxy-ll-deoxycortisol and 
7a-hydroxy-androstenedione were formed by the micro-organism
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Cephalosporium sp. (Bernstein et al., 1959)•
Recently, rat liver homogenates have been found to be 
capable of forming ?a-hydroxy-DHA (Starka & Katova, 1962) and the 
7a-hydroxylation of oestrone has been reported to be effected by 
beef adrenals (Knuppen et al,, 1964). In both these reports, 
the possibility of the 7-oxygenated steroids being auto-oxidation 
products was excluded.
These studies together with those involved in the isolation 
of 7-keto-DHA from human urine, plasma and adrenal venous blood 
(p# 169) point to it being an adrenal product, and that the 
formation of 7-keto-DHA represents another biosynthetic pathway 
in the adrenal cortex, the presence of which now appears to be 
established by the in vitro investigations reported here.
14
UTILIZATION OF DHA-4- C BY NORMAL AND HYPERPLASTIC
HUMAN ADRENAL GLANDS
EFFECTS OF VARIATIONS IN THE AMOUNTS OP TISSUE INCUBATED 
AND IN THE INCUBATION MEDIUM
An alteration in the incubation medium, from the sodium 
chloride-phosphate medium to KRPG with added nicotinamide, was 
made to see if any change occurred in the proportions or rate of 
androstenedione and 7-keto-DHA formation from DHA. In other 
experiments using either type of medium, the amounts of tissue 
incubated and the period of the incubation were both increased to 
raise the chances of detecting steroids formed in trace amounts.
METHODS
0.5 ml. of a 10% (W/V) homogenate of an hyperplastic gland, 
in KRPG with added 0.01M nicotinamide, was incubated (Table XXXIX). 
Using between 1.5 ml. and 2.5 tal. °f 10% (W/V) homogenate, 
comparison of the two types of media were made. The periods of 
incubation varied from 50 to 90 minutes. The detailed incubation, 
conditions are included in the appropriate tables (Table XL &
XLI). Extraction and alumina column chromatography were 
performed as described.
- 176 -
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RESULTS AND DISCUSSION
No difference in the rate of formation of androstenedione or 
7-keto-DHA from DHA-4- C was seen when the hyperplastic gland was 
incubated in KRPG (Table XXXIX) as compared to the sodium chloride 
phosphate medium (Table XXXVII), Both steroids were derived 
only from the added DHA, as shown by comparison of their specific 
activities with that of the substrate. Considerable variation 
in the proportion of the two steroids formed may be seen 
(Table XXXIX).
The substance comprising peaks IV and V of the alumina 
column were found again in this experiment making up a somewhat 
higher percentage of the utilized substrate when the incubation 
was performed in KRPG (Tables XXXIII & XXXIX).
Increasing the period of the incubation and the amount of 
tissue did not lead to any other steroid being found in detectable 
amounts under those conditions (Table XL). The activity of both 
the A(--3pHSD system and the enzyme system(s) responsible for the 
formation of 7-keto-DHA, calculated as pg. formed per minute 
per mg. nitrogen, is lower for the longer periods (60-90 minutes) 
of incubation than found for lower tissue concentrations incubated 
for 30 minutes (Table XL). This is possibly due to a falling 
off of the rate of DHA utilization with time. However, activity/ 
time experiment was not done.
- l8l -
The percentage of the recovered total cpm found in the steroid 
fractions corresponding to peaks IV and V of the alumina column 
is similar to that noted with lower tissue concentrations and/or 
shorter incubation, times (Tables XXXIII & XXXIX).
Essentially similar findings were noted when large tissue 
concentrations were incubated for longer periods of time using KRPG 
as the medium. Only androstenedione and 7-keto-DHA were formed 
in significant quantities and their specific activities corresponded 
closely to those of the recovered substrate DHA indicating that 
they were derived only from the added substrate (Table XLI).
The activity of the A,_-3(3HSD system for DHA and the 7-keto-DHA 
system show a similar decrease in overall activity per unit time 
as was noted with the increased tissue concentrations incubated 
in the sodium chloride-phosphate medium. This fall in activity 
occurs despite a proportional increase in the HAD present with 
the high tissue amounts, when compared with the activity in the 
50 mg. tissue incubations.
The normal gland (Gland 36, Table XL; Gland 39, Table XLI) 
and the hyperplastic gland (Gland 38, Table XL; Gland Table XLI)
are portions of the same gland homogenized and incubated in the 
different media cited. While no difference can be detected in 
the rate of formation of the two major products by the normal gland, 
the activity of the A,_-3PBSD system appears to be less in the
- 182 -
KRPG incubate of the hyperplastic gland (Table XLII). There is a 
corresponding increase in the rate of formation of 7-keto-DHA, 
the sum of the two products formed being the same for both media.
The eluates from the alumina columns, of assays using either 
KRPG or sodium chloride and phosphate buffer, corresponding to 
the zones in which authentic llp-hydroxyandrostenedione, testosterone, 
and adrenosterone would be expected (Shoulder of Peak II), were 
re-chromatographed in the paper systems of Bush after the addition 
of appropriate authentic steroids as carrier. Constant specific 
activity could not be achieved for any of these carrier steroids* 
all radio-activity was lost on repeated chromatography of the 
carrier steroids.
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TEE FORMATION OF 11g rHYDROXYANDROSTEXBDIONE AND TESTOSTERONE 
aIl.
FROM DHA-*f- C BY NORMAL AND HYPERPLASTIC HUMAN ADRENAL GLANDS
In order to confirm that only the four compounds described
1
were formed on the utilization of DHA-^ f- C by normal and hyperplastic 
glands, the extracts of several incubates were submitted to paper 
chromatography without a prior column chromatographic step. It 
was thought that any other trace steroids might be detected more 
readily using this technique,
METHODS
The extracts were initially chromatographed for 8 hours in 
the Bush B^ system. The over-flows ("run-offs”) from each strip 
contained DHA, androstenedione, llj3-hydroxyandrostenedione, 
testosterone and adrenosterone as judged by comparison with the 
mobility of authentic standard samples. The more polar steroids, 
including 7-keto-DHA, remained on the Bush 'B paper chromatograms.
To these overflows, authentic carrier llp-hydroxyandrostenedione 
testosterone and adrenosterone were added and the whole sample 
containing the carrier steroids was then rechromatographed for 
15 hours in the Bush A system. Excellent separation of the carrier 
steroids was achieved. DHA and androstenedione, recovered from the 
overflows of this second chromatogram, were chromatographed for a • 
third time in the Bqsh A system for a period of 6 hours. No
-  18k -
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significant amounts of radio-activity were found in the overflows 
of the third, Bush A, paper chromatograms.
Following radiochromatogram scanning of each of the paper 
chromatograms, the zones of radio-activity corresponding to DHA, 
androstenedione and 7-keto-DHA were eluted, counted and measured 
by either the Zimmermann reaction or spectrophotometry.
The U.V. absorbing zones corresponding to lip-hydroxy- 
androstenedione, testosterone and adrenosterone were eluted from 
the papers, measured at 240 mjj, in the spectrophotometer and their 
specific activities calculated after counting.
Testosterone acetate was made at room temperature with equal 
volumes of acetic anhydride and pyridine for 15 hours (DeCourcy 
et al., 1955). The product was chromatographed on the Bush A 
system, and the specific activity of the derivative determined 
after elution. Subsequent saponification with alcoholic potassium 
bicarbonate (Meyer, 1955) was performed and the free testosterone 
was rechromatographed in the Bush B^ system and the specific 
activity again determined.
lip-hydroxyandrostenedione and adrenosterone were rechromato­
graphed for a second and third time using the Bush B^ and B^ systems. 
Their specific activities were determined after each procedure.
No derivative® of these two steroids were made. Constancy of 
specific activity in three paper systems was taken as evidence of 
their radiochemical purity.
- 186 -
RESULTS
The radiochromatogram scans revealed the presence of five 
peaks of radio-activity of which three corresponded to androstenedione, 
DHA and 7-keto-DHA. Two highly polar discrete zones of radio-activity 
were noted near the origin of the strips run in the Bush B^ system 
and corresponded to the unknown steroids of peaks IV and V of the 
alumina columns. Neither appeared to absorb U.V. light. The 
specific activities of the isolated DHA, androstenedione and 
7-keto-DHA agreed within 10% in every instance (Table XLIII). An 
average of 75% of the added substrate was recovered as unchanged 
DHA, androstenedione and 7-keto-DHA from the various chromatograms.
No radio-activity was detected by radiochromatogram scanning 
in the chromatographic areas corresponding to the carrier steroids, 
lip-hydroxyandrostenedione, adrenosterone and testosterone.
However, four of the six glancfe examined formed trace amounts of 
llp-hydroxyandrostenedione, three of these glands (Glands ^3, A4 &
45, Table XLIV) being hyperplastic and removed from patients with 
Cushing’s syndrome. In one case (Gland ^5* Table XLIV), traces of 
testosterone were also detected. None of the glands formed 
adrenosterone.
TABLE XLI II
UTILIZATION OF DHA-4- C BY NORMAL AND HYPERPLASTIC HITMAN ADRENAL GLANDS
Incubation Extracts Subjected Directly to Paper Chromatography
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
0.15^M sodium chloride and 0.1M phosphate buffer (1:1) 
0.5 ml» of 10% (W/V) homogenate
NAD, 6^ L^g. Final Volume: 0.7 ml.
DHA-4- C, 130 p,g. specific activity either *3^5 cpm/y,g. 
or **k79 cpm/]xg, (***Gland kZ - 200 *ig., specific 
activity, 175 cpm/Vg.)
30 minutes. Gas-phase: air.
Gland
number
Type of 
gland
Isolated Steroids
DHA Androstenedione 7-keto-DHA
VS*
Specific activity 
cpm/pg. VS*
Specific activity 
cpm/jig. VS*
Specific activity 
cpm/iig.
*fl* Normal 25 3bG 30 309 13 339
1+2*** Hyperplasia 98 181 31 163 31 167
k3* Hyperplasia 21 320 29 316 31 330
kk* Hyperplasia 12 3^8 13 331 60 361
4-5** Hyperplasia 15 ^75 k9 V70 l*f 470
^6** Hyperplasia 67 k7% 22 452 9 458
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THE ROUTES OF FORMATION OF 7-KBTO-DEA
Following the investigation of the A,_-3|3HSD system for DHA 
in normal and hyperplastic glands using small amounts of tissue* 
several distinct problems remained.
The identity of the radio-active steroid corresponding to 
peak III of the alumina column elutions was unknown at this time.
It was assumed to be a 17-ketosteroid possessing a A^-3~ketone 
grouping, most probably derived from androstenedione. It had been 
shown not to be ll|3-hydroxyandrostenedione, 6|3-hydroxyandrostenedione 
l6a-hydroxyandrostenedione, or 19-hydroxyandrostenedione, but to 
possess at least one hydroxyl group capable of acetylation. Its 
source from either androstenedione or DHA had not been established.
It was thought that, if incubations using DHA-^ f- C as the substrate 
in the presence of unlabelled androstenedione as a trap were done, 
the specific activity of the isolated 7-keto-DHA would give some 
indication of the relative importance of the two substrates as 
sources of the compound.
The trace amounts of llp-hydroxyandrostenedione and testosterone 
detected in several incubations required further clarification 
and definitive establishment of their production.
It was towards those two problems that three incubations were
planned, one with a normal gland, and the other two with hyperplastic 
1 if
glands. DHA-*f- C alone or in the presence of an androstenedione
- 189 -
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1*f
trap and androstenedione-*!— C were chosen as substrates*
METHODS
Gland *+7 - Normal Adrenal Gland.
3*0 ml* of a 10% (W/V) homogenate, with KRPG containing 0.01M 
nicotinamide as the medium, were incubated with either 260 p,g.
i 1*f 1*f
DHA-*f- C or 1000 p,g. of androstenedione-*!— C as substrates for 
90 minutes in air* Ho NAD was added. The incubates were extracted 
with 5 volumes benzene:chloroform (6:1), taken to dryness and 
subjected directly to paper chromatography using the system of 
Bush with a running time of 8 hours. The zone of radio-activity, 
found by radiochromatogram scanning of the paper, corresponding to 
the "unknown” (7-keto-DHA) was eluted and chromatographed on a 
7*5 g. alumina column. The overflows of those paper chromatograms, 
containing androstenedione, DHA and substances of the polarity of 
lip-hydroxyandrostenedione, were chromatographed on a separate 
7*5 g. alumina column.
Gland 48 - Hyperplastic Adrenal Gland.
Three separate flasks containing 3«0 ml. of a 10% (W/V) 
homogenate in KRPG with added 0.0314 nicotinamide were incubated 
with 30 mg. of NAD added for 90 minutes in air. DHA-*!- C 
was added as substrate to two flasks, one of which also contained 
732 p,g. of unlabelled androstenedione as a trap. The remaining
- 191 -
i±
flask contained 1,000 p,g. of androstenedione-4— C as the substrate*
The flasks were extracted in a similar manner to gland 4-7 and
chromatographed on a 7*5 g. alumina column*
Gland 49 ~ Hyperplastic Adrenal Gland,
KRBG with added 0.01M nicotinamide was the incubation medium.
5*0 ml* of a 10$ (W/V) homogenate were incubated with either 260 pg.
i 14 14-of DHA-4— C or 1,000 p.g. of androstenedione-4- C for 120 minutes
in the presence of 30 mg. of NAD. The gas-phase was 95% oxygen-
5% carbon dioxide. The extraction and chromatographic procedures
were identical with those of gland
RESULTS AND DISCUSSION
The results obtained by the incubation of the normal gland with
DHA and androstenedione are shown in Table XLV. Separate columns
for the isolation of 7-keto-DHA and the less polar 17-ketosteroids
were run. The significant result is the finding of 7-keto-DHA
14-
as a product of androstenedione-4- C. Only 3*3 V-S* 7-keto-DHA 
were formed from this substrate, while 33V-g. were derived from DHA. 
Consequently, the formation of 7-keto-DHA occurs more readily from 
DHA.
The incubation of the hyperplastic gland (Gland 4-8) shows that
1 4-both androstenedione and 7-keto-DHA were formed from DHA-4— C .
14-Using androstenedione-4- C as substrate, 22pg. of 7-keto-DHA were
TABLE XLV
UTILIZATION OF DHA-4-1 AND ANDROSTENEDIONE-4-1\i BY A NORMAL HUMAN ADRENAL GLAND (GLAND V?)
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
KRPG with added O.OLM nicotinamide 
3.0 ml. of 10% (W/V) homogenate
Nil. 14, Final volume: 3.0 ml.1) DHA-4- C, 260 pg..^specific activity 479 cpm/pg.
2) Androstenedione-4- C, 1,000 pg. specific activity 435 cpm/pg. 
90 minutes. Gas-phase: air .
Su
44
bstrate: DHA-4- C 14Substrate: Androstenedione-4- C
Column
peaks
Isolated
steroids Tcpm Vg*
Specific activity 
cpm/pg. Tcpm Hg.
Specific activity 
cpm/pg.
I Androstenedione 43,318 94 460 359,632 806 446
II DHA 47,756 103 463 2,266 - -
Shoulder 
of II
* 2,949 - - 1,602 - -
III 7-keto-DHA 15.573 53 474 1,470 3.3 440
* Substances of the polarity of lip-hydroxyandrostenedione, testosterone and adrenosterone
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formed, compared with 39 pg. from the DHA substrate flask (Table
XLVI). In the presence of the androstenedione trap, 125 Pg.
7-keto-DHA were produced (Table XLVI). From the ratio of the
specific activities of the isolated 7-keto-DHA and DHA (44.5 cpm/pg;
65.0 cpm/pg., Table XLVI), it is possible to calculate that
68.6% of the total 7-keto-DHA, formed in this flask, came directly 
14
from DHA-4- C, the remainder coming from the androstenedione,
present as a trap, which diluted the 7-keto-DHA formed from DHA
itself and caused the observed drop in specific activity.
The increase in the quantity of 7-keto-DHA, in the presence
of androstenedione, would appear to be due to amarked decrease in
the conversion of DHA to androstenedione. The 125 Pg. of
7-keto-DHA is twice the amount formed from DHA and androsteiBdione
when they were incubated separately. This agrees with a decrease
of 59% in the total cpm. incorporated into androstenedione when
14 14the incubates with DHA-4- C and DHA-4- C and androstenedione trap are 
compared (Table XLVI).
14
39 Pg. of 7-keto-DHA were formed from DHA-4- C when incubated
alone (Table XLVI). Approximately twice the total cpm. were
14incorporated into 7-keto-DHA when DHA-4- C and unlabelled 
androstenedione were incubated together. If the assumption is 
made that 78 pg. (i.e., twice the 39 pg. formed from DHA alone)
1 i.
came from DHA-4- C in the trapping incubation, based on the
TABLE XLVI
14
UTILIZATION OF DHA-4- C, IN THE PRESENCE OF ANDROSTENEDIONE AMD 
ANDRQSTSNEDIONE-4-1 C BY A HYPERPLASTIC HUMAN ADRENAL GLAND (GLAND 48)
KRPG with added O.OIM nicotinamide
3*0 ml. of a 10% (W/V) homogenate
NAD, 30 Final Volume: 4.0 ml.
1) DHA-4-lifC, 538 jig., specific activity, 64.8 cpm/pg.
2) DHA-4- C, 538 |ig., specific activity, 64.8 cpm/pg. 
with added 732 yg.^unlabelled androstenedione
3) Androstenedione-4- C, 1,000 pg., specific 
activity, 435 cpn/pg.
90 minutes. Gas-phase: air.
Column
peaks
Isolated
steroids
14
Substrate: DHA-4- C
.. ... "aIT"
Substrate: DHA-4-' C 
with added 732 pg. 
androstenedione
Substrate: 
Androstenedione- 
4- C
Total
cpm Ug.
Specific
activity
cpm./pg.
Total
cpm V-g*
Specific
activity
cpm./pg.
Total
cpm VS*
Specific
activity
cpm./pg,.
I Androstenedione 16,632 264 63 6,951 720 9.3 452,317 902 501
II DHA 10,087 135 65 14,227 219 65 3,230 - -
Shoulder 
of II
* 800 - - 542 - 2,211 - -
III 7-keto-DHA 2,448 39 63 5,578 125 44.6 11,441 22 513
IV - 3,280 - - 3,425 - 2,650 - -
V - 752 - - 1,099 - 2,465 - -
* Substances of the polarity of lip-hydroxyandrostenedione, testosterone and adrenosterone
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
TABLE XLVII
UTILIZATION OF VEk-k-^C and ANDROSTENEDI0NE-4-^ B Y  A HYPEHPLASTIG HUMAN ADRENAL GLAND ( GLAND 49)
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
KRBG with added 0*01M nicotinamide
5.0 ml. of a 10% (W/V) homogenate
NAD, 50 Final Volume: 6.0 ml.
1) DHA-4- C, 260 p,g.^specific activity 4?9 cpm/p,g.
2) Androstenedione-4- C, 1,000 y,g., specific activity 455 cpm/p-g.
120 minutes. Gas-phase: 95% 0^ and 5% 00^
Column
Fractions
Isolated
steroids
1 h-
Substrate: DHA-4- C
i4Substrate: Androstenedione-4- C
Tcpm Tig.
Specific activity 
cpm/Vg. Tcpm Tig*
Specific activity 
cpm/jig.
I Androstenedione 106,538 250 426 327,131 747 483
II DHA 4,274 9 450 1,474 - -
Shoulder 
of II
* 936 - - 3,610 - -
III 7-keto-DHA 1,752 4 441 501 - 1
IV - 306 - - - - -
V - 192 - - - - -
* Substances of the polarity of llp-hydroxyandrostenedione, testosterone and adrenosterone
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At this stage in the investigations, the finding that the
"unknown" substance (peak III, alumina columns: subsequently
established as 7-keto-DHA) could be formed from androstenedione
further supported the assumption that it was a 17-ketosteroid with
a A^-3“ketone grouping.
The accumulated "unknown" fractions from these incubations 
14 14with DHA-4- C, DHA-4- C with unlabelled androstenedione as a
14
trap and androstenedione-4- C were pooled and added to the
1 if.
corresponding fractions isolated from previous DHA-4— C 
incubations. This total sample was chromatographed twice in 
the paper systems, Bush B^ and B^, followed by a further alumina 
column fractionation, from which a single peak-fraction was 
obtained. It was this fraction containing the steroid, derived 
from both sources, i.e., DHA and androstenedione, which was 
examined by infra-red spectrophotometry. The tracing was identical 
with authentic 7-keto-DHA (Fig. 39). Thus it seems assured that 
androstenedione can be converted to 7-keto-DHA.
Previous experiments, using various tissue and substrate 
concentrations and incubation periods, have shown that the rate of 
formation of the sum of androstenedione and 7-keto-DHA from DHA 
did not differ in normal and hyperplastic human adrenal glands.
The difference in the rate of formation of androstenedione and 
7-keto-DHA by the normal and hyperplastic glands (Glands 47 & 48)
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might be due to the omission of NAD from the incubation of Gland 47 
(Table XLVIII). Thus, not only the A^-3|3HSD system but also the 
enzyme system(s) for .the formation of 7-keto-DHA from DHA may 
require the presence of NAD. The fall in the rate of formation 
of androstenedione fromlHA by the hyperplastic gland 49 (Table 
XLVIII) may be related to the different medium the longer period 
of incubation and the larger amounts of tissue compared with 
Gland 48 (Tables XLVI-XLVIII).
The formation of the two more polar compounds, corresponding 
to peaks IV and V of the alumina column eluants, were formed hy 
the hyperplastic gland (Gland 48, Table XLVI) not only from
14 14
DHA-4- C but also from androstenedione-4- C. Peak IV could be
7a-hydroxy-DHA as judged by its chromatographic mobilities. Thus
14its formation from DHA-4- C in the presence of an androstenedione
1 a
trap in similar amounts to that from DHA-4- C alone, is to be 
expected, if one assumes it to be an intermediate in the 7-keto- 
DHA pathway.
These two compounds were formed in only trace amounts as was 
7-keto-DHA in the presence of KRBG as the medium (Gland 49, Table 
XLVII)•
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THE ROUTES OF FORMATION OF llg-HYDROXYANDROSTSNEDIONE,
ADRENOSTERONE AND TESTOSTERONE
HUMAN ADRENAL GLANDS
The appropriate alumina column fractions containing 
llg-hydroxyandrostenedione, testosterone and adrenosterone, as 
judged by the concurrent column chromatography of authentic samples 
of these steroids, were re-chromatographed in the paper systems of 
Bush after the addition of the respective carrier steroids and 
the substances with added carrier isolated. The procedures 
involved have been outlined previously (p. 1&5) • Constancy of 
specific activity after three steps on paper was taken as the 
index of radiochemical purity.
The normal adrenal gland (Gland 47, Table XLIX) was found to
form llg-hydroxyandrostenedione, adrenosterone and testosterone
14 14from both DHA-4- C and androstenedione-4- C. They were formed
in only trace amounts. Taken together as a group, they accounted
for 0.5% of the total cpm of the incubated substrate DHA and
0.04% of the incubated androstenedione cpm.
The higher incorporation of cpm from DHA than androstenedione
suggested that DHA was a more important precursor than androstenedione.
However, the hyperplastic gland associated with Cushing*s syndrome
(Gland 48, Table XLIX) incorporated more radio-activity into
14llg-hydroxyandrostenedione and adrenosterone when DHA-4- C alone
TABLE XLIX
UTILIZATION OF DHA-^-^C AND ANDROSTENEDIONE-4-lifC BY NORMAL AND HYPERPLASTIC HUMAN ADRENAL GLANDS
The Formation of lip-hydroxyandrostenedione, Adrenosterone and Testosterone 
Incubation conditions are as shown in Tables XLV, XLVI and XLVII 
100 iig. of each authentic steroid added as carrier to the appropriate column fractions.
Gland
number
Type of 
gland Substrate
Isolated Steroids
lip-hydroxy-
androstenedione Adrenosterone Testosterone
Tcpm
%*
conversion Tcpm
%
conversion Tcpm
%
conversion
47 Normal
14
DHA-4- C 327 0.26 160 0.13 148 0.12
14Androstenedione-4- C 94 0.02 31 0.007 69 0.015
48 Hyperplasia
1 h.
dha-4- c 160 0.45 47 0.13 97 0.28
14-
DHA-4- C with added 
unlabelled androstenedione 99 0.28 27 0.08 116 0.33
14Androstenedione-4- C 567 0.13 88 0.02 22 0.005
49 Hyperplasia
DHA-4- Not detected Not detected Not detected
i 14Androstenedione-4- C 653 0.14 368 0.08 2513
. .. ■— ■ .....
5.7
* % of total cpm. added as substrate
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was the substrate than when an unlabelled androstenedione trap
also was added. If androstenedione was the major precursor, then
the total cpm. isolated in those two substances should be much
less in the presence of the trap than was actually found. The
total cpm incorporated from DHA into testosterone was elevated in
the presence of unlabelled androstenedione and only 22 cpm. were
14derived from androstenedione-4- C.
In Gland 49 (Table XLIX) no radio-activity could be detected
14in any of these carrier steroids when DHA-4- C served as the 
substrate, but approximately 6% of the substrate androstenedione-
144- C was converted principally to testosterone.
These experiments confirm that trace amounts of these three
14steroids may be formed from DHA-4- C under the present conditions.
In the normal gland and one of the hyperplastic glands (Gland 48) 
it is possible that DHA is a more important source than 
androstenedione as judged by comparison of the total cpm. incorporated 
This is particularly true for testosterone and is evidence ibr 
their formation in some glands, directly from DHA and not from 
androstenedione.
BOVINE ADRENAL GLANDS (BOVINE GLAND 1)
Bovine adrenal glands are known to be capable of producing 
in vitro lip-hydroxyandrostenedione, testosterone and adrenosterone.
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An experiment was designed to test the possibility that these 
three steroids are formed from DHA directly in this tissue.
METHODS
25 ml. of a 10% (W/V) homogenate of bovine adrenal glands,
prepared in equal volumes of 0.154M sodium chloride and 0.1M
phosphate buffer, were incubated in air for 90 minutes. 60 mg.
of NAD were added to a final volume of 27 ml. in each flask.
Three separate flasks were established. In flask 1, 1,700 p,g.
14of DHA-4- C (specific activity 125 cpm/y,g.) was the substrate.
141,700 p,g. of the DHA-4- C and 1,464 |ig of unlabelled androstenedione
were the steroid additions to flask 2 while 1,984 p,g. of
14androstenedione-4- C (specific activity, 145 cpm/p,g.) and 1,750 pig 
of unlabelled DHA served as the substrates for flask 3* The 
incubates were extracted with benzene:chloroform 6:1 (3 times 
5 volumes), and the extracts pooled and taken to dryness.
Alumina column chromatography was performed as described 
previously (p. 146). The androstenedione formed, after counting 
and measurement, was chromatographed twice in the Bush A system, 
constant specific activity of the eluted steroid being achieved.
The appropriate fractions of the alumina columns, containing 
lip-hydroxyandrostenedione, testosterone and adrenosterone, were 
chromatographed on the Bush A, B^ and B^ systems. Their separation
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was achieved using the Bush A system and constant specific activity 
of each steroid was obtained following elutionj counting and 
measurement from each of the three paper systems. Their identities 
were established by comparison with the mobilities of authentic 
steroids run concurrently. No derivatives were made.
RESULTS
The results are tabulated in Table L. The specific activities
of 110-hydroxyandrostenedione, testosterone and adrenosterone are
the same as that for androstenedione in flask 1 in which 
14DHA-4- C alone was the substrate. By contrast in flask 2 in which
unlabelled androstenedione was present their specific activities
are lower than that of androstenedione indicating utilization of
14the unlabelled steroids while when androstenedione-4- C was the
substrate in the presence of unlabelled DHA, their specific
activities are higher than the isolated androstenedione, which was
diluted by unlabelled androstenedione formed from DHA, the higher
specific activities of these three steroids indicating utilization
14of the androstenedione- C.
Consequently, llp-hydroxyandrostenedione, testosterone and 
adrenosterone are formed by the in vitro incubation of bovine 
adrenal glands by a pathway which involves androstenedione. No 
evidence for a direct pathway from DHA is obtained, pointing to a
TABLE L
14 14
UTILIZATION OF DHA-4- C AND ANDROSTENEDIQNE-4- C BY A BOVINE ADRENAL GLAND (BOVINE GLAND 1)
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
Isolated steroids
Flask 1 Flask 2 Flask 3
Tcpm
Specific activity 
cpm/pg. Tcpm
Specific activity 
cpm/pg. Tcpm
Specific activity 
cpVpg*
Androstenedione 181,838 114 169,890 75 233,202 78
llp-hydroxyandrostenedione 7,536 110 3,084 31 22,272 118
Adrenosterone 3,072 112 1,032 31 6,096 114
Testosterone 2,490 110 1,000 32 ^,35^ 124
0.154m sodium chloride and 0.1M phosphate buffer (1:1)
25 ml* of a 10% (W/V) homogenate
NAD, 60 mg. Final Volume: 27 ml.
Flask 1 - DHA-4- .0, 1,700 pg., specific activity, 125 cpm/pg.
Flask 2 - DHA-4- C, 1,700 pg., specific activity 125 cpm/pg. and unlabelled 
androstenedione, 1.464 pg 
Flask 3 - Androstenedione-4- C, 1,964 pg., specific activity, 145 cpm/pg.
and unlabelled DHA, 1,750 Pg*
90 minutes. Gas-phase: air.
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difference between their formation by bovine and human adrenal 
tissue in vitro from DHA.
FORMATION OF DHA-^f-^C FROM ANDROSTENEDIONE-4-1 
BY A NORMAL HUMAN ADRENAL GLAND (GLAND 47)
Following alumina column chromatography of the incubate of
14Gland 47 with androstenedione-4- C, a peak of radio-activity was 
noted associated with the mobility of authentic DHA (Table XLV).
If the substance was found to be DHA, this would be evidence for 
reversibility of the A^-3PHSD system for DHA to androstenedione 
in human adrenal glands.
The appropriate column fractions were submitted to paper 
chromatography in the Bush A system (running time, 6 hours) with 
authentic androstenedione and DHA run concurrently as standards.
Most of the radio-activity possessed the same Rf as androstenedione, 
but a small proportion corresponded to the mobility of DHA. This 
zone was eluted and 200 p,g. of DHA added as carrier. The sample 
was then rechromatographed in the Ligroin-Propylene glycol system 
of Savard and after elution the DHA was measured by the Zimmermann 
reaction and counted, allowing its specific activity to be 
estimated.
The sample was next acetylated and the DHA-acetate run on the 
Bush A system. After elution, counting and measurement, it was 
saponified to the free alcohol and run once more in the Bush A 
system, eluted, measured and counted. Constancy of specific activity 
was taken as evidence of radiochemical purity.
- 207 -
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14A known amount of DHA-4- C was taken through identical
procedures after the addition of DHA to the test sample. From
this, a recovery of 30% of the total cpm. added was found after
the paper chromatographic steps and acetylation procedures which
corresponded well with the final 6l pg. of DHA recovered from the
200 pg. originally added as carrier (31% recovery).
The results are tabulated in Table LI, from which it can be
seen that DHA of constant specific activity was isolated. The
specific activity of 2.1 cpm/pg. found after the second paper
chromatogram altered little on acetylation and subsequent
saponification of the acetate. The total cpm. isolated as DHA
(corrected for overall recovieries) represented a conversion of
14
0.1% of the substrate androstenedione-4- C or 8.6% of the utilized 
substrate.
Luring the course of these investigations, Ward and Engel
(1964) published a report in which sheep adrenal microsomes were
14shown to convert androstaiedione-4- C to DHA in the presence of
NADH. This conversion did not proceed in the presence of NAD.
The omission of NAD from the incubations of the normal human adrenal
gland explains why DHA formation from androstenedione was found
only in this experiment. In Glands 48 and 49, extracts of both
*14of the incubations with androstenedione-4- C as substrate did 
not contain DHA after the various procedures outlined above were
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performed. In both, NAD had been added to the incubation in 
a concentration of 30 mg. per incubate. Only negligable counts 
were detected in the DHA areas after two paper chromatograms of the 
extracts of these incubates. These counts disappeared on 
acetylation of the eluted zones.
However, since 7-keto-DEA can be formed from androstenedione 
in the presence of NAD (Tables XLV, XLVI & XLVII), the reversal of 
the reaction, androstenedione to DHA, would appear to be a different 
mechanism from that involving 7-heto-DHA formation in which the 
presence of NADH is not obligatory.
IN VITRO STUDY OF A BENIGN VIBILISING ADRENAL TUMOUR (GLAND 27)
Virilising tumours of the adrenal cortex are rare causes of 
either the adrenogenital syndrome or Cushing's syndrome. While 
bilateral adrenocortical hyperplasia causing the adrenogenital 
syndrome has been shown, principally by urinary studies, to be due 
to a deficiency of one of the adrenal enzyme systems responsible 
for the stepwise hydroxylation of the steroid molecule, most 
commonly the 21-hydroxylase (Jailer et al., 1955; Bongiovanni, 1958) 
and less frequently either the ll{3-hydroxylase (Eberlein 8c 
Bongionvanni, 1956) or the A^-3pHSD (Bongiovanni, 196l), the 
relationship of these enzyme systems to the causation of virilism 
by adrenocortical tumours is little understood. Two tumours 
causing virilism have been shown to be deficient in A^-3£HSD 
activity for DHA (Gland 26 8e 27» Table XXVIII) as measured by 
in vitro studies presented here.
Lipsett & Wilson (1962) studied 10 functioning adrenal 
tumours associated with both the "mixed" type of Cushing's syndrome 
and virilism and found, from urinary studies, evidence of 
defective lip-hydroxylation in nine, and impaired 21-hydroxylase 
and A^-3(3HSD activity in another two, both of which were associated 
only with virilism. Previously, a deficiency of the A^-3£HSD 
had been postulated as a cause of the high DHA urinary excretion 
in some adrenal tumours (Rubin 8c Dorfman, 1957)*
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Goldman and his colleagues (1964) demonstrated, histochemically
and by in vitro incubation studies, the absence of the A^-3(3HSD
in 5 of 6 adrenal tumours causing virilism. A relative deficiency
of this enzyme system has been reported in this condition by
Rubin and her associates (1963). 17a-hydroxypregnenolone was
converted in vitro to DHA more easily by an adrenal tumour than by
normal adrenal glands (Solomon et al., i960). Thus an abnormality
of the A.--33HSD appears to exist in some of the virilising adrenal
tumours. With the demonstration that several substrate-specific
A_-33HSD systems exist in bovine adrenal tissue (Ewald et al., z> —
1964a, 1964b, 1964c; Kowal et al., 1964a, 1964b; Kruskemper et al., 
1964), a deficiency of the A^-3PHSD system specific for DHA could 
not only explain the increased amounts of urinary DHA in adrenal 
virilism, but also help to explain the occurrence of virilism alone 
in the presence of the secretion of normal amounts of C^  
A^-3-ketosteroids. Whether the DHA produced by the tumour is 
responsible wholly for the virilism is not known as nearly all is 
present as the sulphate conjugate in adrenal and peripheral venous 
plasma (Baulieu, 1962), but DHA and DHA-sulphate are freely 
interconvertible (Roberts et al., 196l).
In 1962, the opportunity arose to study in vitro the 
biosynthetic pathways of a 228 g. adrenal tumour removed from a boy, 
aged 8 years, with precocious homologous pseudopuberty. The
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significant plasma and urinary steroid values are shown in 
Table LII. The clinical and urinary biochemical findings have 
been the subject of a recent report (Mortimer et al., 1964).
Due to the high urinary DHA levels found, the possibility that 
the A^-3pHSD system for DHA was defective in this tumour was 
surmised and incubations were planned to assay the A^-3PHSD for 
DHA and also to determine the activity of the A -3PHSD systems 
acting upon either pregnenolone or 17a-hydroxypregnenolone.
METHODS
The A.--3PHSD system was assayed in duplicate using the
modification of the method of Rubin and her colleagues (1961),
previously described (p. 128 ) . Other aliquots of the homogenate
14were incubated with DHA-4- C as the substrate, these extracts 
being submitted directly to paper chromatography using the Bush A, 
B^and B,_ systems.
A 30% (W/V) homogenate of a portion of the tumour was also 
prepared in KRPG containing 0.01M nicotinamide, and 3.0 ml. of
 ^L\.
this homogenate was incubated with cholesterol-4- C in the 
presence of 30 mg» of NAD for 90 minutes in air. To one of the 
three incubates, 200 y.g. of pregnenolone were added, while to 
another, 230 p,g. of progesterone were added, both to serve as 
trapping agents.
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i 4The incubates which contained cholesterol-4- C as substrate 
were extracted after dilution with 2 volumes of water with 3 volumes 
of benzene:chloroform (6:1), and the extracts taken to dryness 
and then partitioned between 50% aqueous methanol and hexane.
Paper chromatography of the residue of the methanol partition 
fraction was performed in the systems of Bush, Zaffaroni and Savard, 
Pive steroids were tentatively identified after repeated 
chromatography. To each, suitable carrier steroid was added, 
followed by further paper and silica gel column chromatography. 
Derivatives were formed and constancy of specific activity after 
several steps was taken as evidence of radiochemical purity,
RESULTS
The assay procedure using DHA as substrate failed to reveal
any ultraviolet absorbing steroids following silica gel column
chromatography (Table Lilia, see also Gland 27, Table XXVIII),
Loss of ultra-violet absorbing steroids was excluded by the
chromatography, directly on paper, of duplicate extracts with
*14DHA-4- C as substrate. No ultra-violet absorbing areas were 
detected and no radio-activity was found in the zones corresponding 
to the mobilities of androstenedione or 7~keto-DHA (Table LUIb) , 
thus indicating the absence of the A^-3|3HSD system for DHA and the 
system(s) for 7-keto-DHA formation under these conditions.
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The specific activity of the isolated radio-active DHA
from both incubation flasks was found to have decreased from the
608 cpm/p,g. of the added substrate to ^78 cpm/)ig. and **80 cpm/Vg.
respectively. From the ratio of the specific activities of the
*1 *fsubstrate isolated DHA-*f- C (608 cpm/p,g.; *f79 cpm/]ig., Table LIIIB) ,
it is possible to calculate the dilution of the substrate during the
period of incubation. A minimum of kB p,g* of unlabelled DHA
was contributed to the DHA pool during the incubation period from •
endogenous sources by 320 mg. of tumour homogenate.
Consequently, a minimum of 5«0 ]ig. of DHA were produced per
minute per g. net weight of tumour in vitro, so that if the entire
tumour had been functioning constantly at this rate in vivo,
1.6*+ g. of DHA could have been produced per day. However, the
urinary output was of the order of 25**- mg. per day (Table LII).
The difference between the two values may be due to the in vitro
conditions, and that large portions of the tumour were inactive
due to necrosis and haemorrhage.
When portions of the tumour homogenate were incubated with 
1*+cholesterol-*!-- C, five steroids possessing a A^-3-ketone grouping were 
isolated and identified following the addition of carrier steroids 
(Table LIV). 17a-hydroxyprogesterone was isolated from the flask 
to which no trapping agent was added, while deoxycorticosterone and 
corticosterone were identified from the incubation in which
pregnenolone served as a trap. Deoxycorticosterone and cortisol
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were isolated from the remaining flask containing the progesterone 
trap. Neither pregnenolone nor progesterone served as efficient 
traps, little of either added steroid being recovered.
The identification of these steroids possessing a A^-3“&etone 
structure indicates the presence of an intact biosynthetic pathway 
from cholesterol to corticosteroids in the tumour. This is in 
agreement with the preoperative finding of elevated urinary 
17-ketogenic steroids (Table LII). Thus a A^-3£HSD system acting 
upon either pregnenolone or 17a-hydroxypregnenolone was present 
in the tumour in vivo and in vitro. However, as no equivalent 
system acting upon DHA could be demonstrated (Table LIII) the 
possible explanation lies in their being two A,_-3PHSD systems, one 
for either pregnenolone or 17a-hydroxypregnenolone and the other 
for DHA. This finding agrees with the suggestion by Weliky and 
Engel (1962) of multiple substrate-specific A^-3pHSD systems in the 
human adrenal and with the finding that in beef and human adrenal 
tissue, the A..-30HSD can act upon a variety of A^-androstenes 
and A^—pregnenes in vitro (Berliner et al., 1962; Baulieu et al., 
1936b; Kowal et al., 1964a; Pasqualini et al., 1964).
Two substrate specific A^-3-ketosteroid isomerases have been 
found in beef adrenal glands (Ewald et al., 1964a, 1964b, 1964c; 
Kruskemper et al., 1964) and it was found possible to separate the 
A^-pregnene-3,20-dione and the A^-androstene-3»17”dione isomerases
- 220 -
(Ewald et al., 1964c)• Two separate 30*"Ol dehydrogenases for 
^19 s^ero^ s are thought to exist, as epiandrosterone had no 
competitive effect upon the conversion of DHA to androstenedione by 
beef adrenal acetone powders (Kowal et al., 1964b). Whether two 
separate 30-ol dehydrogenases exist capable of acting upon the 
unsaturated 30-hydroxysteroids remains to be elucidated.
The absence of the A^-30HSD system has been noted both 
biochemically in vitro and histochemically in other virilising 
adrenal tumours (Roversi et al., 1963; Goldman et al», 1964; p. 144 ) •
Whether the entire A^-30HSD system for DHA was absent in 
the tumour just discussed, or whether only the isomerase or the 
dehydrogenase system was deficient cannot be stated since no 
intermediates of the overall reaction (i.e., A^-androstene-3»17- 
dione or A^~androstene-3P“*ol”17“One) were incubated.
<i 2j.
UTILIZATION OF DHA-4- C BY HUMAN AND BOVINE ADRENAL GLANDS
IN THE PRESENCE OF PREGNENOLONE AND 17<x-HYDRQXYPREGNSNQLONE
Since the evidence cited points to the existence of separate 
enzyme systems acting upon the A^-pregnenes and A^-androstenes, no 
substrate competition for the enzyme systems acting on DHA should be 
found when DHA and a A^-3^~hydroxypregnene are incubated together.
To determine if this was correct, incubations of homogenates 
prepared from surgically removed adrenal glands were done.
METHODS
Gland 30 - Hyperplastic Human Adrenal Gland.
Three separate flasks were prepared. 5*0 ml. of a 10% (W/V) 
homogenate, prepared in KRBG containing 0.01M nicotinamide and 
30 mg. of NAD, were added to each flask. To two of the preparations 
either 6.0 mg. of pregnenolone or 5.0 mg. of 17a-hydroxypregnenolone 
were added. 272 )ig. of DHA-^- C (specific activity, -^85 cpm/Vg.) 
were used as the substrate in all the flasks. The incubation 
time was 120 minutes, and the preparations were gassed with 95% 
oxygen and 5% carbon dioxide.
Gland 51 - Normal Human Adrenal Gland.
Three separate assays were prepared. 1.5 ml. of a 10% (W/V) 
homogenate, prepared in equal volumes of 0.15^M sodium chloride 
and 0.1M phosphate buffer and containing 12 mg. of NAD, were added
- 221 -
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to each flask. 850 ^g. of DHA-^ f- C (specific activity 125 cpm/p,g.) 
served as substrate in all three flasks, to two of which either 
880 |ig. of pregnenolone or 880 -jig. of 17a-hydroxypregnenolone were 
added. The incubation time was 90 minutes and the gas-phase was 
air.
Normal Bovine Adrenal Gland (Bovine Gland 2).
Five separate flasks were established. 25 ml* of a 10% (W/V)
homogenate, prepared in KRBG containing 0.01M nicotinamide and
. “1 Ll
60 mg. of NAD were added to each flask. 1,700 p,g. of DHA-^ f- C
(specific activity, 125 cpm/p,g.) served as substrate in each
incubation. To two of the flasks, either 2,200 p,g. or 55*2 mg.
of pregnenolone were added and to a further two, either 2,200 y,g.
or 35*2 mg. of 17a-hydroxypregnenolone were added. The incubation
time was 90 minutes and the preparations were gassed with 95%
oxygen and 5% carbon dioxide.
All the preparations were extracted three times with five
volumes benzene:chloroform (6:1) after dilution with 2 volumes of
water. The extracts were pooled and taken to dryness and
chromatographed as previously described on a 7*5 g* alumina column
for both human glands and a 10.0 g. alumina column for the
bovine gland incubation.
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RESULTS AND DISCUSSION
Using a KRBG medium, androstenedione had been found to be 
the principal product resulting from the utilization of DHA in a 
previous incubation (Gland *f9» Table XLVII) and this was confirmed 
in the incubation of the hyperplastic gland (Gland 50, Table LV)•
The formation of 7-keto-DHA amounted to 1.5% of the recovered 
radio-activity in the control flask, 0.^% in the flask with added 
pregnenolone and l.k% in that with added 17a-hydroxypregnenolone.
The isolation of 7-keto-DHA was only possible from the tissue 
incubated with DHA alone.
The recoveries of total cpm., added as substrate, after 
column chromatography were 86% in the control flask, and 72% and 
70% for the incubates with added pregnenolone and 17a-hydroxy- 
pregnenolone.
From Table LV, it can be seen that whereas 106,538 cpm. were 
incorporated into androstenedione from DHA, only 6^,436 cpm. and 
76,358 cpm. were formed in this fraction of the other incubates. 
Accordingly pregnenolone decreased the conversion of DHA to 
androstenedione by a factor of 39*3% and 17«“hydroxypregnenolone by 
a factor of 28.3%. These percentages would be reduced if allowance 
for the recovery of added substrate DHA-4- C is made, bringing the 
percentage decrease with pregnenolone down to 25% and 17oc-hydroxy - 
pregnenolone to 12%. From the y,g. of androstenedione recovered
TABLE LV
1 4
UTILIZATION OF DHA-4- C BY A HYPERPLASTIC HUMAN GLAND IN THE PRESENCE OF PREGNENOLONE AND 17<x-H YDROX YPREGNENQLONE (GLAND 50)
Medium: KRBG with added 0.01M nicotinamide
Tissue; 
Additions! 
Substrate;
Incubation Time;
5.0 ml. of 10% (W/V) homogenate
NAD, 30 mg. .r 
Assay 1:- DHA-4-,.,C, 
Assay 2:- DHA-4- .C, 
Assay 3:- DHA-4- c, 
120 minutes.
Final Volume: 6.0 ml.
272 Ug., specific activity, 485 cpm/Vg.
272 pg., specific activity, 485 cpm/p,g. with added pregnenolone, 6.0 mg.
272 pg., specific activity, 485 cpm/|ig. with added 17a-hydroxypregnenolone, 5.0 mg.
Gas-phase: 95% oxygen, 5% carbon dioxide.
Column
peak Isolated steroids
Assay 1 Assay 2 (Pregnenolone) Assay 3 (17a-hydroxypregnenolone)
Tcpm tig.
Specific activity 
cpm/Vg. Tcpm tig-
Specific activity 
c pm/|ig. Tcpm tig.
Specific activity 
cpm/ng.
I Androstenedione 106,538 250 426 64,436 161 400 76,358 246 310
II DHA 4,274 9.5 450 29,520 63 469 13,042 39.5 330
Shoulder 
of II
Possible llp-hydroxy- 
androstenedione 
testosterone, or 
adrenosterone
936 - - 608 - - 1,128 - -
III 7-keto-DHA 1,752 4.0 438 402 - - 1,314 - -
IV - 306 - - 186 - - 216 - -
V - 192 - « 102 - - 894 - -
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from each incubate, the uncorrected percentage inhibition amounted 
to 35*6% in the presence of pregnenolone, but only 1.5% in the 
case of 17a-hydroxypregnenolone. The reason for this latter 
discrepancy can be seen on comparison of the specific activities 
of the recovered androstenedione and DHA (Table LV).
The specific activity of DHA isolated from the pregnenolone
flask is similar to that of the control, while the DHA from the
17<x-hydroxypregnenolone flask is much lower. This is due to
"] 4dilution of the added DHA-4- C substrate by unlabelled DHA derived 
by side chain cleavage of the 17a-hydroxypregnenolone by the tissue 
during the period of incubation. A total of 99 t-ig. of 17a- 
hydroxypregnenolone was converted to DHA. This is calculated from 
the ratio of the specific activities of the isolated DHA in the 
control and experimental flasks (450 cpm/p,g.:330 cpm/pg.). The 
specific activities of the isolated androstenedione from the control 
and 17a-hydroxypregnenolone flasks are the same as those of the 
appropriate substrate DHA isolated. Pregnenolone reduced the 
amount of androstenedione formed from DHA and there is a fall in 
the specific activity of androstenedione as compared to the DHA 
substrate possibly due to some formation of androstenedione from 
pregnenolone via 17a-hydroxypregesterone.
Thus in this hyperplastic gland (Gland 50) pregnenolone led 
to a significant inhibition in the conversion of DHA to androstenedione
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while 17a-hydroxypregnenolone was without significant effect, the
fewer cpm, found in the androstenedione fraction being due to
1 4dilution of the substrate DHA-4- C by unlabelled DHA derived from
17<x-hydroxypr egnenolone,
Table LVI presents the results of the utilization of 
14DHA-4- C by a normal human adrenal gland in the presence of 
equimolar amounts of pregnenolone and 17a-hydroxypregnenolone•
Both androstenedione and 7-keto-DHA were formed in each incubation.
The 7-keto-DHA formed amounted to 2,9% of the recovered radio­
activity in the control flask, 4,2% in the flask with added 
pregnenolone and 3*2% in that with added 17a-hydroxypregnenolone.
The recoveries of total cpm., added as substrate, after column 
chromatography were 93%> 94% and 93% the control, pregnenolone 
and 17oc-hydroxypregnenolone incubations.
It can be seen that similar amounts of radio-activity were 
incorporated into androstenedione from DHA, in the control (21,790 cpm) 
and 17<x-hydroxypregnenolone (23*700 cpm.) flasks, while in the 
pregnenolone incubation, only 14,496 cpm. were found as 
androstenedione. This represents a decrease in the conversion of 
DHA to androstenedione of 33*5%» From the iig. of androstenedione 
recovered from each incubation, the percentage inhibition due 
to pregnenolone is 30%* while an apparent enhancement Oocured with 
17«-hydroxypregnenolone, 12.3% more androstenedione being formed.
TABLE LVI
'I L
UTILIZATION 0? DHA-4- Q BY A NORMAL HUMAN GLAND IN THE PRESENCE OF
PREGNENOLONE AND 17a-HYDR0XYPREGNEN0L0NE (GLAND 51)
Mediums 
Tissues 
Additionss 
Substrates
Incubation Times
0*154m sodium chloride and 0,1M phosphate buffer (lsl) 
1*5 nil. of 10% (W/V) homogenate
Final Volumes 1*9 ml*
8^0 jig.,
850 pg.,
850 pg.,
NAD, 12 mg. 14,Assay 1 - DHA-4-„'/C,
Assay 
Assay 
90 minutes.
142 - dha-4- 7c,
3 - d h a -4- c,
specific activity, 125 cpm/pg. 
specific activity, 125 cpm/pg. 
specific activity, 125 cpm/p,g. 
Gas-phases air.
and pregnenolone, 880 pg.
and 17ot-hydroxypregnenolone, 88© tig-
Isolated steroids
Assay 1 Assay 2 (pregnenolone) Assay 3 (17a-hydroxypregnenolone)
Tcpm V-S*
Specific activity 
cpm/pg. Tcpm P-g.
Specific activity 
c pm/ng. Tcpm P-g*
Specific activity 
cpm/pg.
Androstenedione 21,790 183 119 14,496 128 113 23,700 206 115
DHA 69,840 325 133 76,880 600 128 66,794 526 127
7-keto-DHA 2,964 23 129 4,214 32 130 3,200 25 128
Peak IV 1,686 - - 1,578 - - 1,600 - -
Peak V 3,132 - - 2,894 - - 3,744 - -
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The specific activities of the DHA isolated from each of the
flasks is similar, so that none of the added pregnenolone or
17a-hydroxypregnenolone was converted to DHA by this normal gland.
The specific activities of the isolated androstenedione and
7-keto-DHA are all within the same range as the isolated substrates
except perhaps for the androstenedione of the pregnenolone flask
14which is 12% lower than the corresponding DHA-4- C. Consequently,
some androstenedione might have been formed from the added
pregnenolone, although this decrease in specific activity is
probably not significant.
Thus, in this normal gland (Gland 51), no inhibition was
exerted by 17a-hydroxypregnenolone upon the conversion of DHA to
androstenedione, but pregnenolone, as in the hyperplastic gland
(Gland 50), led to a significant decrease in the conversion of DHA
to androstenedione.
The bovine adrenal gland (bovine gland 2) was studied to
ascertain whether pregnenolone and 17a-hydroxypregnenolone exerted
14similar effects upon the conversion of DHA-4- C to androstenedione 
as in human adrenal glands. Similar amounts of pregnenolone and 
17a-hydroxypregnenolone relative to DHA were added to the flasks 
as were present in the incubations of human glands 50 and 51.
The results are tabulated in Table LVII.
Bovine adrenal glands do not produce, in vitro from DHA,
TABLE LVII
14
UTILIZATION OF DHA-4- C BY A BOVINE ADRENAL GLAND IN THE
PRESENCE OF PREGNENOLONE AND 17<x-HYDROXYPREGNENOLQNE
(BOVINE GLAND 2)
Medium: KRBG with added O.OIM nicotinamide
Tissue: 25 ml. of 10% (W/V) homogenate 
Additions: NAD, 60 mg. Final Volume: 27 ml. 
Substrate: See below
Incubation Time: 90 minutes. Gas-phase: 95% oxygen
and 5% carbon dioxide.
Substrates
Isolated Steroids
Androstenedione Other UV 
absorbing 
steroids *
Tcpm
Specific
activity
cpm./Vg. Tcpm
1A
DHA-4- C, 1,700 Tig. 
specific activity, 125 cpm/p-g. 180,560 133 5,328
1 4DHa-4- C, 1,700 \Lg*, specific 
activity, 125 cpm/ixg. with 
added 2,200 p-S* pregnenolone
176,280 113 5,872
*14
DHA-4- C, 1,700 p,g., specific 
activity, 125 cpm/p,g. with 
added 55*2 mg. pregnenolone
150,264 103 6,682
41ADHA-4- C, 1,700 pg., specific 
activity, 125 cpm/Vg. with 
added 2,200 jig. 17a-hydroxy- 
pregnenolone
176,536 125 8,100
"14DHA-4- C, 1,700 Tig., specific 
activity, 125 cpm/iig., with 
added 55.2 mg. 17«-hydroxy- 
pregnenolone
178,416 102 8,200 
-- ' ^
* lip-hydroxyandrostenedione, adrenosterone and testosterone 
identified in this fraction from every incubation.
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appreciable amounts of 7-keto-DHA. The formation of androstenedione, 
llp-hydroxyandrostenedione, adrenosterone and testosterone was 
found in the present study. The recoveries of the total cpm., 
added as substrate, was between 86% and 87% for all the flasks with 
the exception of that in which 55*2 mg. of pregnenolone was added.
Here the recovery was only 74%.
If the recovery in this incubation is corrected for losses,
then similar amounts of radio-activity were incorporated into
androstenedione from DHA in all the flasks, no inhibition of the
conversion of DHA occurring with either approximately equimolar or
very high amounts of the C^  A^-5P~hydroxysteroids. The total
cpm. incorporated into the lip-hydroxyandrostenedione, adrenosterone
and testosterone fraction tended to rise in the flasks containing
either pregnenolone or 17oc-hydroxypregnenolone, especially the
latter, so that there was no inhibition in their formation. No 
*14DHA-4- C was recovered from any of the flasks.
The specific activities of the recovered androstenedione in 
the control flask and that with 2,200 p,g. of 17a-hydroxypregnenolone 
are the same. However, some androstenedione may be formed from 
pregnenolone and 17a-hydroxypregnenolone, more especially when 
they are present in high amounts, judged by the lower androstenedione 
specific activities from these flasks.
Thus, in bovine adrenal glands, no inhibition of the conversion
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of DHA to androstenedione occurs in the presence of equimolar 
or very high amounts of pregnenolone or 17a-hydroxypregnenolone. 
This is in agreement with the work of Kowal and his colleagues 
(1964b) who noted no inhibition of the conversion of DHA to 
androstenedione by either of these C ^  A^-3P”hydroxysteroids in 
acetone powder preparations of bovine adrenal glands.
In bovine adrenal tissue, different Aj_-*3|3HSD systems exist 
for the A,_-pregnenes and A^-androstenes, while in human adrenal 
glands, different enzymes are present for DHA and 17a-hydroxy- 
pregnenolone. The inhibition of the conversion of DHA to 
androstenedione exerted by pregnenolone may be due to either 
interference or competition with some enzyme involved, in which 
case they may show a common A^-3pHSD in part or whole, or a 
direct inhibiting effect. However, the degree of inhibition 
noted is unlikely to be due to a direct effect as the large amounts 
of pregnenolone added should have led to almost inhibition under 
those circumstances.
UTILIZATION OF DHA-4-1 BY A HUMAN BENIGN VIRILISING
ADRENAL TUMOUR (GLAND 25)
A further adrenal tumour, probably benign, associated with 
virilism in a young male child, aged 15 years, has been studied*
The incubations were planned to assay the A^-3PHSD system for DHA 
and to observe if 7-3£eto-DHA was formed by the tumour and whether 
a similar pathway was present as was observed in normal and 
hyperplastic glands.
METHODS
The Aj--3pHSD system for DHA was assayed in duplicate by a
modification of the method of Rubin et al. (1961) described
previously (p.128 ) by incubating 1.6 ml. of a 20% (W/V) homogenate
with DHA. Further assays were performed in triplicate using 
14DHA-4- G as substrate. To one of these flasks, 732 p,g. of 
unlabelled androstenedione were added as a trap. The incubates 
were extracted and chromatographed initially upon a 1.5 g. silica 
gel column and then the combined column fractions were re­
chromatographed on a 7*5 6# alumina column.
Further incubations were performed using KRPG as the medium 
and utilizing 7*5 ml* of a 10% (W/V) homogenate. DHA-4-1^C
was the substrate in two flasks, to one of which 732 p,g. of
1 ifandrostenedione was added as a trap. Androstenedione-4- C served
- 232 -
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as the substrate in the third flask. All the samples were
incubated for 90 minutes and following extraction, they were
chromatographed and over-run in a Bush B^ system for 8 hours. The
overflows, which would contain steroids of the polarity of DHA,
androstenedione, adrenosterone, testosterone and llp-hydroxy-
androstenedione, were submitted to alumina column chromatography.
The 7-keto-DHA zone from the Bush B^ paper chromatogram was eluted
and chromatographed on a separate alumina column.
The column fractions corresponding to llp-hydroxyandrostenedione,
testosterone and adrenosterone were rechromatographed using the
Bush A, B., and B„ systems with appropriate carrier steroid added.
5 *
The procedures to isolate any labelled DHA formed from
14androstenedione-4- C by the tumour were performed as described 
on page 207•
RESULTS AND DISCUSSION
The results of the studies on the utilization of DHA in which
the total U.V. absorbing steroids were measured following silica
gel column chromatography have been presented previously (Gland 25, 
Table XXVIII). The mean value of 0*90 p.g. U.V. absorbing steroid 
formed per minute per mg. nitrogen is not a true measure of the 
A(.-3PHSD activity of the tissue, due to the formation of both 
androstenedione and 7-keto-DHA by the tumour. Subsequent alumina
- 234 -
chromatography showed that the proportion of androstenedione to the 
total U.V. absorbing steroids formed ranged from 15% to ?6%
(Table LVIII). The mean activity of the A,--3pHSD system for DHA 
is 0.35 Hg« androstenedione formed per minute per mg. nitrogen, 
while that for the enzyme system(s) leading to 7-keto-DHA is 0*55 V-g* 
per minute per mg. nitrogen. No equivalent assays have been 
performed with normal adrenal tissue in which the androstenedione and 
7-keto-DHA have been separated so that no direct comparison of the 
activity of these enzyme systems can be made with that of normal 
tissue. However, the sum of the activities of both enzyme systems 
(0.9 p<g» per minute per mg. nitrogen) is less than that found for 
their sum in normal and hyperplastic tissues as measured by the 
silica gel column technique (between 1.83 and 1.94 pg. per minute 
per mg. nitrogen, Table XXIII). This may indicate a relative 
deficiency of both systems in this tumour.
The variation in the proportions of the two steroids formed 
by the tumour (Table LVIII) is similar to that found in other 
adrenal gland incubations, yet the sum of the steroids formed is 
similar in amount in each assay within the incubation.
In Table LIX, the effect of an androstenedione trap upon 
the A^-3PHSD system for DHA is seen. An apparent enhancement of 
the reaction would seem to have occurred, indicated by the increase 
in total cpm. incorporated into androstenedione in the presence
TABLE LVIII
*14
UTILIZATION OF DHA AND DHA-4- C BY A HUMAN
VIRILIZING ADRENAL TUMOUR (GLAND 25) 
Medium:
Tissue: 
Additions: 
Substrate:
Incubation Time:
0.154 M sodium chloride and 0.1M phosphate 
buffer (1:1)
1.6 ml. of 20% (W/V) homogenate 
6 mg. NAD. Final Volume: 1.8 ml.
1) DHA, 200 pg.
2) DHA-4- C, 130 pg., specific 
activity 479 cpm/pg.
30 minutes. Gas-phase: air.
Substrate
Isolated Steroids
Total pg. formed 
from DHA
Androstenedione 7-keto-DHA
pg. formed pg. formed
DHA 11 61 72
DHA 51 16 67
DHA-4-1ifC 17 50 67
Mean pg. androstenedione formed per minute per mg. nitrogen 
- 0.35
Mean pg. 7-keto-DHA formed per minute per mg. nitrogen - 0.55
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TABLE LIX
UTILIZATION OF DHA-4-1J*C AND ANDROS TENEDIQNE-4-lZfC BY A HUMAN 
VIRILISING ADRENAL TUMOUR (GLAND 25)
0.154 M sodium chloride and 0.1M phosphate buffer (1:1)
1.6 ml. of a 20% (W/V) homogenate
NAD, 6 mg.. Final Volume: 1.8 ml.
1) DHA-4-^C, 130 pg., specific activity, 479 cpm/pg.
2) DHA-4-- C, 130 ]xg., specific activity, 4-79 cpm/pg. with added
unlabelled androstenedione, 732 pg.
30 minutes. Gas-phase: air.
Column
peak
Isolated
steroids
‘14Substrate: DHA-4— C
*14
Substrate: DHA-4- C with added 
androstenedione as a trap
Tcpm P-g/.
Specific activity 
cpm/pg. Tcpm v-s*
Specific activity 
Cpm/pg.
I Androstenedione 6,216 14-.2 4-36 15,186 550.5 27.6
II DHA 13,828 31 44-6 6,846 15.8 433
Shoulder 
of II
* 702 - - 618 - -
III 7-keto-DHA 17,382 4-1 424 7,866 23.3 337
IV - 2,376 - - 612 - -
V - 1,636 - - 588 - -
* Substances of the polarity of lip-hydroxyandrostenedione, adrenosterone and testosterone
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
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of the trap when compared with the control flask with DHa-4-
alone. However, in view of the variability in androstenedione
formed as noted in the other assays (Table LVIII), the
androstenedione formed from DHA-4- C may represent only slight
inhibition in the presence of the trap. From the ratio of the
specific activities of the isolated DHA and 7-keto-DHA (424 cpm/pg.:
337 cpm/pg., Table LIX) it is possible to calculate that 79%
14of the 7-keto-DHA arose directly from DHA-4- C, the remainder 
coming from the androstenedione trap. The ratio found in a 
hyperplastic gland for this product was 69% (Gland 48, Table 
XLVI).
Greater amounts of both androstenedione and 7-keto-DEA were 
*14formed from DHA-4- C when larger amounts of the tumour tissue
were incubated for a longer period of time (Table LX). 74 pg.
*l4
of androstenedione were formed from DHA-4- C by the control, while
14only 53 pg. were formed from DHA-4- C in the presence of the 
androstenedione trap. This is calculated from the total cpm. 
incorporated into androstenedione related to the specific activity
14
of the isolated substrate DHA-4- C (24,323 + 460 = 59 Pg.).
As 90 pg. of 7-keto-DHA were formed in the control flask
14
and 103 pg. were formed from DHA-4- C in the flask with added 
androstenedione (Calculated from the total cpm. incorporated into 
7-keto-DHA related to the specific activity of the isolated substrate
TABLE LX
UTILIZATION OF DHA-4-lZfC AND ANDROSTENEDIOME-^-^C BY A HUMAN VIRILISING ADRENAL TUMOUR (GLAND 25)
Medium:
Tissue:
Additions:
Substrate:
Incubation Time:
KRPG with added O.OIM nicotinamide 
7*5 ml* of 10# (W/V) homogenate
NAD, 30 m ^  Final Volume: 8,5 ml.
1) DHA-4-^C, 260 ]j,g., specific activity, 479 cpm/p-g.
2) dha-4- c,  260 jig*.^specific activity, 479 cpm/p.g., with added androstenedione, 732 jig,
3) Androstenedione-4- C, 300 ]ig., specific activity, 4-35 cpm/v,g.
90 minutes. Gas-phase: air,
Column
peak
Isolated
steroids
14
Substrate: DHA-4- C
--------
Substrate: DHA-4- C with added 
androstenedione as a trap
14Substrate: Androstenedione-4- C
Tcpm Hg*
Specific activity 
cpm/iig. Tcpm yg.
Specific activity 
cpm/Vg. Tcpm Tig*
Specific activity 
cpm/v,g.
I Androstenedione 33,208 74 473 24,323 353 44 95,650 220 457
II DHA 1,877 3.8 473 1,668 3.6 460 5,584 - -
Shoulder 
of II
* 7,159 - - 8,611 - - 10,788 - -
III 7-keto-DHA 42,667 90 474 47,262 148 320 10,756 24.4 440
* Substances of the polarity of lip-hydroxyandrostenedione, adrenosterone and testosterone
- 238 -
- 239 -
A h
DHA-^+- C, ^7,262 ♦ k60 = 103 p-g.)., some decrease in the utilization 
of DHA by the A^-30HSD system would appear to have occurred, when 
compared with the rates of formation of the two substances indicated 
in Table LX.
70% of the 7-keto-DHA formed in the presence of the androstene-
dione trap is derived from DHA-^ 4— C, This is calculated from the
ratio of the specific nativities of DHA and 7-keto-DHA isolated
(*f60 cpm/Vg.: 320 cpm/Vg., Table LX) • This compares well with the
79% formed from DHA-k- C by the other incubation of the tumour
1 k(Table LIX) and by the 69% formed from DHA-^ t— C by an hyperplastic
gland (Gland *f8, Table XLVI) .
Additional proof that 7-keto-DHA could be formed by this
tumour from androstenedione as in normal and hyperplastic human
adrenal glands was shown by the finding of its formation from an
1A
incubation in which androstenedione-4- C was the sole substrate*
2k -jig. of labelled 7-keto-DHA being isolated (Table LX) •
Table LXI summarises the activities of the two enzyme systems 
studied in this tumour. Their activities show a marked decrease 
with increasing amounts of tissue and time of incubation. Although 
no normal or hyperplastic Human gland has been incubated under 
exactly comparable conditions, a comparison can be made with 
Gland A-8 (Table XLVIII). Even taking into account the decrease 
in rate of DHA utilization with increasing tissue amounts, the
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rate found in this tumour is much lower, possibly indicating a 
relative deficiency of the A^-3PHSD system for DHA and the 
system(s) leading to 7-keto-DHA formation from DHA.
14
Peak II from the alumina column of the androstenedione-4- C 
incubation was thought to represent DHA (Table LX)• Following 
the addition of authentic carrier DHA to the column fraction and 
its acetylation, the radio-activity separated from carrier DHA 
on a Bush A chromatogram.
The radio-activity corresponding to the mobility of 
ll(3-hydroxyandrostenedione, testosterone and adrenosterone, eluted 
from the alumina column (Table LX), was submitted to paper 
chromatography after the addition of 100 p,g. of authentic appropriate 
carrier steroids. The zones corresponding to either adrenosterone 
or testosterone contained no radio-activity. llfj-hydroxy-
■j if.
androstenedione was formed from both DHA-4- G and androstenedione- 
144- C (Table LXII). Since the total cpm. found in the lip-hydroxy-
androstenedione zone after the addition of carrier, when 
14DHA-4- G was the substrate in the presence of androstenedione as
a trap, were greater than the equivalent ll|3-hydroxyandrostenedione
14 14zone isolated when either DHA-4- G or androstenedione-4- C
were the sole substrates, it is possible that the traces of 
llp-hydroxyandrostenedione may be formed mainly from DHA directly, 
not by lip-hydroxylation of the formed androstenedione. Similar
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findings were noted in a normal and an hyperplastic human adrenal 
gland (Glands 47 & 48, Table XLIX).
The lack of testosterone formation, in even trace amounts, 
in any of the incubations of the tumour cited, is puzzling 
considering that the lesion was of the virilising type. However, 
if a relative deficiency of the A^-3pHSD system for DHA utilization 
was present, it may be that the large amounts of secreted DHA 
could itself have led to the virilism.
A STUDY OF THE A,_-30HSD SYSTEMS IN AN 
ADRENOCORTICAL TUMOUR OF THE MOUSE
Female mice of the CE strain are known to develop spontaneous 
adrenocortical tumours when gonadectomised shortly after birth.
No reports of their steroid biosynthetic activity in vivo or 
in vitro appear to have been recorded in the literature.
The principal reason for examining the biosynthetic pathways 
in these tumours was to determine whether they possessed A^-3PHSD 
activity, not only for DHA but also pregnenolone and 17a-hydroxy- 
pregnenolone•
Recently Fukushima and Gallagher (1963) studied three 
”non-functioning” human adrenal tumours and found evidence in two 
of the lesions, from urinary studies, of a deficiency of the 
A^-3|3HSD acting upon pregnenolone. In the other patient, there 
was no evidence of abnormal steroid function. Thus, although 
some tumours cause no endocrine upsets, this may be due not to 
their being ”non-functioning”, but to the absence of the necessary 
enzymes required for active steroid hormone synthesis, so that 
they are able to produce only non-hormonally active steroids.
Dr. John Anderson and Miss Maureen McIntyre, working in the 
University Department of Pathology at Glasgow Royal Infirmary, were 
able to show that successful tissue culture of these CE strain 
adrenal tumours was possible. Incubations were carried out after
- 244 -
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20 days, culture to determine whether the viable cells still 
possessed the same steroid biosynthetic enzymes as could be demon­
strated in vitro immediately after killing the mice.
METHODS
1. Incubation of CE Mouse Adrenal Tumour Tissue Homogenates.
Five complete tumours were homogenised in a medium consisting 
of equal volumes of 0.154m sodium chloride and 0.0IM phosphate 
buffer to give a 10% (W/V) final tissue concentration. 10 ml. 
of this preparation were added to each of four flasks, containing 
60 mg. of NAD in a final volume of 12 ml. Different substrates 
were added to each flask: 500 p,g. of pregnenolone - 16T (specific
activity, 4.4 x 10 cpm/pg.), 500 jig. of 17a-hydroxypregnenolone-
5 147T (specific activity 1.5 x 10 cpm/y,g.) or 520 p,g. of DHA-4- C
(specific activity, 479 cpm/Vg.). A fourth flask was prepared 
14using DHA-4- C as substrate as before, but containing 1,474 |ig. 
of unlabelled androstenedione as a trap. The incubates were 
shaken at 37°C in air for 90 minutes. At the end of this time, 
after dilution with 2 volumes of water, they were extracted three 
times with 5 volumes of benzene:chloroform (6:1) and the pooled 
extracts of each incubate taken to dryness.
The extracts from flasks incubated with pregnenolone-l6T 
and 17<x-hydroxypregnenolone-7T were submitted to paper chromatography.
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After tentative identification of progesterone, 17ia-hydroxy-
progesterone, deoxycorticosterone, 11-deoxycortisol, and cortisol
appropriate carrier steroids were added to the eluted zones and
the material taken to constaht specific activity using the paper
chromatographic systems of Bush and of Savard and in some cases
silica gel chromatography as previously described. Derivatives
of all of the eluted steroids with the exception of progesterone
14were made as subsequently shown. The extracts from the DHA-4- C
incubations were submitted directly to alumina column chromatography
as described previously.
2. Analysis of Tissue Culture Medium.
After 20 days of tissue culture, the medium, Glaxo 199
(pH 7*4) from two cultures, was replaced with 5 ml. of a fresh
"14solution containing 12 |ig. of progesterone-4- C (specific activity,
ii
9.15 x 10 cpm/pg.) dissolved in 0.01 ml. of propylene glycol.
The flasks were replaced in the incubator and incubated without 
shaking at 37°C for 24 hours in an atmosphere of 5% carbon dioxide 
in air (Anderson & McIntyre, personal communication).
The cells and medium from one flask and the medium only 
from the other flask (these cells being kept for autoradiography), 
were extracted, after dilution with water, three times with 
3 volumes of benzene:chloroform (6:1). The pooled dried extracts 
were submitted to paper chromatography. After preliminary
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identification of the steroids, suitable carrier steroids were 
added and the material taken to constant specific activity using 
the paper techniques of Bush and of Savard and silica gel 
chromatography for 17a-hydroxyprogesterone. Derivatives of all 
of the steroids were formed as will be described.
RESULTS AND DISCUSSION
The steroids formed by the tumour from 17a-hydroxypregnenolone 
are shown in Table LXIII. Each of these steroids was taken to a 
constant specific activity (cpm/Vg.) by the procedures indicated. 
The formation of 17a-hydroxyprogesterone, 11-deoxycortieol and 
cortisol could only be expected to occur if a A^-3PHSD system 
is present capable of acting upon 17a-hydroxypregnenolone.
Mature mouse adrenal glands appear either to be unable to 
form 17-hydroxylated steroids or to form them only in trace amounts 
(Hofman, 1956; Bloch & Cohen, I960; Varon & Touchstone, 1964).
Thus a A^-3PHSD system is present in the tumour capable of acting 
upon C0/1 Ar.-30-hydroxysteroids possessing a 17<x-hydroxyl group.
21 5
Labelled progesterone deoxycorticosterone, 17a-hydroxy- 
progesterone and cortisol were isolated from the tumour incubation 
with A^-pregnenolone as substrate (Table LXIV). Each was taken 
to constant specific activity after the addition of carrier by the 
procedures indicated. Thus the presence of a A<_-3pHSD capable
TABLE LXIII
UTILIZATION OFlTo-HYDROXYPREGNENOLONE BY MOUSE ADRENAL TUMOURS
Medium: 
Tissue: 
Additions: 
Substrate:
Incubation Time:
0.154m sodium chloride and 0.1M phosphate buffer (1:1)
10 ml. of 10% (W/V) homogenate
NAD, 60 mg. Final Volume: 12 ml.
17«-hydrpxypregnenolone-7aT, 500 p,g., specific activity, 
1.5 x Kr cpm/jig.
90 minutes. Gas-phase: air.
■jig. carrier 
steroid 
added*
Steroid
Derivatives
Chromatography Specific
activity
cpm./tig.Isolated steroids Procedures Paper Column
- - Bush B_ - 956
17a-hydroxy- 250
- - Bush A - 710
progesterone - - - Silica Gel 603
Oxidation Androstenedione Bush A - 626
- - Bush B_ - 589
11-deoxycortisol 
(compd. S) 100 Acetylation S-acetate Bush A - 407
Saponification Compd. S Bush B^ - 388
- - Bush B^ - 488
Cortisol 
(compd. F)
100 Acetylation F-acetate Bush B^ - 111
Saponification Compd. F Bush B_ 
5
- 107
* Carrier steroid added after preliminary identification using paper chromatography
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of acting upon A^-pregnenolone has also been shown. Surprisingly,
5
17-hydroxylated A^-3-ketosteroids (l7a-hydroxyprogesterone and 
cortisol) were also found in this extract. Whether these steroids 
were formed via the 17a-hydroxylation of progesterone or of 
pregnenolone is not known. If the pathway is similar to that 
occurring in human adrenal glands, then 17a-hydroxypregnenolone 
may be the more likely intermediate (Eichorn 8c Hechter, 1957;
Berliner et al., 1958; Eichorn & Hechter, 1959; Mulrow & Cohn,
1961; Lipsett & Hokfelt, 1961; Weliky 8c Engel, 1962).
17<*-hydroxylation has been shown to occur in incubations 
of adrenal glands from immature mice and its activity was found 
to diminish with the development of sexual maturity (Varon et al., 
1963; Varon 8c Touchstone, 1964). The present tumours were 
derived from female mice which had been oophorectomized shortly 
after birth.
In the extract derived from the incubation of pregnenolone,
no radio-activity was demonstrable in corticosterone added as
carrier. Several other steroids were formed from pregnenolone
and 17<x-hydroxypregnenolone, but only the major steroid products
were isolated and identified.
14DHA-4- C was metabolised by the tumour in a manner similar 
to that in human adrenal glands (Table LXV). Not only 
androstenedione and 7-keto-DHA were formed, but also the radio-active
TABLE LXV
UTILIZATION OF DHA BY MOUSE ADRENAL TUMOURS
Medium: 
Tissue: 
Additions: 
Substrate: 
Incubation Time:
0.154M sodium chloride and 0.1M phosphate buffer (1:1) 
10 ml. of 10% (W/V) homogenate
NAD, 60img* Final Volume: 12 ml.
DHA-4- C, 520 tig., specific activity, 4?9 cpm/pg.
90 minutes. Gas-phase: air.
Column
peaks
Isolated
steroids
it
Substrate: DHA-4- C
.—  ....... -.- »■- r r --------- -----
Substrate: DHA-4- C with 1474 jig. 
androstenedione as a trap
Tcpm Ug.
Specific activity 
cpiVVg. Tcpm Vg*
Specific activity 
cpm/pg.
I Androstenedione 134,598 277 485 120,924 1,619 74.7
II DHA 27,516 39 470 41,225 83 494
III 7-keto-DHA 25,176 34 465 25,794 83 313
IV - 11,856 - - 9,120 - -
V - 1,820 - - 1,260
_ _ --- i
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fractions corresponding to the unknown steroids comprising the
alumina column peaks, IV and V, previously described. As before,
these steroid zones did not absorb U.V. light.
In the presence of the androstenedione trap, DHA was seen
to be converted directly to 7-keto-DHA as in the human tissue to
the extent of 63%. This is calculated from the ratio of the
specific activities of the isolated 7-keto-DHA and DHA (313 cpm/p.g:
494 cpm/p.g. = 63.3)* This percentage is slightly lower than
the 70% and 79% obtained with the human virilising tumour (Gland 25
PP» 237 & 239) • From the specific activity of DHA and the total
cpm. incorporated into the androstenedione trap, it can be
14calculated that 245 Ug. of DHA-4- C were transformed directly to
androstenedione. This represents a negligable (10%) decrease
14compared with the control DHA-4- C incubation,
Thus, these tumours possess the A^-3PHSD systems capable of
acting upon pregnenolone, 17a-hydroxypregnenolone and DHA. In
addition, since the 17<*i 21 and ll{3-hydroxylases are all present,
the reason why these lesions failed to show any obvious in vivo
hormonal function is obscure. It may be related to their vascular
supply and drainage as has been suggested for ,fnon-function”
in some human adrenal tumours (Dobbie 8c Symington, 1965).
The compounds identified from the 24 hour incubation of 
14progesterone-4- C with the tissue culture of the tumour are
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shown in Table LXVI. Each was combined with the corresponding 
carrier steroid after preliminary isolation on paper and constant 
specific activities were achieved by the methods shown in Table 
LXVI.
In this instance, deoxycorticosterone and corticosterone were
*1 £)■
identified as products of progesterone-4- C. The persistence
of the 17a-hydroxylase system was confirmed by the isolation
and purification of both 17a-hydroxyprogesterone and cortisol.
Thus the biosynthetic capacity of the cells was not altered as
a result of the tissue culture procedure.
1 4Progesterone-4- C of high specific activity was chosen as 
the substrate in order to obtain identifiable products of reasonable 
specific acitivty after the addition of carrier. However, on 
performing the incubation, it was found that the ’’clones", about 
20-40 in all, were responsible for converting an appreciable amount 
of the added substrate in 24 hours.
Using a histochemical technique, the A^-3?HSD system for 
DHA was demonstrable in the surviving cells after 20 days of 
culture (Anderson & McIntyre, personal communication). Presumably 
the Aj--3PHSD system for pregnenolone and for 17a-hydroxypregnenolone 
was also present, although the demonstration of these systems 
was not attempted.
This experiment shows the value in relating structure and
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biochemical activity and reveals that these tumours possess 
steroid biosynthetic enzyme systems similar to those of the human 
gland. Moreover, this tumour was shown to have the A._-3|3HSD 
systems capable of utilizing DHA, pregnenolone and 17a-hydroxy- 
pregnenolone. Qualitatively these enzyme systems were still 
functional after 20 days of tissue culture and were similar 
in pattern to those found in homogenates of the tumour incubated 
shortly after death of the animals.
DISCUSSION
The incubation of DHA with human adrenal tissue results in 
the formation of two principal products, A^-androstene-3»17~dione 
and At--androstene-3|3-ol-7,l7-dione (7-keto-DHA) , both of which 
absorb U.V. light at 2^0 mp,. Consequently, methods of assay of 
the A^-3(3-hydroxysteroid dehydrogenase (A,_-3PHSD) for DHA must, 
of necessity, differentiate between those two steroids, since, 
presumably, only androstenedione represents the product of the 
activity of this enzyme system. Therefore, the technique of 
assay involving the use of a preparatory silica gel column is of 
no value. Moreover, methods, in which the formed steroids are 
measured by direct spectrophotometric comparison of the incubates 
of human adrenal glands against suitable tissue blanks using 
similar in vitro incubation conditions and with DHA as substrate, 
are open to the same criticism (Rubin et al,, 1961; Bloch et al., 
1962; Rubin et al,, 1963)*
Separation of androstenedione and 7-keto-DHA is easily achievec 
using alumina column chromatography. These two steroids are 
responsible for nearly all of the total U.V. light absorbing 
steroids measured by the silica gel column technique, as judged 
by the comparison of the same incubation extracts by silica gel 
and then alumina chromatography. The trace amounts of lip-hydroxy- 
androstenedione, adrenosterone and testosterone, formed in some
- 256 -
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incubations, do not contribute appreciably to the total formed 
steroid from DHA as measured by U.V. light absorption alone.
7-keto-DHA is a biosynthetic product of the human adrenal 
cortex, the possibility of its being an auto-oxidation product 
of DHA in vitro having been excluded experimentally (p. 173) and 
by others (Starka & Katova, 1962)• It was not produced by 
homogenised bovine adrenal glands in vitro in appreciable amounts, 
but it was isolated from the mouse adrenocortical tumours 
incubated with labelled DHA.
Androstenedione, 7-keto-DHA and the increased substrate DHA 
isolated after incubation all have specific activities which fall 
within the same range. As there is no significant decrease in 
the specific activity of the substrate DHA in the incubations, 
with exception of one virilising tumour (Gland 27, Table LIII), 
it can be concluded that DHA is not formed from endogenous sources 
under these in vitro conditions. Consequently, the amounts of 
androstenedione and 7-keto-DHA measured or found reflect the 
activities of the 2i^ -3(3HSD system and the enzyme system(s) leading 
to the formation of 7-keto-DHA respectively.
No difference is detected in the activity of either enzyme 
systems in normal compared with hyperplastic human adrenal glands, 
although a tendency for greater utilization of DHA appears to occur 
in hyperplastic tissues. The activity of both enzyme systems
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falls with increasing tissue amounts and times of incubation, but 
still no difference between those two types of adrenal tissue is noted,
The values found in the present work for the activity of
the A^-3£HSD system for DHA are much lower than those reported
by others (Rubin et al,, 1961; Bloch et al., 1962; Rubin et al.,
1963)• This is due primarily to the separation of the products
of DHA utilization, which was not done by the previous workers.
They noted a wide variation in the activity of the A..-3SHSD
5
system in two normal adrenal glands (3«9 pg. and 8.2 p,g. U.V. 
absorbing steroid formed per minute per mg. nitrogen). A smaller 
variation is observed in the present study in both normal and 
hyperplastic glands. Such variations from gland to gland may be 
due to differences in the proportions of compact cells, derived 
from the zona reticularis, present in the homogenate. These 
cells have been shown histochemically and by in vitro incubation 
techniques to possess less A^-3f3HSD activity than the clear cells 
of the zona fasciculata (Wattenberg, 1958; Dawson et al., 1961; 
Cavallero & Chiappino, 1962; Grant, 1962)• Nothing is known of 
either the cellular or intracellular distribution of the enzyme 
system(s) leading to 7-keto-DHA fromation from DHA.
Several factors may affect the accuracy of the present assay 
methods for these enzyme systems. The reversibility of the 
Acj-3(3HSD system in vitro has been reported to occur in isolated
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shee-p microsomes in the presence of NADH (Ward 8c Engel, 196*0.
1**In one of the present experiments, androstenedione-**- C was also
found to be converted to radio-active DHA in low yield when NAD
was omitted from the medium. No labelled DHA was formed from
”1 **androstenedione-**- C in several other incubations of hyperplastic 
and neoplastic adrenal tissue in the presence of NAD. Thus, as 
NAD was present in all the incubations in which the A,--3(3HSD 
system for DHA was assayed, the results found in the present work 
appear to be valid.
7-keto-DHA can be derived from androstenedione when the latter 
is present in high amounts. This is illustrated not only by the 
decrease in the specific activity of the 7-keto-DHA formed from
i 1**DHA-4- C in the presence of an unlabelled androstenedione trap,
'1 **but by the incubation of androstenedione-**- C itself. Therefore, 
androstenedione and 7“keto-DHA presumably are in equilibrium so 
that the assay procedures used in the present work are still valid 
for the comparison of one gland with another.
In the present investigation, 7-keto-DHA was found to be 
formed from two sources. The more important is from DHA directly. 
7a-hydroxy-DHA and 7a-hydroxy-oestrone have been shown to be 
produced by rat liver and bovine adrenal tissues respectively 
(Starka 8c Katova^ 1962; Knuppeg et al., 196**) while both 7« and 
7p-hydroxylation can be effected by micro-organisms (Epstein et al.,
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1956; Bernstein et al., 1959; Dodson et al., 1959)* Thus
7a-hydroxy-DHA may serve as an intermediate in the formation of
7-keto-DHA from DHA and peak IV of the alumina column fractions
has the approximate polarity reported for 7a-hydroxy-DHA in
the Bush Bc system (Starka & Katova^ 1962). The other route 
5
involves a reversal of the reaction of the 3£-ol-dehydrogenase
and A^-3-keto-isomerase systems without apparently involving DHA
as an intermediate (Fig. ^0), since 7-keto-DHA can be formed from
unlabelled androstenedione in the presence of DHA-^ f- C without
”1appreciable dilution of the substrate DHA-*f- C (Tables XLV,
XLVI & XLVII). This pathway has not been fully investigated but 
is present in normal, hyperplastic and neoplastic human adrenal 
tissue.
The rate of formation of U.V. light absorbing steroids from 
DHA, expressed in jig. per minute per mg. nitrogen, measured by 
silica gel column chromatography, falls within the same range 
for normal and hyperplastic adrenal glands. Separation of these 
steroids into androstenedione and 7-keto-DHA by alumina column 
chromatography reveals no difference in the average rate of 
formation of either steroid from DHA in normal or hyperplastic 
glands (Table XXXVII). However, although the sum of these two 
steroids formed is similar, the proportion contributed by either 
one varies inversely, in that when most of the total steroid formed
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from DHA is androstenedione, 7-keto-DHA is low. The converse is 
also true. This suggests the existence of an intermediate compound 
on the route DHA to androstenedione which can be utilized to form 
either androstenedione, or presumably via 7-hydroxylation, be 
converted to 7-keto-DHA and that there is some competition for this 
intermediate between the enzyme systems responsible for the 
formation of the two products.
In bovine adrenal gland preparations, androstenedione was 
shown to inhibit the conversion of DHA to androstenedione in vitro 
presumably by product inhibition of the 3P-ol-Hehydrogenase 
(Kowal et al., 1964b). Thus by inference, the rate of formation 
of both androstenedione and 7-keto-DHA from DHA would be expected 
to be decreased in human adrenal tissue in the presence of 
androstenedione. However, in an hyperplastic human gland and in 
a virilising tumour, although the formation of androstenedione
14from DHA-4- C was in fact found to be decreased in the presence 
of large amounts of unlabelled androstenedione, 7-keto-DHA was 
formed in amounts similar to those found from DHA alone (Tables 
XLVI & LX)• These resits tend to argue against a common 
dehydrogenase for which competition exists, but differences exist 
between the Aj--3£HSD system present in human and bovine adrenal 
glands (see below). The alternative intermediate, for which 
there is competition, may thus be A,_-androstene-3>,17-dione.
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In the present experiments, no significant radio-activity 
was detected in the aqueous phase of several incubations after 
extraction in which phase DHA-sulphate would be expected to remain. 
DHA-sulphate was found to be formed in vitro by normal (Adams,
1963* 1964; Bostrom et al., 1964; Killinger 8c Solomon, 1965) 
and by neoplastic human adrenal glands (Cohn et al., 1963;
Migeon, 1963; Wallace & Lieberman, 1963). DHA-sulphate was 
detected in vivo in the adrenal and peripheral venous blood and 
in the urine of cases of adrenal tumours (Baulieu, 1962). Its 
formation from cholesterol sulphate and pregnenolone sulphate 
has also been demonstrated in vivo (Calvin et al., 1963; Roberts 
et al., 1964) although pregnenolone and not pregnenolone sulphate 
was converted in vitro to DHA-sulphate by normal adrenal tissue 
(Killinger 8c Solomon, 1965).
However, the rate of formation of DHA-sulphate from DHA by 
normal human adrenal glands incubated in vitro was found to be 
between 21 mp,M per g. wet weight per 2 hours and 228 mp,M per g. 
wet weight per hour depending upon the in vitro system (Adams,
1963, 1964; Bostrom et al., 1964). This corresponds to a rate 
of 0.01 p,g. to 0.1 p,g. per minute per mg. nitrogen. Thus the 
adrenal sulphokinase activity is between 22 and 240 times less 
active than either the A,_-3PHSD system for DHA or of the system(s) 
for 7-keto-DHA formation. It is thus not surprising that no
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significant radio-activity was detected in the aqueous residues 
where one would expect steroid sulphates of incubates after 
extraction with the organic solvents.
The A^-3PHSD occupies a key position in the synthesis of 
adrenal C ^  and A^-3-ketosteroids. Its deficiency in the 
adrenal cortex has been reported in virilising conditions associated 
with congenital adrenal hyperplasia (Bongiovanni, 1961; Goldman 
et al., 196*f) and the Stein-Leventhal syndrome (Axelrod et al.,
1965) in which disease it is also present in lower activity than 
normal in the ovary (Axelrod & Goldzieher, 1962).
A deficiency of this enzyme was invoked to explain the high 
urinary excretion of DHA in patients with adrenal tumours (Rubin 
& Dorfman, 1957) and by a study of the urinary steroids, such a 
deficiency was in fact demonstrated in a virilised patient with 
an adrenal tumour (Lipsett 8c Wilson, 1962). In the present 
investigation, an absolute deficiency of a A^-3pHSD system specific 
for DHA and of the system(s) leading to 7-keto-DHA, were
demonstrated in two adrenal tumours (Gland 26 8c 27» Table XXVIII).
"1 *fThis was confirmed in the latter tumour using DHA-*4— C as 
substrate. The absence of this enzyme system for DHA has been 
shown by others using histochemistry (Roversi et al., 1963;
Goldman et al., 196*0 and by in vitro incubation techniques for 
pregnenolone conversion (Goldman et al., 196*0 in several
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virilising adrenal tumours. Not every tumour failed to show 
A,--3PHSD activity (Goldman et al., 1964). The activity, however, 
can be less than normal (Gland 25, Tables XXVIII & LXI).
Rubin and her co-workers (1963) reported a relative 
deficiency, by in vitro techniques, in two carcinomas, one 
associated with Cushing's syndrome, the other with virilism. It 
should be noted, however, that since DHA was used as substrate 
and no attempt was made to distinguish between androstenedione and 
7-keto-DHA formation, the result could only be expressed as total 
U.V. steroids formed per minute per mg. nitrogen. The same 
criticism can be levelled at the results reported here from the 
tumour associated with Cushing's syndrome (Gland 24, Table XXVIII).
Thus virilism is not always associated with an absolute 
deficiency of the A^-3|3HSD system but a lowered activity of the 
system may be seen in some cases. This lowered activity allows 
the accumulation of DHA and its secretion in excess by such lesions. 
Although it has been detected as the sulphate ester in adrenal 
venous blood in such conditions (Baulieu, 1962) and DHA-sulphate 
has been shown to be metabolically inert in vitro (Kowal et al., 
1964b), this does not preclude the sulphate having physiological 
action as it is freely interconvertible with DHA in vivo (Roberts 
et al., 1961).
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Kowal and his colleagues (1964b) have proposed another 
suggestion, whereby A^-3f3HSD deficiency is not necessarily a 
prerequisite for the occurrence of virilism, as a result of their 
finding of an inhibition of DHA utilization by its oxidation 
products, androstenedione and llpJ-hydroxyandrostenedione• They 
suggested an intracellular feed-back mechanism for the control of 
DHA utilization, whereby it would accumulate and lead to virilism 
in the presence of excess amounts of its oxidation products.
The incubation of the virilising adenoma (Gland 27, Tables
*14LIII & LIV) with cholesterol-4- C as substrate led to the 
isolation of radio-active A^-3-ketosteroids. This occurred in 
the absence of any conversion of DHA to androstenedione by aliquots 
of the same tumour, so that at least two A^-3pHSD systems must exist 
in the human adrenal cortex, one acting upon DHA and the other, 
or others, upon the C21~A,--30-hydroxysteroids. The presence of 
multiple substrate-specific A^-3pHSD systems was proposed by 
Weliky and Engel (1962) and confirmed by the in vitro incubation 
of both human and bovine adrenal gland preparations with DHA 
and with a variety of hydroxylated A^-3p-hydroxysteroids
(Berliner et al., 1962; Kowal et al., 1964a; Pasqualini, 1964) 
and by histochemical methods in the mouse testis (Baillie & 
Griffiths, 1964).
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Bovine adrenal glands have been reported to contain two
different A^-3“keto isomerase components of the A,_-30HSD system,
one, the A^-pregnene isomerase, acting upon A^-pregnene-3,20-dione
and the second, the A^-androstene isomerase, acting upon
A^-androstene-3»l?“<iioae (Ewald et al., 196*fa; 196Vb; 196^c ;
Kruskemper et al,, 196^).
The results obtained in the virilising adenoma (Gland 27,
Tables LIII & LIV) also pointed to the existence of at least two
Aj_-3(3HSD systems in human adrenal tissue that for DHA being absent
in this one case. A study, conducted on two human glands, one
normal, the other hyperplastic (Glands 50 & 51» Tables LV & LVI)
”1where the utilization of DHA-*t~ C was determined in the presence
of pregnenolone and 17a-hydroxypregnenolone, confirmed this view.
The formation of androstenedione from DHA in the presence of
17cc-hydroxypregnenolone occurred at the same rate as in the
-iA
incubation with DHA- C alone even when 17<x-hydroxypregnenolone 
was present in eight times the molar concentration of DHA. The 
fewer cpm. incorporated into androstenedione in this particular 
flask, was due to the conversion of unlabelled 17a-hydroxy- 
pregnenolone to DHA and by dilution, a decrease in the specific 
activity of the substrate. Consequently, different A^-3f3HSD 
systems must exist for these two substrates. However, when 
pregnenolone was present in equimolar or in eight times the molar
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concentration of DHA, a significant decrease in the conversion 
of DHA to androstenedione was found. Therefore, pregnenolone 
must exert either competition for a component of the A^-3£HSD- 
isomerase systems for DHA or inhibit these systems directly. The 
latter seems unlikely as nearly complete inhibition of the 
utilization of DHA would be expected when pregnenolone is also 
present in eight times the molar concentration of DHA.
In their study of the A^-3pHSD systems using acetone powder 
preparations of bovine adrenal glands, Kowal and his associates 
(196^ -b) showed that neither pregnenolone nor 17a-hydroxypregnenolone 
inhibited the conversion of DHA to androstenedione. Using whole 
homogenates of beef adrenal glands, similar findings were noted 
in the present work (Table LVII) when equimolar and eight times 
the molar concentration of both C^  A^-3(3-hydroxysteroids were 
incubated with DHA.
It can be concluded that different AE_~3f3HSI> systems exist in 
bovine glands for C^  and A^-OP-hydroxysteroids, but that in 
man, although there are apparently separate systems for DHA 
and 17ct-hydroxypregnenolone, pregnenolone and DHA may share an 
enzyme system. The finding of deoxycorticosterone and 
corticosterone formation from cholesterol by the tumour (Gland 27, 
Table LIV) which lacked the A^-3pHSD system for DHA, points to 
pregnenolone being utilized by a different A,_-3PHSD system.
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However, the aetiology of the inhibitory effect of pregnenolone 
upon DHA utilization must await kinetic studies with purified 
enzyme systems.
In one normal gland (Table LVI) the formation of 7-keto-DHA 
from DHA was increased by 39% in the presence of pregnenolone 
over the control flask, while the formation of androstenedione 
from DHA was decreased by ^3%» This is some evidence for a 
common enzyme system for the formation of androstenedione and 
7-keto-DHA from DHA, This probably is the 3(3”°1 dehydrogenase 
since the isomerase most likely is not concerned with 7-keto-DHA 
formation, and thus the inhibiting effect of pregnenolone may be 
exerted upon the isomerase component of the A,_-3|3HSD for DHA,
The occurrence of virilism with high DHA excretion and a low 
or normal cortisol secretion, due to adrenal tumours, can be 
explained by assumming two A^-3[3HSD systems, the one for DHA 
being absent or of very low activity, while that for 17<x- 
hydroxypregnenolone or pregnenolone is present, possibly in lower 
amounts than normal. This could result in a deviation of the 
biosynthetic pathway to increased DHA formation from either 
cholesterol or pregnenolone, but still allow near-normal dortisol 
production. Alternatively, the inhibiting effect of DHA itself 
upon the conversion of pregnenolone and 17a-hydroxypregnenolone 
to A, -3-ketosteroids may account for the cortisol output found
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in such cases (Kowal et al., 196^ -b) . This latter possibility is 
unlikely, as the occurrence of Cushing’s syndrome and virilism 
together (i.e., ’’mixed” Cushing's syndrome) due to adrenal tumours, 
can be associated with increased DHA excretion (Gallagher, 1958; 
Lipsett & Wilson, 1962)• It is more likely that higher activities 
of the A^-3pHSD system for the C ^  A^-3P-hydroxysteroids are 
present in these tumours by comparison with those only causing 
virilism and so allow increased formation of cortisol.
The relationship of 7-keto-DHA to the causation of virilism
is unknown. The 7-hydroxylation of both androstenedione and
11-deoxycortisol is associated with loss of their physiological
effects (Bernstein et al., 1959)» so that 7-keto-DHA may represent
a metabolic degradation product of DHA. The steric configuration
of the Ac-7-keto group is similar to that of the physiologically 
5
active A^-3-ketosteroids, so that an assessment of its physiological 
potential would be of great interest.
lip-hydroxyandrostenedione and adrenosterone have been found 
to be produced on the in vitro perfusion of bovine adrenal glands 
(Bloch et al., 195&) and both DHA and androstenedione have been 
shown to be precursors of lip-hydroxyandrostenedione in beef 
adrenals (Hayano & Dorfman, 1955; Jeanloz et al., 1955; Meyer 
et al., 1955; Rosenfeld et al., 1955)* It was assumed that 
lip-hydroxyandrostenedione, adrenosterone and testosterone were
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formed from DHA via androstenedione. This pathway was found to
exist in bovine adrenal tissue in the present work (Table L)•
These three compounds were found only in trace amounts on in vitro
incubation of normal and hyperplastic human adrenal glands with
DHA-4- C as substrate and were isolated only after the addition
of carrier steroids. In one gland (Gland 49, Table XLIX), with
1 4androstenedione-^- C as substrate, these steroids were detected, 
but in other incubations (Glands XLVII & XLVIII, Table XLIX), 
more radio-activity was incorporated into these three steroids
”1 4 14from DHA-4- C than from androstenedione-^— C, especially with
the testosterone fraction. Consequently, an alternative pathway 
in the formation of these compounds from DHA, not involving andros­
tenedione as an intermediate, may exist in human adrenal glands. 
Similarly, in one virilising tumour (Gland 25, Table LXII) 
lip-hydroxyandrostenedione appeared to be formed from DHA directly. 
No testosterone formation in vitro was demonstrated in this 
virilising lesion from DHA. That A^-androstene-3P,17£-diol could 
serve as a precursor of testosterone was shown by the in vitro 
incubation of an human adrenal tumour associated with virilism 
(Baulieu et al., 1963b). This steroid has been isolated from 
the urine and adrenal venous plasma of patients with virilism 
(Hirschmann & Hirschmann, 1945; Mason & Kepler, 1945a, 1945b; 
Hirschmann et al., I960) and is indirect evidence of a decrease
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in A,_-3|3HSD activity for DHA in virilising syndromes#
Thus androstenediol can serve as an intermediate in 
testosterone formation from DHA, reduction of the 17-ketone group 
occurring before the action of the A^-3|3HSD system. Similarly, 
lip-hydroxylation and subsequent 11-oxidation of DHA may take place 
before the A^-3PHSD system acts, to form lip-hydroxyandrostenedione 
and adrenosterone.
lip-hydroxyandrostenedione, in the present investigations 
was found to be a major product from both DHA and androstenedione 
only in beef adrenal incubations. It is formed in only trace 
amounts in human adrenal gland studies from these substrates.
While DHA has been reported to inhibit llp-hydroxylation 
(Sharma etal., 1963)» this cannot be the explanation of the 
findings in the present incubations for only trace amounts are 
formed from androstenedione even in the absence of added DHA.
It is difficult to interpret these findings of low rates 
of formation since llp-hyaroxyandrostenedione has been found to 
be a major human adrenal steroid secretion as determined in adrenal 
venous blood (Romanoff et al., 1953; Sweat, 1955; Bush et al.,
1956; Grant et al., 1957; Bush & Mahesh, 1959; Lombardo et al., 
1959; Short, i960). A possible explanation may reside in the 
similarity of the properties of chromatographic mobility and 
U.V. light absorbtion of ll|3-hydroxyandrostenedione and 7-keto-DHA.
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However, the latter compound has only been detected as the 
sulphate in adrenal venous blood (Baulieu, 1962) and ll|3-hydroxy- 
androstenedione isolated as the free steroid and in most instances, 
characterised beyond doubt. It may be that ll(3-hydroxy- 
androstenedione arises not from either DHA or androstenedione 
in vivo,but by the side chain cleavage of cortisol. In further
incubation studies a study of co-factor requirements and the use
14 14of DHA-^ f- C and androstenedione-^- G of high specific activity
would be necessary before these postuMed pathways for the
formation of lip-hydroxyandrostenedione, adrenosterone and
testosterone in human adrenal tissue can be elucidated.
Three points of interest arise from the in vitro studies
of the mouse adrenal tumours occurring spontaneously in gonadectomised
female mice of the CE strain. They were found to be capable of
In­forming 7-keto-DHA, from both DHA-A-- C and from androstenedione
and in similar amounts from either substrate as was found in
the human material studied, This is the first demonstration of
the formation of this steroid by adrenal tissues of animals
other than man.
This study of the A^ _-3|3HSD systems for DHA, pregnenolone 
and 17a-hydroxypregnenolone indicates that all are present in 
these tumours.
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The presence of 17<x-hydroxylation was noted to occur not only 
in the tumour homogenate studied by in vitro incubation, but also 
in the ’'clones1* from the tumour after 20 days of tissue culture* 
Difference of opinion exist as to whether 17a-hydroxylation 
takes place in the adrenal cortex of mice and rats. It is 
generally accepted that this 17-hydroxylation system is absent in 
rats (Peron, I960; Laplante et al*, 196^) and mice (Hofman, 1956 > 
Bloch & Cohen, i960). However, the adrenal tissue of rats with 
adrenal regeneration hypertension produces 17a-hydroxylated 
steroids (Brownell et al., 1963) and 17a-hydroxylation has been 
shown to occur in sexually immature mice, this ability being 
suppressed after sexual maturation (Varon & Touchstone, 196^ -) •
The tumours used in the present study were derived from sexually 
immature mice, which had undergone gonadectomy shortly after birth. 
In vitro incubations with adrenocortical tumours of mice of a 
different strain showed the presence of lip and 21-hydroxylase 
activities and an active 17s20-desmolase (Hofman & Christy, 1961)• 
No appreciable 17a-hydroxylation could be detected, yet these 
tumours also arose in animals gonadectomised shortly after birth. 
(Hofman et al., i960)•
Consequently, in the adrenal tumours of mice of the CE strain 
the biosynthetic pathways show a remarkable similarity to those 
occurring in man (Fig. bO),
SUMMARY
An investigation has been undertaken of the A^-30-hydroxy- 
steroid dehydrogenase activity in normal and pathological human 
adrenal tissues, utilizing A^-androstene-30-ol-17-one (DHA) 
as substrate.
The principal products of DHA metabolism by the in vitro 
incubation of human adrenal tissue are A^-androstene-3»17-dione
and A_-androstene-30-ol-7,17-dione (7-keto-DEA), both of which
Z>
are U.V. light absorbing steroids.
7-keto-DHA has been shown previously to occur in the urine 
from patients with normal and raised adrenocortical function 
and to be produced by the in vitro incubation of rat liver, 
but this is the initial demonstration of its production in vitro 
by human adrenal glands.
Radiochemical evidence is presented which shows that most of 
the 7-keto-DHA formed is derived directly from DHA, but that 
androstenedione can contribute to the 7-keto-DHA pool, if present 
in large amounts.
Separation of the two principal products of DHA utilization, 
androstenedione and 7-keto-DHA, by alumina column chromatography 
gives a measure of the activities of the A^-30-hydroxysteroid 
dehydrogenase system and of the enzyme system(s) leading to 
7-keto-DHA formation respectively.
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The rate of formation of the total U.V. light absorbing 
steroids (androstenedione and 7-keto-DHA) does not differ in 
normal and hyperplastic human adrenal glands. The activities 
of the A^-3p-hydroxysteroid dehydrogenase and the enzyme 
system(s) for 7-keto-DHA are also found not to differ in those 
two types of adrenal glands*
One benign and one malignant adrenocortical tumour, both 
associated with virilism show an absolute deficiency in the 
conversion of DHA to both androstenedione and 7-keto-DHA.
In the benign tumour, the conversion of cholesterol to U.V. 
light absorbing steroids (cortisol, corticosterone, deoxycortico­
sterone and 17<x-hydroxyprogesterone) is demonstrated. This is 
further evidence for the existence of several substrate-specific
Ac-3P-hydroxysteroid dehydrogenase systems, for one of which 
5
(for DHA) an absolute deficiency exists in this tumour.
In vitro experiments using bovine adrenal glands confirmed 
the existence of different Ae-30-hydroxysteroid dehydrogenase 
systems for the C^  A^-30-hydroxysteroids, pregnenolone and 
17a-hydroxypregnenolone, and for the C ^  A,_-3P-hydroxysteroid,
DHA. While there are different systems for 17a-hydroxy- 
pregnenolone and DHA in human adrenal glands, the observed 
inhibitory effect of pregnenolone may be due to either competition 
for the same enzyme system or to its having a direct inhibitory 
effect.
276 -
The At--30“hydroxysteroid dehydrogenase system is found to be 
a reversible enzymic process converting androstenedione to DHA.
The formation of 7-keto-DHA from androstenedione, on the other 
hand, occurs by a pathway not involving DHA as an intermediate.
The possibility that testosterone, adrenosterone and 
ll(3*-hydroxyandrostenedione may be formed by the human adrenal gland 
by a pathway not necessarily involving androstenedione is raised.
In the study of spontaneous adrenocortical tumours, 
developing in gonadectomised mice of the CE strain, it is shown 
that the biosynthetic pathways in the tumours are similar to 
those of the human adrenal cortex, and include the presence of 
17a-hydroxylation.
A C K N O W L E D G E M E N T S .
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